

=> d his

(FILE 'HOME' ENTERED AT 10:32:34 ON 31 MAY 2000)

FILE 'REGISTRY' ENTERED AT 10:32:47 ON 31 MAY 2000

L1               STRUCTURE UPLOADED  
L2               24 S L1  
L3               STRUCTURE UPLOADED  
L4               0 S L3  
L5               16 S L3 FULL  
L6               STRUCTURE UPLOADED  
L7               2 S L6  
L8               30 S L6 FULL  
L9               46 S L5 OR L8

FILE 'USPATFULL' ENTERED AT 10:42:33 ON 31 MAY 2000

L10              8 S L9

FILE 'CAPLUS' ENTERED AT 10:44:48 ON 31 MAY 2000

L11              22 S L9

L10 ANSWER 1 OF 8 USPATFULL  
 ACCESSION NUMBER: 2000:47233 USPATFULL  
 TITLE: Means to achieve sustained release of synergistic drugs  
 INVENTOR(S): by conjugation  
 Ashton, Paul, Boston, MA, United States  
 Crooks, Peter Anthony, Lexington, KY, United States  
 Cynkowski, Tadeusz, Lexington, KY, United States  
 Cynkowska, Grazyna, Lexington, KY, United States  
 Guo, Hone, Malden, MA, United States  
 PATENT ASSIGNEE(S): University Of Kentucky Research Foundation,  
 Lexington,  
 KY, United States (U.S. corporation)

NUMBER	DATE
US 6051576	20000418
US 1997-791071	19970129 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-38855, filed on 15 Feb 1995, now abandoned which is a

continuation-in-part of Ser. No. US 1994-187462, filed on 28 Jan 1994  
 DOCUMENT TYPE: Utility  
 PRIMARY EXAMINER: MacMillan, Keith D.  
 LEGAL REPRESENTATIVE: McDermott, Will & Emery  
 NUMBER OF CLAIMS: 37  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)  
 LINE COUNT: 1243


CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB A codrug composition of at least two drug compounds covalently linked to one another via a labile bond to form a single codrug composition, or ionically linked to one another to form a single workings composition, and methods of use of the codrug for the treatment of various medical conditions. The codrug may be administered by itself or in the form of a bioerodible or nonbioerodible substance.

IT 169047-14-7P 169047-15-8P  
 (codrug compns. for controlled drug delivery)  
 RN 169047-14-7 USPATFULL  
 CN Pregnan-20-one, 21-[2-(2-fluoro[1,1'-biphenyl]-4-yl)-1-oxopropoxy]-17-hydroxy-3-(phenylmethoxy)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 1 OF 8 USPATFULL (Continued)  
 hydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 169047-12-5 USPATFULL  
 CN Pregnan-20-one, 21-[2-(2-fluoro[1,1'-biphenyl]-4-yl)-1-oxopropoxy]-3-[[[5-fluoro-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]carbonyl]oxy]-17-hydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

L10 ANSWER 1 OF 8 USPATFULL (Continued)




RN 169047-15-8 USPATFULL  
 CN Pregnan-20-one, 3-[[[chlorocarbonyl]oxy]-21-[2-(2-fluoro[1,1'-biphenyl]-4-yl)-1-oxopropoxy]-17-hydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 169047-11-4P 169047-12-5P  
 (codrug compns. for controlled drug delivery)  
 RN 169047-11-4 USPATFULL  
 CN Pregnan-20-one, 21-[2-(2-fluoro[1,1'-biphenyl]-4-yl)-1-oxopropoxy]-3-[[[5-fluoro-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]methoxy]carbonyl]oxy]-17-

L10 ANSWER 1 OF 8 USPATFULL (Continued)




L10 ANSWER 2 OF 8 USPATFULL  
 ACCESSION NUMBER: 1999:81822 USPATFULL  
 TITLE: Neuroactive steroids of the androstane and pregnane series  
 INVENTOR(S): Upasani, Ravindra B., Foothill Ranch, CA, United States  
 Fick, David B., Mission Viejo, CA, United States  
 Hogenkamp, Derk J., Carlsbad, CA, United States  
 Lan, Nancy C., South Pasadena, CA, United States  
 PATENT ASSIGNEE(S): CoCensys, Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5925630	19990720
APPLICATION INFO.:	US 1996-659192	19960606 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-467404, filed	
DOCUMENT TYPE:	on 6 Jun 1995	
PRIMARY EXAMINER:	Utility	
ASSISTANT EXAMINER:	Deas, Jose' G.	
LEGAL REPRESENTATIVE:	Radio, Barbara	
NUMBER OF CLAIMS:	Sterne, Kessler, Goldstein & Fox P.L.L.C.	
EXEMPLARY CLAIM:	24	
NUMBER OF DRAWINGS:	1	
LINE COUNT:	1 Drawing Figure(s); 1 Drawing Page(s)	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	3047	

AB The invention relates to 3.alpha.-hydroxy, 17-(un)substituted derivatives of the androstane series and 3.alpha.-hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at a recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC active agents (such as depression) and seizure activity. The steroid derivatives of this invention are those having the general structural Formula:   
 #STR1#  
 wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are further defined herein and the dotted lines are single or double bonds. The structure includes androstanes, pregnanes (R.sub.4 = methyl), 19-norandrostanes, and norpregnanes (R.sub.4 = H).  
 IT 186264-62-0P 186264-76-6 (prepn. of neuroactive steroids of androstane and pregnane series)  
 RN 186264-62-0 USPATFULL  
 CN Pregnane-20-one, 3-hydroxy-3-methyl-21-[(4-nitrophenoxy)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)]

L10 ANSWER 2 OF 8 USPATFULL (Continued)  
 Absolute stereochemistry.




RN 186264-76-6 USPATFULL  
 CN Pregnane-20-one, 21-[(4-fluorophenyl)sulfonyl]-3-hydroxy-3-(methoxymethyl)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.




IT 186264-31-3P 186264-33-5P 186264-64-2P  
 186264-65-3P 186264-66-4P 186264-67-5P  
 186264-81-3P 186264-82-4P  
 (prepn. of neuroactive steroids of androstane and pregnane series)  
 RN 186264-31-3 USPATFULL  
 CN Pregnane-20-one, 3-hydroxy-3-(methoxymethyl)-21-[(4-nitrophenyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

L10 ANSWER 2 OF 8 USPATFULL (Continued)




RN 186264-33-5 USPATFULL  
 CN Pregnane-20-one, 21-[(4-fluorophenyl)thio]-3-hydroxy-3-(methoxymethyl)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.




RN 186264-64-2 USPATFULL  
 CN Pregnane-20-one, 21-[(4-(dimethylamino)phenoxy)-3-hydroxy-3-methyl-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)]  
 Absolute stereochemistry.

L10 ANSWER 2 OF 8 USPATFULL (Continued)




RN 186264-65-3 USPATFULL  
 CN Pregnane-20-one, 21-[(4-(dimethylamino)phenyl)thio]-3-hydroxy-3-(methoxymethyl)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.



RN 186264-66-4 USPATFULL  
 CN Pregnane-20-one, 3-hydroxy-3-(methoxymethyl)-21-[(4-nitrophenyl)sulfonyl]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.


L10 ANSWER 2 OF 8 USPATFULL (Continued)



RN 186264-67-5 USPATFULL

CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[[4-(1-pyrrolidinyl)phenyl]sulfonyl]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 186264-81-3 USPATFULL

CN Pregnan-20-one, 21-[[4-(aminophenyl)thio]-3-hydroxy-3-(methoxymethyl)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L10 ANSWER 2 OF 8 USPATFULL (Continued)



RN 186264-82-4 USPATFULL

CN Benzenaminium, 4-[[[(2.beta.,3.alpha.,5.alpha.)-3-hydroxy-20-oxo-2-propoxy]pregnan-21-yl]oxy]-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I -

L10 ANSWER 3 OF 8 USPATFULL

ACCESSION NUMBER:

90:93264 USPATFULL

TITLE:

.DELTA..sup.9(11) -angiostatic steroids

INVENTOR(S):

Aristoff, Paul A., Portage, MI, United States  
Skulnick, Harvey I., Kalamazoo, MI, United States  
Wierenga, Wendell, Kalamazoo, MI, United States

PATENT ASSIGNEE(S):

(U.S.)

The Upjohn Company, Kalamazoo, MI, United States corporation)

NUMBER DATE

PATENT INFORMATION:

US 4975537 19901204

APPLICATION INFO.:

US 1989-351977 19890515 (7)

RELATED APPLN. INFO.:

Continuation-in-part of Ser. No. US 1987-87228,

filed

on 19 Jun 1987, now abandoned which is a continuation-in-part of Ser. No. US 1985-790564,

filed

on 23 Oct 1985, now abandoned which is a continuation-in-part of Ser. No. US 1985-811866,

filed

on 20 Dec 1985, now abandoned

DOCUMENT TYPE:

Utility

PRIMARY EXAMINER:

Shah, Mukund J.

ASSISTANT EXAMINER:

Ward, Edward C.

NUMBER OF CLAIMS:

7

EXEMPLARY CLAIM:

1

LINE COUNT:

1654

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB

Disclosed are .DELTA..sup.9(11) -steroids of the formula ##STR1##

which have been found to be angiostatic and therefore are useful in the control of embryogenesis, inflammatory conditions, tumor growth as well

as other abnormalities.

IT 111245-66-0P

(formation of, in prepn. of antiangiogenesis agents)


RN 111245-66-0 USPATFULL

CN Pregn-9(11)-en-20-one,

21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-, (3.alpha.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 3 OF 8 USPATFULL (Continued)



IT 111245-67-1P 133442-74-7P


(prepn. and reaction of, in prepn. of antiangiogenesis agents)

RN 111245-67-1 USPATFULL

CN Pregn-9(11)-en-20-one,

21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-, (3.alpha.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 133442-74-7 USPATFULL

CN Pregn-9(11)-en-20-one,

21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-, (5.alpha.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 3 OF 8 USPATFULL (Continued)



L10 ANSWER 4 OF 8 USPATFULL

ACCESSION NUMBER: 76:39285 USPATFULL

TITLE: 20.beta.,21-Epoxy-3.alpha.-hydroxy-5.alpha.-pregnanes and derivatives thereof

INVENTOR(S): Philipps, Gordon Hanley, Wembley, England  
Newall, Christopher Earle, London, England  
PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, England (non-U.S. corporation)

NUMBER	DATE
US 3969345	19760713
US 3969345	19750220 (5)


PATENT INFORMATION: Division of Ser. No. US 1971-208961, filed on 16 Dec 1971, now patented, Pat. No. US 3882151

NUMBER	DATE
GB 1970-60065	19701217



PRIORITY INFORMATION: Utility  
DOCUMENT TYPE: Roberts, Elbert L.  
PRIMARY EXAMINER: Bacon & Thomas  
LEGAL REPRESENTATIVE: 4  
NUMBER OF CLAIMS: 1  
EXEMPLARY CLAIM: 1213  
LINE COUNT: 1213  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention provides 3.alpha.-oxygenated pregnane 21-ethers possessing a hydroxy group in the 3.alpha.-position; a hydrogen atom or a methyl group at the 10-position; a hydrogen atom in the 17.alpha.-position; a keto group in the 20-position; and an etherified hydroxyl group in the 21-position.  
IT 38601-34-2P 38601-47-7P (prepn. of)  
RN 38601-34-2 USPATFULL  
CN Pregnane-11,20-dione, 21-(4-aminophenoxy)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 4 OF 8 USPATFULL (Continued)



Absolute stereochemistry.



$R = H$   
 $R_1 = H$   
 $R_2 = \text{C=O}$   
 $R_3 = \text{C=O-CH}_2\text{-O-E}$   
 $R_7 = H$   
 $R_9 = H$   
 $R_8 = H$   
 $R_{10} = H$   
 $R_5 = H$   
 $R_4 = \text{CH}_3$

L10 ANSWER 5 OF 8 USPATFULL

ACCESSION NUMBER: 76:29138 USPATFULL

TITLE: Anaesthetic steroids of the pregnane and 19-norpregnane

INVENTOR(S): Philipps, Gordon Hanley, Wembley, England  
Lawrence, Robin, Stoke Poges, England  
Newall, Christopher Earle, London, England  
Wright, Michael, Stoke Poges, England  
PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, England (non-U.S. corporation)

NUMBER	DATE
US 3959260	19760525
US 1974-488989	19740716 (5)


PATENT INFORMATION: Continuation of Ser. No. US 1973-356097, filed on 1 May 1973, now Defensive Publication No.

NUMBER	DATE
GB 1972-21145	19720505

PRIORITY INFORMATION: Utility  
DOCUMENT TYPE: Roberts, Elbert L.  
PRIMARY EXAMINER: Bacon & Thomas  
LEGAL REPRESENTATIVE: 22  
NUMBER OF CLAIMS: 1  
EXEMPLARY CLAIM: 1493  
LINE COUNT: 1493  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Steroid anaesthetics of the pregnane and 19-norpregnane series are described, the compounds possessing a 3.alpha.-hydroxy group, a 17.alpha.-hydrogen atom, a 20-oxo group and at the 21-position the residue of a sulphur nucleophile or a sulphone or sulfoxide grouping.  
IT 51086-87-4P 51086-88-5P 51086-89-6P 51086-90-9P 51086-99-8P 51087-12-8P (prepn. of)  
RN 51086-87-4 USPATFULL  
CN Pregnane-11,20-dione, 21-(benzoylthio)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 5 OF 8 USPATFULL (Continued)



RN 51086-88-5 USPATFULL  
CN Pregnane-11,20-dione, 3-hydroxy-21-[(2-iodobenzoyl)thio]-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51086-89-6 USPATFULL  
CN Pregnane-11,20-dione, 3-hydroxy-21-[(2-nitrobenzoyl)thio]-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 5 OF 8 USPATFULL (Continued)




RN 51087-12-8 USPATFULL  
CN Pregnane-11,20-dione, 3-hydroxy-21-[(phenylmethyl)thio]-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L10 ANSWER 5 OF 8 USPATFULL (Continued)



RN 51086-90-9 USPATFULL  
CN Pregnane-11,20-dione, 21-[[2-(ethoxycarbonyl)benzoyl]thio]-3-hydroxy-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51086-99-8 USPATFULL  
CN Pregnane-11,20-dione, 3-hydroxy-21-[(2-methylthio)benzoyl]thio]-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 6 OF 8 USPATFULL

ACCESSION NUMBER: 75:25277 USPATFULL  
TITLE: Novel 3.alpha.-hydroxysteroids of the  
5.alpha.-pregnane series  
INVENTOR(S): Philipps, Gordon Hanley, Wembley, England  
Newall, Christopher Earle, Acton, England  
Cook, Martin Christopher, Chalfont St. Peter,  
England  
PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, Middlesex,  
England (non-U.S. corporation)

NUMBER	DATE
US 3883569	19750513
US 3883569	19711216 (5)

NUMBER	DATE
GB 1970-60066	19701217

PRIORITY INFORMATION: GB 1970-60066 19701217  
DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Roberts, Eibert L.  
LEGAL REPRESENTATIVE: Bacon & Thomas  
NUMBER OF CLAIMS: 12  
EXEMPLARY CLAIM: 1  
LINE COUNT: 845

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Steroids of the 5.alpha.-pregnane series possessing a 3.alpha.-hydroxy group, a 10-hydrogen atom or methyl group, an 11-oxo group, a 17.alpha.-hydrogen atom, a 20-oxo group, and a group of the formula -XR at the 21-position wherein -XR represents --OCOR, --OOCOR, --CCOSR or --OCONHR and R represents (a) a solubilising group containing a basic nitrogen atom, (b) a nitrobenzyl group (c) a lower alkyl group (when X is not --OCO--) or (d) a halogenoalkyl group.

The steroids possess anaesthetic properties.

IT 38392-70-08 38392-71-1P


(prepn. of)

RN 38392-70-0 USPATFULL

CN Pregnane-11,20-dione, 3-hydroxy-21-[[4-(nitrophenyl)acetyl]oxy]-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 6 OF 8 USPATFULL (Continued)




RN 38392-71-1 USPATFULL  
 CN Pregnane-11,20-dione, 21-[(4-aminophenyl)acetyl]oxy-3-hydroxy-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L10 ANSWER 7 OF 8 USPATFULL (Continued)



RN 38601-47-7 USPATFULL  
 CN Pregnane-11,20-dione, 3-hydroxy-21-(phenylmethoxy)-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 7 OF 8 USPATFULL

ACCESSION NUMBER: 75:23860 USPATFULL  
 TITLE: Chemical compounds  
 INVENTOR(S): Philipps, Gordon Hanley, Wembley, England  
 Newall, Christopher Earle, London, England  
 PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, Middlesex,  
 England (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3882151	19750506
APPLICATION INFO.:	GB 1971-208961	19711216 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1970-60065	19701217
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	Bacon & Thomas	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1258	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides 3.alpha.-oxygenated pregnane 21-ethers possessing a hydroxy group in the 3.alpha.-position; a hydrogen atom or a methyl group at the 10-position; a hydrogen atom in the 17.alpha.-position; a keto group in the 20-position; and an etherified hydroxyl group in the 21-position.

IT 38601-34-2P 38601-47-7P  
 (prepn. of)

RN 38601-34-2 USPATFULL  
 CN Pregnane-11,20-dione, 21-(4-aminophenoxy)-3-hydroxy-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 8 OF 8 USPATFULL

ACCESSION NUMBER: 72:39193 USPATFULL  
 TITLE: PROCESS FOR PREPARING 17.alpha.-HYDROXY-20-KETO AND 17.alpha.,21-DIHYDROXY-20-KETO PREGNANES AND DERIVATIVES AND INTERMEDIATES THEREOF  
 INVENTOR(S): Crabbe, Pierre, Mexico City, Mexico  
 Velarde, Esperanza, Mexico City, Mexico  
 PATENT ASSIGNEE(S): Syntex Corporation, Panama, Panama

	NUMBER	DATE
PATENT INFORMATION:	US 3681410	19720801
APPLICATION INFO.:	US 1970-62201	19700807 (5)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1969-854742, filed	

DOCUMENT TYPE: on 2 Sep 1969, now abandoned  
 Utility  
 PRIMARY EXAMINER: Gotta, Lewis  
 ASSISTANT EXAMINER: Love, Ethel G.  
 LEGAL REPRESENTATIVE: Merker, Evelyn K.  
 NUMBER OF CLAIMS: 25  
 LINE COUNT: 1282

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB New processes for preparing 17.alpha.-hydroxy-20-keto and 17.alpha.,21-dihydroxy-20-keto pregnanes and derivatives thereof, which compounds are useful as progestational and anti-inflammatory agents. The processes utilize the steps of converting a 17.alpha.-ethynyl-17.beta.-acetoxy steroid to the corresponding 17-vinylidene steroid with zinc in an ethylene glycol ether and oxidizing the 17-vinylidene steroid to form the corresponding product pregnanes. The novel 17-vinylidene compounds are useful as intermediates as herein described and are also useful anti-androgenic agents.

IT 33458-61-8P 36025-59-9P  
 (prepn. of)

RN 35458-61-8 USPATFULL  
 CN Pregnane-20-one, 3-(acetoxy)-21-[(3-chlorobenzoyl)oxy]-17-hydroxy-,  
 (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 8 OF 8 USPATFULL (Continued)




RN 36025-59-9 USPATFULL

CH Pregnan-20-one,

21-[(3-chlorobenzoyl)oxy]-3,17-dihydroxy-6,16-dimethyl-,  
(3.beta.,5.alpha.,6.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





=> d ibib ab hitstr 1-22


L11 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 1999:450892 CAPLUS  
 DOCUMENT NUMBER: 131:102428  
 TITLE: Preparation of neuroactive steroids of the androstane and pregnane series  
 INVENTOR(S): Upasani, Ravindra B.; Fick, David B.; Hogenkamp, Derk  
 J.; Lan, Nancy C.  
 PATENT ASSIGNEE(S): Cocosys, Inc., USA  
 SOURCE: U.S., 28 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5925630	A	19990720	US 1996-659192	19960606
CA 2223996	AA	19961219	CA 1996-2223996	19960606
CN 1190404	A	19980812	CN 1996-195360	19960606
			US 1995-467404	19950606

PRIORITY APPL. INFO.: MARPAT 131:102428  
 OTHER SOURCE(S):  
 AB Neuroactive steroids of formula I [R = H, NH<sub>2</sub>, thio, sulfinyl, sulfonyl, halo, alkoxy, alkyl, alkenyl, alkynyl, etc.; R<sub>1</sub> = H, alkyl, alkenyl, alkynyl, haloalkyl, aryl, etc.; R<sub>2</sub> = H, alkoxy, keto, Me<sub>2</sub>N; R<sub>3</sub> = alkoxy, alkenyloxy, alkynyloxy; R<sub>4</sub> = H, Me; R<sub>5</sub> = H, absent; R<sub>6</sub> = H, alkanoyl, etc.; R<sub>7</sub> = H, halo, OH, alkoxy, etc.; R<sub>8</sub> = H, halo; R<sub>9</sub> = H, halo, alkyl, alkoxy, arylalkoxy, amino; R<sub>10</sub> = H, halo, alkyl, OH, alkoxy, CN, etc.] are prepd. These derivs. are capable of acting at a recently identified site on the GABA receptor complex (GRC), thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. Thus, 2-methyl-1-buten-3-yne was added to 17 $\beta$ -methyl-5 $\beta$ -androstane-3-one to give II. II protected 87.5% of mice injected with metrazol from convulsions.  
 IT 186264-62-0P 186264-76-6P  
 RL: BAC (Biological activity or effector, except adverse); ACT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of neuroactive steroids of androstane and pregnane series)  
 RN 186264-62-0 CAPLUS


L11 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)  
 (Preparation); USES (Uses)  
 (prepn. of neuroactive steroids of androstane and pregnane series)  
 RN 186264-31-3 CAPLUS  
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[(4-nitrophenyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-33-5 CAPLUS  
 CN Pregnan-20-one, 21-[(4-fluorophenyl)thio]-3-hydroxy-3-(methoxymethyl)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 186264-64-2 CAPLUS  
 CN Pregnan-20-one, 21-[(4-(dimethylamino)phenoxy)-3-hydroxy-3-methyl]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)  
 CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(4-nitrophenyl)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-76-6 CAPLUS  
 CN Pregnan-20-one, 21-[(4-fluorophenyl)sulfonyl]-3-hydroxy-3-(methoxymethyl)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 186264-31-3P 186264-33-5P 186264-64-2P  
 186264-65-3P 186264-66-4P 186264-67-5P  
 186264-81-3P 186264-82-4P  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

L11 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)

RN 186264-65-3 CAPLUS  
 CN Pregnan-20-one, 21-[(4-(dimethylamino)phenyl)thio]-3-hydroxy-3-(methoxymethyl)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-66-4 CAPLUS  
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[(4-nitrophenyl)sulfonyl]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 186264-67-5 CAPLUS  
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[[4-(1-pyrrolidinyl)phenyl]sulfonyl]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 186264-81-3 CAPLUS  
 CN Pregnan-20-one, 21-[[4-(aminophenyl)thio]-3-hydroxy-3-(methoxymethyl)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 186264-82-4 CAPLUS  
 CN Benzenaminium, 4-[[[(2.beta.,3.alpha.,5.alpha.)-3-hydroxy-20-oxo-2-propoxypregnan-21-yl]oxy]-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:  
 REFERENCE(S):

81  
 (5) Anon; FR 1437361 1966 CAPLUS  
 (6) Anon; FR 1437361 1966 CAPLUS  
 (7) Anon; DE 2156094 1972 CAPLUS  
 (8) Anon; GB 1380248 1975 CAPLUS  
 (9) Anon; GB 1432135 1976 CAPLUS

L11 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2000 ACS


ACCESSION NUMBER: 1998:741916 CAPLUS  
 DOCUMENT NUMBER: 130:121185  
 TITLE: A method for the determination of steroid 5.alpha.-reductase activity by high-performance liquid chromatography with a fluorescence detector  
 AUTHOR(S): Hayashi, Katsuhiko; Yamakawa, Hidefumi; Koshizaka, Takuya; Suzuki, Takehiko; Kato, Eiichi; Kuno, Masayasu; Ohishi, Nobuko; Yagi, Kunio  
 CORPORATE SOURCE: Institute of Applied Biochemistry, Gifu, 505-0116, Japan  
 SOURCE: J. Clin. Biochem. Nutr. (1998), 24(3), 113-123  
 CODEN: JCBNER; ISSN: 0912-0009  
 PUBLISHER: Institute of Applied Biochemistry  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB A method for the detn. of the activity of steroid 5.alpha.-reductase in rat ventral prostate has been newly developed. It includes the enzyme reaction with cortexolone as a substrate, and the process of derivatization of androgens with fluorescent agent and their sepn. by high-performance liq. chromatog. with fluorescence detection. After the enzyme reaction at 35.degree. and pH 6.6 in the presence of 100 .mu.M NADPH, cortexolone and redn. products (5.alpha.-pregnane-17.alpha.,21-diol-3,20-dione and 5.alpha.-pregnane-3.alpha.,17.alpha.,21-triol-20-one) were derivatized by treatment with 1-anthroyl nitrile. The resulting fluorescent esters of the three compds. were sepd. on an ODS column using 84% (vol./vol.) methanol in water as a mobile phase, and the enzyme activity was estd. from the amts. of the products. The detection limit was 0.2 pmol as an injection amt. of each deriv. The applicability of this method was successfully demonstrated in the measurement of the inhibition of the 5.alpha.-reductase activity by certain steroids.  
 IT 219929-20-19  
 RL: ASG (Analytical reagent use); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses) (derivatization of 5.alpha.-reductase substrate and products)  
 method for detn. of prostate steroid 5.alpha.-reductase activity by HPLC with fluorescence detector and study of inhibition of 5.alpha.-reductase by steroids)  
 RN 219929-20-1 CAPLUS  
 CN Pregnan-20-one, 21-[(1-anthracenylcarbonyl)oxy]-3,17-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

```

L11 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1998:112239 CAPLUS
DOCUMENT NUMBER: 128:186632
TITLE: Use of GABA agonists and NMDA receptor
antagonists for the treatment of migraine headache
INVENTOR(S): Lan, Nancy C.
PATENT ASSIGNER(S): Cogenzyme, Inc., USA; Lan, Nancy C.
SOURCE: PCT Int. Appl., 47 pp.
CODEN: P1XXD2
DOCUMENT TYPE: Patent
LANGUAGES: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

```



18  
(1) Andersson, S; Proc Natl Acad Sci USA 1990,  
P3640 CAPLUS  
(2) Belham, J; Biochim Biophys Acta 1969, V187,  
CAPLUS  
(3) Bruchovsky, N; J Biol Chem 1968, V243, P2012  
CAPLUS  
(4) Frederiksen, D; J Biol Chem 1971, V246, P2584  
CAPLUS  
(5) Goto, J; Anal Chim Acta 1983, V147, P397

ALL CITATIONS AVAILABLE IN THE RE FORMAT

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	WO 9805337	A1	19980212	WO 1997-US3430	19970731
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,			
DE,		DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR,			
KZ,		LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,			
PL,		PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,			
US,		UZ, VN, YU, ZW, AM, AZ, BY, BG, CZ, MD, RU, TJ, TM,			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,			
FR,		GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,			
GA,		GN, ML, MR, NE, SN, TD, TG			
	AU 9739672	A1	19980225	AU 1997-39672	19970731
PRIORITY APPL. INFO.:				US 996-22937	19960801
				WO 1997-US13430	19970731

AB Methods are disclosed for treating or preventing migraine headache by administering to an animal a GABA receptor agonist (e.g. a neuroactive steroid) and/or an NMDA receptor antagonist (e.g. a dihydroquinoline deriv.). Also disclosed are pharmaceutical compns. and kits for the treatment or prevention of migraine headache.

17 Treatment of prevention of magazine headlines:  
186264-31-3 186264-33-5 186264-62-0  
186264-64-2 186264-65-3 186264-66-4  
186264-67-5 186264-76-6 186264-81-3  
186264-82-4 186265-72-5 186265-73-6  
203714-64-1


203714-04-1  
RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(GABA agonists and NMDA receptor antagonists for migraine h  
treatment)

186264-31-3 CAPLUS  
Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[(4-nitrophenyl)thio]-,  
(3.alpha.,.5.alpha.)- (9CI) (CA INDEX NAME)

L11 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)


RN 186264-33-5 CAPLUS  
CN Pregnan-20-one,  
21-[(4-fluorophenyl)thio]-3-hydroxy-3-(methoxymethyl)-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**




RN 186264-62-0 CAPLUS  
CN Pregnan-20-one, 3-hydroxy-3-methyl-21-(4-nitrophenoxy)-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**



RN 186264-64-2 CAPLUS  
CN Pregnan-20-one, 21-[4-(dimethylamino)phenoxy]-3-hydroxy-3-methyl-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


**Absolute stereochemistry.**



RN 186264-65-3 CAPLUS  
CN Pregnan-20-one, 21-[[4-(dimethylamino)phenyl]thio]-3-hydroxy-3-(methoxymethyl)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


### Absolute stereochemistry.

L11 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 186264-66-4 CAPLUS  
 CN Pregnan-20-one,  
 3-hydroxy-3-(methoxymethyl)-21-[(4-nitrophenyl)sulfonyl]-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-67-5 CAPLUS  
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[(4-(1-pyrrolidinyl)phenyl)sulfonyl]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 186264-82-4 CAPLUS  
 CN Benzenaminium, 4-[[[(2.beta.,3.alpha.,5.alpha.)-3-hydroxy-20-oxo-2-propoxy]pregnan-21-yl]oxy]-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186265-72-5 CAPLUS  
 CN Pregnan-20-one,  
 3-hydroxy-3-(methoxymethyl)-21-[(4-nitrophenyl)sulfonyl]-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 186264-76-6 CAPLUS  
 CN Pregnan-20-one,  
 21-[(4-fluorophenyl)sulfonyl]-3-hydroxy-3-(methoxymethyl)-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-81-3 CAPLUS  
 CN Pregnan-20-one, 21-[(4-aminophenyl)thio]-3-hydroxy-3-(methoxymethyl)-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 186265-73-6 CAPLUS  
 CN Benzenaminium,  
 4-[[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 203714-64-1 CAPLUS  
 CN Pregnan-20-one, 21-[(4-(dimethylamino)phenoxy]-3-hydroxy-2-propoxy-,  
 (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



L11 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)  
 amino; R10 = H, halogen, OH, alkyl, etc.] are prep. as neuroactive prodrugs, due to their ability to modulate the GABA<sub>A</sub> receptor-chloride ionophore complex. These derivs. are capable of acting at a recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. Thus, 2-methyl-1-buten-3-yl was added to 17.beta.-methoxy-5.beta.-androstane-3-one to give II. FI (10 mg/kg IP) protected 87.5% of mice injected with metrazol from convulsions.  
 IT 186264-31-3P 186264-62-0P 186264-76-6P  
 RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of neuroactive androstanes and pregnanes)  
 RN 186264-31-3 CAPLUS  
 CN Pregnane-20-one, 3-hydroxy-3-(methoxymethyl)-21-[(4-nitrophenyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-62-0 CAPLUS  
 CN Pregnane-20-one, 3-hydroxy-3-methyl-21-[(4-nitrophenyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1997:113460 CAPLUS  
 DOCUMENT NUMBER: 126:131695  
 TITLE: Preparation of neuroactive steroids of the androstane and pregnane series  
 INVENTOR(S): Upasani, Ravindra B.; Fick, David B.; Hogenkamp, Dert  
 J.; Lan, Nancy C.  
 PATENT ASSIGNEE(S): Cocensys, Inc., USA  
 SOURCE: PCT Int. Appl., 94 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640043	A2	19961219	WO 1996-US10115	19960606
WO 9640043	A3	19970327		
W: AL, AM, AT, AU, AZ, BE, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, RW: KE, LS, MW, SD, SZ, UC, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, CA 2223996 AA 19961219 CA 1996-2223996 19960606 AU 9661725 A1 19961230 AU 1996-61725 19960606 EP 837874 A2 19980429 EP 1996-919372 19960606 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, SI, LT, LV, FI, CN 1198404 A 19980812 CN 1996-195360 19960606 BR 9608592 A 19990629 BR 1996-8592 19960606 JP 11507643 T2 19990706 JP 1996-502210 19960606 NO 9705608 A 19980206 NO 1997-5608 19971204 FI 9704448 A 19971205 FI 1997-4448 19971205 US 1995-467404 19950606 WO 1996-US10115 19960606				


PRIORITY APPLN. INFO.:  
 OTHER SOURCE(S): MARPAT 126:131695  
 AB Comps. of formula I [R = H, NH<sub>2</sub>, thio, sulfinyl, sulfonyl, halogen, alkoxy, alkyl, etc.; R1 = H, alkyl, alkenyl, alkynyl, aryl, etc.; R2 = H, OH, alkoxy, alkanoyloxy, carbalkoxy, keto, amino; R3 = H, alkoxy, alkenyloxy, etc.; R4 = H, alkyl; R5 = H, absent; R6 = H, alkanoyl, aminocarbonyl, alkoxy-carbonyl; R7 = H, halogen, OH, alkoxy, alkanoyloxy, carbalkoxy; R8 = H, halogen; R9 = H, halogen, alkyl, alkoxy, arylalkoxy,

L11 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)




RN 186264-76-6 CAPLUS  
 CN Pregnane-20-one, 21-[(4-fluorophenyl)sulfonyl]-3-hydroxy-3-(methoxymethyl)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 186264-29-9P 186264-33-5P 186264-64-2P  
 186264-65-3P 186264-66-4P 186264-67-5P  
 186264-81-3P 186264-82-4P 186265-72-5P  
 186265-73-6P  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of neuroactive androstanes and pregnanes)  
 RN 186264-29-9 CAPLUS  
 CN Pregnane-20-one, 21-[(4-aminophenyl)thio]-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

L11 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)  
Absolute stereochemistry.



RN 186264-33-5 CAPLUS  
CN Pregnan-20-one,  
21-[(4-aminophenyl)thio]-3-hydroxy-3-(methoxymethyl)-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-64-2 CAPLUS  
CN Pregnan-20-one, 21-[(4-(dimethylamino)phenoxy)-3-hydroxy-3-methyl-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 186264-67-5 CAPLUS  
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[[4-(1-pyrrolidinyl)phenyl]sulfonyl]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-81-3 CAPLUS  
CN Pregnan-20-one, 21-[(4-aminophenyl)thio]-3-hydroxy-3-(methoxymethyl)-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 186264-65-3 CAPLUS  
CN Pregnan-20-one, 21-[(4-(dimethylamino)phenyl)thio]-3-hydroxy-3-(methoxymethyl)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-66-4 CAPLUS  
CN Pregnan-20-one,  
3-hydroxy-3-(methoxymethyl)-21-[(4-nitrophenyl)sulfonyl]-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 186264-82-4 CAPLUS  
CN Benzenaminium, 4-[[[(2.beta.,3.alpha.,5.alpha.)-3-hydroxy-20-oxo-2-propoxy]pregnan-21-yl]oxy]-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186265-72-5 CAPLUS  
CN Pregnan-20-one,  
3-hydroxy-3-(methoxymethyl)-21-[(4-nitrophenyl)sulfonyl]-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)




RN 196265-73-6 CAPLUS

CN Benzenaminium

4-[[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● I<sup>-</sup>

L11 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1995:858705 CAPLUS

DOCUMENT NUMBER: 123:266118

TITLE: Codrugs as a method of controlled drug delivery

INVENTOR(S): Ashton, Paul; Crooks, Peter Anthony; Riggs, Robert

PATENT ASSIGNEE(S): Mack; Cynkowski, Tadeusz; Cynkowska, Grazyna

SOURCE: University of Kentucky Research Foundation, USA

PCT Int. Appl., 57 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9520567	A1	19950803	WO 1994-US1659	19940217
W: AU, CA, JP				
RV: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2182228	AA	19950803	CA 1994-2182228	19940217
AU 9462545	A1	19950815	AU 1994-62545	19940217
AU 705226	B2	19990520		
EP 740650	A1	19961106	EP 1994-909643	19940217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09509151	T2	19970916	JP 1994-520023	19940217
US 6051576	A	20000418	US 1997-791071	19970129
PRIORITY APPLN. INFO.:				
			US 1994-187462	19940128
			WO 1994-US1659	19940217
			US 1995-388855	19950215

AB A codrug compn. of at least two drug compds. covalently linked to one another via a labile bond to form a single codrug compn., and methods of

use of the codrug for the treatment of various medical conditions are disclosed. The codrug may be administered by itself or as a

bioerodible or nonbioerodible dosage form, such as injection, liposome, suspension, microsphere, nanoparticle, ointment, transdermal patch, etc.

IT 169047-14-7P 169047-15-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(codrug compns. for controlled drug delivery)

RN 169047-14-7 CAPLUS

CN Pregnan-20-one, 21-[2-(2-fluoro[1,1'-biphenyl]-4-yl)-1-oxopropoxy]-17-hydroxy-3-(phenylmethoxy)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1996:616744 CAPLUS

DOCUMENT NUMBER: 126:8374

TITLE: The Total Synthesis of a Natural Cardenolide:

(+)-Digitoxigenin

AUTHOR(S): Stork, Gilbert; West, Fred; Lee, Hee Yoon; Isaacs,

Richard C. A.; Manabe, Shino

CORPORATE SOURCE: Department of Chemistry, Columbia University, New

York, NY, 10027, USA

SOURCE: J. Am. Chem. Soc. (1996), 118(43), 10660-10661

CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 126:8374

AB The authors report the total synthesis of natural (+)-digitoxigenin

(I), the biol. active cardenolide which, as its trisaccharide deriv.

digitoxin,

is one of the most frequently used of the active principles isolated

from Digitalis species. I was prepd. from chiral decalone II via

octahydrophenanthrenone III (TBS = Me<sub>3</sub>CSiMe<sub>2</sub>) and steroidal aldehyde

IV.

IT 183615-75-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(total synthesis of (+)-digitoxigenin from (S)-Wieland-Miescher

ketone)


RN 183615-75-0 CAPLUS

CN Pregnan-20-one,


3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-14-hydroxy-21-

(phenylmethoxy)-, (3.beta.,5.beta.,14.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L11 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)




RN 169047-15-8 CAPLUS

CN Pregnan-20-one,

3-[[[(chlorocarbonyl)oxy]-21-[2-(2-fluoro[1,1'-biphenyl]-4-yl)-1-oxopropoxy]-17-hydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 169047-11-4P 169047-12-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL

(Biological

study); PREP (Preparation); USES (Uses)

(codrug compns. for controlled drug delivery)

RN 169047-11-4 CAPLUS

CN Pregnan-20-one,

21-[2-(2-fluoro[1,1'-biphenyl]-4-yl)-1-oxopropoxy]-3-[[[(5-


fluoro-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)methoxy]carbonyl]oxy]-17-hydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)




L11 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 169047-12-5 CAPLUS


CN Pregnan-20-one,

21-(2-(2-fluoro[1,1'-biphenyl]-4-yl)-1-oxopropoxy)-3-[[5-

fluoro-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]carbonyloxy]-17-hydroxy-,  
(3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



L11 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1991:185851 CAPLUS

DOCUMENT NUMBER: 114:185851

TITLE: Preparation and formulation of pregnane

derivatives as

antiangiogenesis agents

INVENTOR(S): Aristoff, Paul A.; Skulnick, Harvey I.; Wierenga,

Wendell

PATENT ASSIGNEE(S): Upjohn Co., USA

SOURCE: U.S., 17 pp. Cont.-in-part of U.S. Ser. No.

87,228,

abandoned.

DOCUMENT TYPE: CODEN: USXOAM

LANGUAGE: Patent

FAMILY ACC. NUM. COUNT: 2 English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4975537	A	19901204	US 1989-351977	19890515
PRIORITY APPL. INFO.:				
			US 1985-790564	19851023
			US 1985-811866	19851220
			US 1987-87228	19870619

OTHER SOURCE(S): MARPAT 114:185851

AB Title steroids I [R1 = .beta.-Me, .beta.-Et; R2 = H and R3 = O, OH, alkoxy, alkanoyloxy, (un)substituted aryloxy, aralkanyloxy, heteroaryloxy, carbanoyloxy, aryloxy, carbonyloxy, alkoxy, carbonyloxy,

R2 = .alpha.-Cl, R3 = .beta.-Cl; R2R3 = O, bond; R2 = .alpha.-F, R3 = .beta.-OH; R4 = H, Me, Cl, F; R5 = H, OH, F, Cl, Br, Me, Ph, CH2CH2, CH2CH2; R6 = H, Me; R9 = H, OH, Me, F, CH2; R10 = H, OH, Me; R9R10 =

bond; R12 = H; R13 = OH, O, OP(O)(OH)2, O2C(CH2)nCO2H; n = 2-6; R14 =

H; R12R14 = bond; R15 = O, H(OH); R23 = OH or various derivs.; R10R23 = .alpha.-OP(O)(OH)2; various specific provisos and excluded compds.]

are

prepd. as antiangiogenic agents. Dropwise addn. of 0.68 mL distd. pyrophosphoryl chloride to 1.65 g

6.alpha.-fluoro-17,21-dihydroxy-16.beta.-

methyl-3,20-dioxopregna-4,9(11)-diene in THF at -35.degree. gave

91.5% of the corresponding 21-phosphate deriv. (II). At 50 .mu.g./10 .mu.L

polymeric vehicle in chick embryos and in the presence of a similar

amt. of heparin, II inhibited angiogenesis by 58% of control. An

injectable soln. contained 155 mg II.2Na and dil. NaOH (to pH 5.3) in sterile

H2O to 1 mL.

IT 111245-66-OP

RL: FORM (Formation, nonpreparative); SPN (Synthetic preparation);

PREP (Preparation)

(formation of, in prepn. of antiangiogenesis agents)


RN 111245-66-0 CAPLUS

L11 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)

CN Pregn-9(11)-en-20-one,

21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-,  
(3.alpha.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 111245-67-1P 133442-74-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)


(prepn. and reaction of, in prepn. of antiangiogenesis agents)

RN 111245-67-1 CAPLUS

CN Pregn-9(11)-en-20-one,

21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-,  
(3.beta.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 133442-74-7 CAPLUS

CN Pregn-9(11)-en-20-one,

21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-,  
(5.alpha.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



L11 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1987:617933 CAPLUS  
 DOCUMENT NUMBER: 107:217933  
 TITLE: Pregnane derivatives as angiostatic agents, their pharmaceutical formulations, and processes for their preparation  
 INVENTOR(S): Aristoff, Paul A.; Skulnick, Harvey I.; Wierenga, Wendell  
 PATENT ASSIGNEE(S): Upjohn Co., USA  
 SOURCE: PCT Int. Appl., 53 pp.  
 CODEN: PIXX02  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8702672	A1	19870507	WO 1986-US2189	19861016
JP 221705	A1	19870513	EP 1986-308031	19861016
EP 245357	A1	19871119	EP 1986-906631	19861016
EP 245357	B1	19910807		
JP 63501292	T2	19880519	JP 1986-505818	19861016
JP 2545522	B2	19961023		
AT 66002	E	19910815	AT 1986-906631	19861016
ES 2041245	T3	19931116	ES 1986-906631	19861016
			US 1985-790564	19851023
			US 1985-811866	19851220
			EP 1986-906631	19861016
			WO 1986-US2189	19861016

PRIORITY APPLW. INFO.:  
 AB Title steroids I (R1 = .beta.-Me, .beta.-Et; R2 = H and R3 = O, OH, alkoxy, alkanyloxy, (un)substituted acyloxy, aralkanyloxy, heteroacyloxy, carbamoyloxy, aryloxy, carbonyloxy, alkoxy, carbonyloxy; R2 = .alpha.-Cl, R3 = .beta.-Cl; R2R3 = O, bond; R2 = .alpha.-F, R3 = .beta.-OH; R4 = H, Me, Cl, F; R5 = H, OH, F, Cl, Br, Me, Ph, CH2CH2, CH2CH:CH2; R6 = H, Me; R9 = H, OH, Me, F, CH2; R10 = H, OH, Me; R9R10 = bond; R12 = H; R13 = OH, O, OP(O)(OH)2, O2C(CH2)nCO2H; n = 2-6; R14 = H; R12R14 = bond; R15 = O, H(OH); R23 = OH or various derivs.; R10R23 = .alpha.-OP(O)(OH)O; various specific provisos and excluded compounds.)  
 are prepd. as antiangiogenic agents. Dropwise addn. of 0.68 ml. distd. pyrophosphoryl chloride to 1.65 g 6.alpha.-fluoro-17,21-dihydroxy-16.beta.-methyl-3,20-dioxopregna-4,9(11)-diene in THF at -35.degree. gave 91.5% of

L11 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)  
 the corresponding 21-phosphate deriv. (II). At 50 .mu.g./ml 0.1 .mu.L polymeric vehicle in chick embryos and in the presence of a similar

amt. of heparin, II inhibited angiogenesis by 58% of control. An injectable soln. contained 155 mg II.2Na and dil. NaOH (to pH 5.3) in sterile H2O to 1 mL.


IT 111245-66-OP 111245-67-1P 111245-68-2P  
 111245-69-3P

RI: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as antiangiogenic agent)

RN 111245-66-0 CAPLUS

CN Pregn-9(11)-en-20-one,  
 21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-,  
 (3.alpha.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 111245-67-1 CAPLUS  
 CN Pregn-9(11)-en-20-one,  
 21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-,  
 (3.beta.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 111245-68-2 CAPLUS  
 CN Pregn-9(11)-en-20-one,  
 21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-,  
 (3.alpha.,5.alpha.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 111245-69-3 CAPLUS  
 CN Pregn-9(11)-en-20-one,  
 21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-,  
 (3.beta.,5.alpha.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 1972:502035 CAPLUS  
 DOCUMENT NUMBER: 77:102035  
 TITLE: 3.alpha.-Hydroxy-5.alpha.-pregnane-11,20-diones  
 INVENTOR(S): Philipps, Gordon Hanley; Newall, Christopher  
 Earle;  
 PATENT ASSIGNEE(S): Cook, Martin Christopher  
 Glaxo Laboratories Ltd.  
 SOURCE: Ger. Offen., 35 pp.  
 CODEN: GWCKBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2162592	A	19720706	DE 1971-2162592	19711216
BE 776787	A1	19720616	BE 1971-111747	19711216
NL 7117250	A	19720620	NL 1971-17250	19711216
FR 2118119	A5	19720728	FR 1971-45227	19711216
FR 2118119	B1	19751128		
AU 7136960	A1	19730621	AU 1971-36960	19711216
US 383569	A	19750513	US 1971-208985	19711216
CA 979885	A1	19751216	CA 1971-130274	19711216
ZA 7108464	A	19730829	ZA 1971-8464	19711217
			GB 1970-60066	19701217

PRIORITY APPL. INFO.:  
 AB Sixteen 3.alpha.-hydroxy-11,20-dioxo-5.alpha.-pregnan-21-yl esters  
 (I, R =  
 H, MeO; R1 = O2CH2C6H4NH2-p, nicotinoyloxy, O2CH2C1, O2CH2I,  
 O2CH2NMe2, morpholinoacetoxy, 4-methyl-1-piperazinylacetoxy, OCO2Et,  
 O2CH2NH2, O2CH2NMe2, O2CH2C6H4NO2-p) were prepd. by bromination of  
 I (R  
 = H, MeO; R = H) at the 21 position followed by reaction with the  
 corresponding acid. Thus, I (R = R1 = H) in MeOH was treated with Br  
 in  
 the presence of AcCl to give I (R = H, R1 = Br), which reacted with  
 p-O2NC6H4CH2CO2H to give I (R = H, R1 = O2CH2C6H4NO2-p).  
 IT 38392-70-0P 38392-71-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 38392-70-0 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(4-nitrophenyl)acetyl]oxy]-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 38392-71-1 CAPLUS  
 CN Pregnane-11,20-dione, 21-[(4-aminophenyl)acetyl]oxy]-3-hydroxy-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 1972:141212 CAPLUS  
 DOCUMENT NUMBER: 76:141212  
 TITLE: Intermediates and process for preparing  
 progestational  
 and antiinflammatory 17.alpha.-hydroxy- and  
 17.alpha.,21-dihydroxy-20-oxo pregnanes and their  
 derivatives  
 INVENTOR(S): Fried, John H.  
 PATENT ASSIGNEE(S): Syntex Corp.  
 SOURCE: U.S., 11 pp.  
 CODEN: USXOAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3637670	A	19720125	US 1969-854746	19690902

AB The title pregnanes were prepd. by treating 17-oxoandrostanes with  
 Ph3P:CH2 (I), converting the 17-methyleneandrostanes obtained to  
 17-spiroandrostanes with a dihalocarbene, converting these to  
 17-vinylidene-androstanes, and oxidizing the latter. Thus,  
 5.alpha.-androstane-3.beta.-ol-17-one [II, R = H, (R1R2) = O] with I in  
 C6H6-Me2SO 14 hr at 85.degree. gave II [R = H, (R1R2) = CH2], which on  
 refluxing with CHBr3-KOCMe3 in Me3COH-C6H6 gave II [R = H, (R1R2) =  
 CBr2CH2]. This was treated with BuLi in Et2O at -10.degree. to give  
 II [R  
 = H, (R1R2) = C:CH2], which was acetylated to give II [R = Ac, (R1R2)  
 =  
 C:CH2] (III). III was oxidized with OsO4 in pyridine 10 days at room  
 temp. to give II [R = Ac, R1 = OH, R2 = HOCH2CO].  
 IT 35458-61-8P 36025-59-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 35458-61-8 CAPLUS  
 CN Pregnan-20-one, 3-(acetyloxy)-21-[(3-chlorobenzoyl)oxy]-17-hydroxy-,  
 (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L11 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)

RN 36025-59-9 CAPLUS  
 CN Pregnan-20-one,  
 21-[(3-chlorobenzoyl)oxy]-3,17-dihydroxy-6,16-dimethyl-,  
 (3.beta.,5.alpha.,6.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L11 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 1972:46378 CAPLUS  
 DOCUMENT NUMBER: 76:46378  
 TITLE: Two-step synthesis of the pregnane and corticoid sidechains  
 AUTHOR(S): Biollaz, M.; Haefliger, W.; Velarde, E.; Crabbe, P.;  
 Fried, J. H.  
 CORPORATE SOURCE: Res. Lab., Syntex, S. A., Mexico D. F., Mex.  
 SOURCE: J. Chem. Soc. D. (1971), (21), 1322-3  
 CODEN: CCJDAO  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB 17.alpha.-Ethynyl-3.beta.,17.beta.-diacetoxy-5.alpha.-androstane was reduced with Zn dust in refluxing anhyd. diglyme to give 86% the allene  
 (I). I reacted with OsO<sub>4</sub>-pyridine in benzene, followed by cleavage of the osmate ester (Na<sub>2</sub>SO<sub>3</sub>-K<sub>2</sub>CO<sub>3</sub>), to give 53% 17.alpha.,21-diol (II). I reacted with excess m-chloroperbenzoic acid in CHCl<sub>3</sub> buffered with Na<sub>2</sub>HPO<sub>4</sub> to give a pregnane-3.beta.,17.alpha.-diol on hydrolysis.  
 IT 35458-61-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)  
 RW 35458-61-8 CAPLUS  
 CN Pregnane-20-one, 3-(acetyloxy)-21-[(3-chlorobenzoyl)oxy]-17-hydroxy-, (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.



L11 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)  
 CA 1037026 A2 19780822 CA 1975-217940 19750115  
 PRIORITY APPLN. INFO.: GB 1969-31371 19690620  
 US 1970-47163 19700617  
 CA 1970-85973 19700619  
 DK 1970-3179 19700619  
 CH 1970-9417 19700622  
 AB 3.beta.-Acetoxy-5.alpha.-pregn-16-ene-11,20-dione in dioxane and aq. KOH was kept 1 hr at room temp. and heated 1 hr at 40.degree. to give 3.beta.-hydroxy-5.alpha.-pregn-16-ene-11,20-dione. This in dry C<sub>5</sub>H<sub>5</sub>N was treated with p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>Cl to give the 3.beta.-p-toluenesulfonate. This in aq. DMF heated 2.5 hr at 115.degree. with KOAc and worked up gave 3.alpha.-hydroxy-5.alpha.-pregn-16-ene-11,20-dione, hydrogenated over 5% Pd-C to give 3.alpha.-hydroxy-5.alpha.-pregnane-11,20-dione. Many other examples, and compns. for use, were given.  
 IT 32226-13-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)  
 RW 32226-13-4 CAPLUS  
 CN Pregnane-11,20-dione, 21-(benzoyloxy)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.



L11 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 1971:464114 CAPLUS  
 DOCUMENT NUMBER: 75:64114  
 TITLE: Anesthetic pharmaceutical preparations containing 3.alpha.-hydroxy-5.alpha.-pregnane-11,20-dione  
 INVENTOR(S): Davis, Benjamin; Pearce, Derek R.; Cook, Martin  
 Christopher; Weir, Niall G.; Nevall, Christopher  
 E.: Ayres, Barry E.; Gregory, Gordon I.; Philipp, Gordon  
 H.: Glaxo Laboratories Ltd.  
 SOURCE: S. African, 57 pp.  
 CODEN: SFXKAB  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ZA 7003861	A	19710224	ZA 1970-3861	19700608
GB 1317184	A	19730516	GB 1969-31371	19690620
BR 6915173	A0	19730208	BR 1969-215173	19691215
IL 34713	A1	19750625	IL 1970-34713	19700612
US 3714352	A	19730130	US 1970-47163	19700617
BE 752165	A	19701218	BE 1970-752165	19700618
SE 406038	C	19790510	SE 1970-8517	19700618
SE 406038	B	19790122		
NL 7009002	A	19701222	NL 1970-9002	19700619
NL 169480	B	19820216		
NL 169480	C	19820716		
FR 2052999	A1	19710416	FR 1970-22783	19700619
FR 2052999	A5	19710416		
FR 2052998	A1	19710416	FR 1970-22782	19700619
FR 2052998	A5	19710416		
DE 2065332	A1	19730405	DE 1970-2065332	19700619
ES 380943	A1	19730701	ES 1970-380943	19700619
DE 2065513	A1	19740404	DE 1970-2065513	19700619
AT 315375	B	19740527	AT 1970-5555	19700619
DK 129390	B	19741007	DK 1970-3179	19700619
NO 133716	B	19760308	NO 1970-2396	19700619
CA 1001073	A1	19761207	CA 1970-85973	19700619
JP 48043905	B4	19731221	JP 1970-53223	19700620
CH 578016	A	19760730	CH 1975-2408	19700622
CH 591517	A	19770930	CH 1970-9417	19700622
US 3763195	A	19731002	US 1971-114036	19710209
US 3816624	A	19740611	US 1971-208922	19711216
DK 134996	B	19770221	DK 1971-6420	19711229
AT 7207108	A	19750315	AT 1972-7108	19720817
JP 51040135	B4	19761101	JP 1972-93152	19720916
US 3781435	A	19731225	US 1973-321274	19730105
SE 401512	B	19780516	SE 1974-2197	19740219

L11 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 1971:420793 CAPLUS  
 DOCUMENT NUMBER: 75:20793  
 TITLE: Anesthetic steroidal compositions  
 INVENTOR(S): Davis, Benjamin; Pearce, Derek R.; Cook, Martin  
 Christopher; Weir, Niall G.; Ayres, Barry E.;  
 Gregory, Gordon I.; Philipps, Gordon Hanley  
 Glaxo Laboratories Ltd.  
 SOURCE: Ger. Offen., 53 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2030402	A	19710121	DE 1970-2030402	19700619
DE 2030402	B2	19750430		
DE 2030402	C3	19751211		
GB 1317184	A	19730516	GB 1969-31371	19690620
BR 6915173	A0	19730208	BR 1969-215173	19691215
IL 34713	A1	19750625	IL 1970-34713	19700612
US 3714352	A	19730130	US 1970-47163	19700617
BE 752165	A	19701218	BE 1970-752165	19700618
SE 406038	C	19790510	SE 1970-8517	19700618
SE 406038	B	19790122		
NL 7009002	A	19701222	NL 1970-9002	19700619
NL 169480	B	19820216		
NL 169480	C	19820716		
FR 2052999	A1	19710416	FR 1970-22783	19700619
FR 2052999	A5	19710416		
FR 2052998	A1	19710416	FR 1970-22782	19700619
FR 2052998	A5	19710416		
DE 2065332	A1	19730405	DE 1970-2065332	19700619
ES 380943	A1	19730701	ES 1970-380943	19700619
DE 2065513	A1	19740404	DE 1970-2065513	19700619
AT 315375	B	19740527	AT 1970-5555	19700619
DK 129390	B	19741007	DK 1970-3179	19700619
NO 133716	B	19760308	NO 1970-2396	19700619
CA 1001073	A1	19761207	CA 1970-85973	19700619
JP 48043905	B4	19731221	JP 1970-53223	19700620
CH 578016	A	19760730	CH 1975-2408	19700622
CH 591517	A	19770930	CH 1970-9417	19700622
US 3763195	A	19731002	US 1971-114036	19710209
US 3816624	A	19740611	US 1971-208922	19711216
DK 134996	B	19770221	DK 1971-6420	19711229
AT 7207108	A	19750315	AT 1972-7108	19720817
JP 51040135	B4	19761101	JP 1972-93152	19720916
US 3781435	A	19731225	US 1973-321274	19730105
SE 401512	B	19780516	SE 1974-2197	19740219
CA 1037026	A2	19780822	CA 1975-217940	19750115
PRIORITY APPLN. INFO.:			GB 1969-31371	19690620
			US 1970-47163	19700617
			CA 1970-85973	19700619
			DK 1970-3179	19700619

L11 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)  
CH 1970-9417 19700622

L11 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)

AB Aq. solns. contg. more than 1 mg/ml  
3.alpha.-hydroxy-5.alpha.-pregnane-  
11,20-dione (I) were prepd. by addn. of more than 1% of a nonionic  
surface active compd. (HLB-value 9-18) that is tolerated in parental  
application,  
such as polyethoxylated derivs. of fatty C12-20 glyceride oils, e.g.  
Cremophor EL (II), a polyethoxylated castor oil contg. about 40  
ethylene  
oxide units per triglyceride unit, polyoxyethylene polyoxypropylene  
ethers, polyoxyethylene ethers of alkyl phenols, etc. Thus,  
3.beta.-acetoxy-5.alpha.-pregn-16-ene-11,20-dione was sapon. with  
aq. KOH  
to give 3.beta.-hydroxy-5.alpha.-pregn-16-ene-11,20-dione, which was  
converted into the 3.beta.-tosylate (III) with p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>Cl.  
Treatment  
of III with KOAc in DMF-H<sub>2</sub>O 2.5 hr at 115.degree. gave  
3.alpha.-hydroxy-5.alpha.-pregn-16-ene-11,20-dione, which was  
hydrogenated  
in THF over 5% Pd/C to give I. Also prepd. were 4 21-acyloxy derivs.  
of I and nitrate and hemisuccinate esters of pregnan-3(and 21)-ols. I  
(0.03)  
pulverized to 5 .mu. particles, and 2 g II were mixed and warmed in  
N-atm.  
to 70.degree. until a soln. was obtained. Subsequent diln. with H<sub>2</sub>O  
contg. 0.025 g NaCl to 10 ml with stirring gave a homogeneous soln.  
IT 32226-13-49  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)  
RN 32226-13-4 CAPLUS  
CN Pregnane-11,20-dione, 21-(benzoyloxy)-3-hydroxy-, (3.alpha.,5.alpha.)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2000 ACS  
ACCESSION NUMBER: 1970:121828 CAPLUS  
DOCUMENT NUMBER: 72:121828  
TITLE: Pregnane ethers as orally effective  
mineralo-corticoids  
PATENT ASSIGNER(S): Merck, E., A.-G.  
SOURCE: Brit., 9 pp.  
CODEN: BRGXAA  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

L11 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1183899		19700311		


PRIORITY APPLN. INFO.: DE 19671213  
AB Title compds., orally effective mineralo-corticoids without  
glucocorticoid  
side effects, were prepd. Thus, 100 mg  
3.alpha.,21-dihydroxypregn-4-en-20-  
one 3-(p-toluenesulfonate) was kept 24 hr in 5 ml MeOH contg. 10 mg  
p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H to give 3.alpha.-methoxy-21-hydroxypregn-4-en-20-one  
(I), m.  
143-5.degree.. This (500 mg), 3 ml pyridine, and 3 ml Ac<sub>2</sub>O stirred 3  
hr  
gave 3.alpha.-methoxy-21-acetoxypregn-4-en-20-one. 20,20-  
Ethylenedioxy-21-hydroxy-3.beta.,21-diol (2.6 g) and 230 mg  
p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H  
in 1.3 l. MeOH kept 8 hr gave  
3.beta.-methoxy-21-hydroxypregn-4-en-20-one,  
m. 101-3.degree. and I (sepd. by chromatog. on silica gel). Other  
compds.  
(.apprx.10) were also prepd.  
IT 26623-69-8P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)  
RN 26623-69-8 CAPLUS  
CN Pregn-4-en-20-one, 3.beta.-methoxy-21-(trityloxy)- (8CI) (CA INDEX  
NAME)

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 19-Norpregn-17(20)-en-3-ol, 3-methyl-, (3.alpha.,5.beta.,17Z)- (9CI)  
 MF C21 H34 O


Absolute stereochemistry.  
 Double bond geometry as shown.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-[(3,4-dimethoxyphenyl)ethynyl]-3-hydroxy-,  
 (3.alpha.,5.beta.)- (9CI)  
 MF C31 H42 O4


Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-[(4-chlorophenyl)ethynyl]-3-hydroxy-,


(3.alpha.,5.beta.)- (9CI)  
MF C29 H37 Cl O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregn-20-one, 21-(acetyloxy)-3-ethynyl-3-hydroxy-, (3.alpha.,5.beta.)-  
(9CI)  
MF C25 H36 O4

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregn-17(20)-en-3-one, (5.beta.,17Z)- (9CI)  
MF C21 H32 O

Absolute stereochemistry.  
Double bond geometry as shown.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Androstane-17-methanol, 3-hydroxy-3-methyl-,  
 (3.alpha.,5.alpha.,17.beta.)-  
 (9CI)  
 MF C21 H36 O2


Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):50

L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-3,20-diol, 20-methyl-, (3.alpha.,5.alpha.)- (9CI)  
 MF C22 H38 O2


Absolute stereochemistry.






L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-([1,1'-biphenyl]-4-ylethynyl)-3-hydroxy-,  
 (3.alpha.,5.beta.)- (9CI)  
 MF C35 H42 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Androstan-3-ol, 17-(methoxymethylene)-, (3.alpha.,5.beta.,17Z)- (9CI)  
 MF C21 H34 O2

Absolute stereochemistry.  
 Double bond geometry as shown.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-pentynyl)-,  
 [3.alpha.,3(S),5.alpha.]- (9CI)  
 MF C26 H40 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 19-Norpregn-17(20)-en-3-ol, (3.alpha.,5.alpha.,17Z)- (9CI)  
 MF C20 H32 O

Absolute stereochemistry.  
 Double bond geometry as shown.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 21-(3-carboxy-1-oxopropoxy)-3-hydroxy-,  
 (3.alpha.,5.beta.)- (9CI)  
 MF C25 H38 O6  
 CI COM

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Estran-3-one, 17-(methoxymethylene)-, (5.alpha.)- (9CI)  
MF C20 H30 O2

Absolute stereochemistry.  
Double bond geometry unknown.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnane-3,20-diol, 3-ethynyl-, (3.alpha.,5.beta.,20R)- (9CI)  
MF C23 H36 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN 19-Norpregn-17(20)-en-3-ol, 3-(trifluoromethyl)-, (3.alpha.,5.beta.)- (9CI)  
MF C21 H31 F3 O

Absolute stereochemistry.  
Double bond geometry unknown.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-(chloroethynyl)-3-hydroxy-, (3.alpha.,5.beta.)- (9CI)  
 MF C23 H33 Cl O2

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Androstane-17-methanol, 3-hydroxy-, (3.alpha.,5.alpha.,17.beta.)- (9CI)  
 MF C20 H34 O2


Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Silane, (1,1-dimethylethyl)dimethyl[[(3.alpha.,5.alpha.)-pregn-20-yn-3-yl]oxy]- (9CI)  
 MF C27 H46 O Si

The chemical structure shows a steroid nucleus with four fused rings. A silyl ether group is attached to the first ring, consisting of a silicon atom bonded to a tert-butyl group (t-Bu), two methyl groups (Me), and an oxygen atom that is linked to the ring. The ring itself has a substituent R and a hydrogen atom (H) in a dashed position. The second ring has a methyl group (Me) in a wedged position, a substituent R, and a hydrogen atom (H) in a dashed position. The third ring has a hydrogen atom (H) in a wedged position, a substituent R, and a hydrogen atom (H) in a dashed position. The fourth ring has a methyl group (Me) in a wedged position, a substituent R, and a hydrogen atom (H) in a dashed position. A propargyl group (C≡CH) is attached to the fourth ring in a wedged position.

Absolute stereochemistry.




Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 19-Norpregnan-20-one, 3-hydroxy-3-(trifluoromethyl)-, (3.alpha.,5.beta.)-  
 (9CI)  
 MF C21 H31 F3 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-methyl-, (3.alpha.,5.alpha.)- (9CI)  
 MF C22 H36 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 19-Norpregnan-20-one, 21-bromo-3-hydroxy-3-(trifluoromethyl)-,  
 (3.alpha.,5.beta.)- (9CI)  
 MF C21 H30 Br F3 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-(2,3-butadienyl)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)  
 MF C25 H38 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 5-Hexynenitrile, 6-[(3.alpha.,5.beta.)-3-hydroxy-20-oxopregnan-3-yl]- (9CI)  
 MF C27 H39 N O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 1-Propanone, 1-[(3.alpha.,5.beta.,17.beta.)-3-hydroxyandrost-17-yl]-3-methoxy- (9CI)  
 MF C23 H38 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 21-(acetyloxy)-3-hydroxy-, (3.alpha.,5.beta.)- (9CI)  
MF C23 H36 O4

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN 1-Propanone,  
3-(dimethylamino)-1-[(3.alpha.,5.alpha.,17.beta.)-3-hydroxy-3-  
methylandrostan-17-yl]- (9CI)  
MF C25 H43 N O2


Absolute stereochemistry.






L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-, (3.alpha.,5.alpha.)- (9CI)  
MF C23 H38 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-[(2,4-difluorophenyl)ethynyl]-3-hydroxy-,  
(3.alpha.,5.beta.)- (9CI)  
MF C29 H36 F2 O2

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-hydroxy-3-methyl-21-(phosphonooxy)-, disodium salt,  
(3.alpha.,5.alpha.)- (9CI)  
MF C22 H37 O6 P . 2 Na


Absolute stereochemistry.



● 2 Na


L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)  
 MF C21 H34 O2

Absolute stereochemistry. Rotation (+).




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Silane, (1,1-dimethylethyl)dimethyl[[ (3.alpha.,5.alpha.,17Z)-21-norchol-  
 17(20)-en-3-yl]oxy]- (9CI)  
 MF C29 H52 O Si

Absolute stereochemistry.  
 Double bond geometry as shown.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-phenyl-, (3.alpha.,5.beta.)- (9CI)  
 MF C27 H38 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 1-Propanone, 1-[(3.alpha.,5.beta.,17.beta.)-3-hydroxyandrostane-17-yl]-  
 (9CI)  
 MF C22 H36 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 21-(acetyloxy)-3-hydroxy-3-(trifluoromethyl)-,  
 (3.alpha.,5.beta.)- (9CI)  
 MF C24 H35 F3 O4

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Androstan-17-one, 3-hydroxy-, (3.alpha.,5.beta.)- (9CI)  
 MF C19 H30 O2  
 CI COM

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Androstane-17-methanol,  
 3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-.alpha.-  
 ethyl-, [3.alpha.,5.alpha.,17.beta.(S)]- (9CI)  
 MF C28 H52 O2 Si


Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-(phenylethynyl)-, (3.alpha.,5.beta.)- (9CI)

MF C29 H38 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS

IN Pregnan-20-one, 3-hydroxy-3-[(4-methoxyphenyl)ethynyl]-,  
(3.alpha.,5.beta.)- (9CI)

MF C30 H40 O3

Absolute stereochemistry.





L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS

IN Pregnan-20-one, 3-hydroxy-3-(iodomethyl)-, (3.alpha.,5.alpha.)- (9CI)

MF C22 H35 I O2


Absolute stereochemistry.






L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 19-Norpregnane-3,20-diol, (3.alpha.,5.alpha.,20S)- (9CI)  
 MF C20 H34 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-20-one, 3-ethyl-3-hydroxy-, (3.alpha.,5.beta.)- (9CI)  
 MF C23 H38 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Spiro[oxirane-2,3'-pregnan]-20'-one, (3'.alpha.,5'.alpha.)- (9CI)  
 MF C22 H34 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-,  
 (3.alpha.,5.beta.)- (9CI)  
 MF C31 H40 O3

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-(fluoromethyl)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)  
 MF C22 H35 F O2


Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS


IN Pregnan-20-one, 3-hydroxy-3-(3-hydroxy-1-butynyl)-,  
[3.alpha.,3(S),5.alpha.]- (9CI)  
MF C25 H38 O3

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-[(3,4-dimethoxyphenyl)ethynyl]-3-hydroxy-,  
(3.beta.,5.beta.)- (9CI)  
MF C31 H42 O4


Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 21-bromo-3-hydroxy-, (3.alpha.,5.beta.)- (9CI)  
MF C21 H33 Br O2


Absolute stereochemistry.






L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3,21-dihydroxy-3-methyl-, (3.alpha.,5.alpha.)- (9CI)  
 MF C22 H36 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 19-Norpregnan-20-one, 3-hydroxy-3-methyl-, (3.alpha.,5.beta.)- (9CI)  
 MF C21 H34 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-[(3-hydroxyphenyl)ethynyl]-,  
 (3.alpha.,5.beta.)- (9CI)  
 MF C29 H38 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(methylsulfonyl)oxy]-,  
(3.alpha.,5.alpha.)- (9CI)  
MF C23 H38 O5 S

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregn-17(20)-en-3-ol, (3.alpha.,5.beta.,17E)- (9CI)  
MF C21 H34 O

Absolute stereochemistry.  
Double bond geometry as shown.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-ethynyl-3-(nitrooxy)-, (3.beta.,5.alpha.)- (9CI)  
 MF C23 H33 N O4

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-ethyl-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)  
 MF C23 H38 O2

Absolute stereochemistry.




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):50

L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-[(2-hydroxyphenyl)ethynyl]-,


(3.alpha.,5.beta.)- (9CI)  
MF C29 H38 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)-  
(9CI)  
MF C26 H37 N O2 S

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-hydroxy-, cyclic 1,2-ethanediyl acetal,  
(3.alpha.,5.beta.)- (9CI)  
MF C23 H38 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 21-[[bis(phenylmethoxy)phosphinyl]oxy]-3-hydroxy-3-  
 (trifluoromethyl)-, (3.alpha.,5.alpha.)- (9CI)  
 MF C36 H46 F3 O6 P

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 21-(3-carboxy-1-oxopropoxy)-3-hydroxy-3-methyl-,  
 (3.alpha.,5.alpha.)- (9CI)  
 MF C26 H40 O6  
 CI COM

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-[4-(3-carboxy-1-oxopropoxy)-1-pentynyl]-3-hydroxy-,  
 monosodium salt, [3.alpha.,3(R),5.beta.]- (9CI)  
 MF C30 H44 O6 . Na


Absolute stereochemistry.




● Na

L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 1-Propanone, 1-[(3.alpha.,5.alpha.,17.beta.)-3-hydroxy-3-methylandrostan-  
 17-yl]- (9CI)  
 MF C23 H38 O2


Absolute stereochemistry.






L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.beta.)- (9CI)  
 MF C21 H34 O3  
 CI COM

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Estran-3-ol, 17-(methoxymethylene)-, (3.alpha.,5.alpha.)- (9CI)  
 MF C20 H32 O2


Absolute stereochemistry.  
 Double bond geometry unknown.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-pentynyl)-,


[3.alpha.,3(R),5.beta.]- (9CI)  
MF C26 H40 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-hydroxy-3-(6-oxo-1-heptynyl)-, (3.alpha.,5.beta.)- (9CI)  
MF C28 H42 O3

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-(bromomethyl)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)  
MF C22 H35 Br O2


Absolute stereochemistry.






L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-, (3.alpha.,5.beta.)- (9CI)  
 MF C21 H34 O2  
 CI COM

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-ethynyl-3,21-dihydroxy-, (3.alpha.,5.beta.)- (9CI)  
 MF C23 H34 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-[2-(3,4-dimethoxyphenyl)ethyl]-3-hydroxy-,  
 (3.alpha.,5.beta.)- (9CI)  
 MF C31 H46 O4

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-(1-octynyl)-, (3.alpha.,5.beta.)- (9CI)  
 MF C29 H46 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 21-(3-carboxy-1-oxopropoxy)-3-ethynyl-3-hydroxy-,  
 (3.alpha.,5.beta.)- (9CI)  
 MF C27 H38 O6  
 CI COM

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Estran-3-ol, 17-(methoxymethylene)-, (3.alpha.,5.alpha.,17Z)- (9CI)  
 MF C20 H32 O2

Absolute stereochemistry.  
 Double bond geometry as shown.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Androstan-3-ol, 17-propylidene-, (3.alpha.,5.alpha.,17Z)- (9CI)  
 MF C22 H36 O

Absolute stereochemistry.  
 Double bond geometry as shown.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 21-(3-carboxy-1-oxopropoxy)-3-hydroxy-,  
 (3.alpha.,5.alpha.)- (9CI)  
 MF C25 H38 O6  
 CI COM

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 19-Norpregnan-20-one, 3-ethynyl-3-hydroxy-, (3.alpha.,5.beta.)- (9CI)  
 MF C22 H32 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-3,20-diol, 3-methyl-, (3.alpha.,5.alpha.,20S)- (9CI)  
 MF C22 H38 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregn-17(20)-en-3-ol, 3-methyl-, (3.beta.,5.alpha.)- (9CI)  
 MF C22 H36 O

Absolute stereochemistry.  
Double bond geometry unknown.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN 19-Norpregnane-3,20-dione, cyclic 20-(1,2-ethanediyl acetal), (5.beta.)- (9CI)  
MF C22 H34 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-hydroxy-, cyclic 1,2-ethanediyl acetal, (3.alpha.,5.alpha.)- (9CI)  
MF C23 H38 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 21-bromo-3-hydroxy-3-methyl-, (3.alpha.,5.alpha.)- (9CI)  
 MF C22 H35 Br O2

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3,21-dihydroxy-3-(trifluoromethyl)-, (3.alpha.,5.beta.)- (9CI)  
 MF C22 H33 F3 O3


Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS


IN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-methoxy-, (3.alpha.,5.beta.)-  
(9CI)  
MF C24 H36 O3

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-hydroxy-21-(phosphonooxy)-3-(trifluoromethyl)-,  
disodium  
salt, (3.alpha.,5.beta.)- (9CI)  
MF C22 H34 F3 O6 P . 2 Na


Absolute stereochemistry.



●2 Na


L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-[[ (1,1-dimethylethyl)dimethylsilyl]oxy]-,  
(3.alpha.,5.alpha.)- (9CI)  
MF C27 H48 O2 Si

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregn-20-en-20-ol, 3-[[ (1,1-dimethylethyl)dimethylsilyl]oxy]-, diethyl  
 phosphate, (3.alpha.,5.alpha.)- (9CI)  
 MF C31 H57 O5 P Si

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Androstane-17-methanol, .alpha.-ethyl-3-hydroxy-,  
 [3.alpha.,5.alpha.,17.beta.(S)]- (9CI)  
 MF C22 H38 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 19-Norpregnan-20-one, 3-hydroxy-3-(trifluoromethyl)-,  
 (3.alpha.,5.alpha.)-




(9CI)  
MF C21 H31 F3 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-hydroxy-3-[(1E)-2-phenylethenyl]-, (3.alpha.,5.alpha.)-  
(9CI)  
MF C29 H40 O2


Absolute stereochemistry.  
Double bond geometry as shown.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Androstane-17-carbonitrile, 3-hydroxy-, (3.alpha.,5.alpha.,17.beta.)-  
(9CI)  
MF C20 H31 N O


Absolute stereochemistry. Rotation (+).






L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 19-Norpregnan-20-one, 21-[[bis(phenylmethoxy)phosphinyl]oxy]-3-hydroxy-3-(trifluoromethyl)-, (3.alpha.,5.beta.)- (9CI)  
 MF C35 H44 F3 O6 P

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-(2-propynyl)-, (3.alpha.,5.alpha.)- (9CI)  
 MF C24 H36 O2


Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-[[4-[(acetyloxy)acetyl]phenyl]ethynyl]-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)


(3.alpha.,5.beta.)- (9CI)  
MF C33 H42 O5

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-hydroxy-3-(trifluoromethyl)-, (3.alpha.,5.beta.)- (9CI)  
MF C22 H33 F3 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Androstan-3-ol, (3.alpha.,5.alpha.)- (9CI)  
MF C19 H32 O

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 2-Propen-1-one, 1-[(3.alpha.,5.alpha.,17.beta.)-3-hydroxy-3-methylandrostan-17-yl]- (9CI)  
 MF C23 H36 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-3-acetonitrile, 3-hydroxy-20-oxo-, (3.alpha.,5.alpha.)- (9CI)  
 MF C23 H35 N O2


Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-(3-hydroxy-1-propynyl)-, (3.alpha.,5.beta.)- (9CI)  
 MF C24 H36 O3


Absolute stereochemistry.






L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one,  
 21-(3-carboxy-1-oxopropoxy)-3-hydroxy-3-(trifluoromethyl)-  
 , (3.alpha.,5.beta.)- (9CI)  
 MF C26 H37 F3 O6  
 CI COM

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-3,20-diol, (3.alpha.,5.alpha.,20S)- (9CI)  
 MF C21 H36 O2  
 CI COM

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-(fluoromethyl)-3-hydroxy-, cyclic 1,2-ethanediyl  
 acetal,  
 (3.alpha.,5.alpha.)- (9CI)  
 MF C24 H39 F O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-(phenylmethyl)-, (3.alpha.,5.beta.)- (9CI)  
 MF C28 H40 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-[(pentafluorophenyl)ethynyl]-,  
 (3.alpha.,5.beta.)- (9CI)  
 MF C29 H33 F5 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-(chloromethyl)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)  
 MF C22 H35 Cl O2

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-3,20-diol, (3.alpha.,5.beta.,20R)- (9CI)  
 MF C21 H36 O2  
 CI COM


Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):50


L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN 19-Norpregnan-20-one, 3-hydroxy-21-methoxy-3-(trifluoromethyl)-,  
(3.alpha.,5.beta.)- (9CI)  
MF C22 H33 F3 O3

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-hydroxy-3-(2-phenylethyl)-, (3.alpha.,5.beta.)- (9CI)  
MF C29 H42 O2


Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-hydroxy-3-[[4-(trifluoromethyl)phenyl]ethynyl]-,  
(3.alpha.,5.beta.)- (9CI)  
MF C30 H37 F3 O2


Absolute stereochemistry.






L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregn-17(20)-en-3-ol, 3-(trifluoromethyl)-, (3.alpha.,5.beta.,17Z)- (9CI)  
 MF C22 H33 F3 O

Absolute stereochemistry.  
 Double bond geometry as shown.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregn-17(20)-en-3-one, cyclic 1,2-ethanediyl acetal, (5.beta.)- (9CI)  
 MF C23 H36 O2

Absolute stereochemistry.  
 Double bond geometry unknown.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Androstane-17-carboxylic acid, 3-hydroxy-3-methyl-,  
(3.alpha.,5.alpha.,17.beta.)- (9CI)  
MF C21 H34 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Spiro[oxirane-2,3'-pregnan]-20'-one, cyclic 1,2-ethanediyl acetal,  
(3'.alpha.,5'.alpha.)- (9CI)  
MF C24 H38 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-[[4-(dimethylamino)phenyl]ethynyl]-3-hydroxy-,  
(3.alpha.,5.beta.)- (9CI)  
MF C31 H43 N O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregn-17(20)-en-3-ol, 3-methyl-, (3.alpha.,5.alpha.)- (9CI)  
 MF C22 H36 O

Absolute stereochemistry.  
 Double bond geometry unknown.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregn-20-one, 3-[4-(3-carboxy-1-oxopropoxy)-1-pentynyl]-3-hydroxy-,  
 monosodium salt, [3.alpha.,3(S),5.beta.]- (9CI)  
 MF C30 H44 O6 . Na

Absolute stereochemistry.




● Na



● Na


L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-(phenylmethyl)-, (3.beta.,5.beta.)- (9CI)  
 MF C28 H40 O2

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 21-(acetyloxy)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)  
 MF C23 H36 O4


Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS


IN 19-Norpregn-17(20)-en-3-one, (5.beta.,17Z)- (9CI)  
MF C20 H30 O

Absolute stereochemistry.  
Double bond geometry as shown.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnane-3,20-diol, 3-ethynyl-, (3.alpha.,5.beta.,20S)- (9CI)  
MF C23 H36 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN 19-Norpregn-17(20)-en-3-ol, 3-ethynyl-, (3.alpha.,5.beta.,17Z)- (9CI)  
MF C22 H32 O

Absolute stereochemistry.  
Double bond geometry as shown.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 21-bromo-3-ethynyl-3-hydroxy-, (3.alpha.,5.beta.)- (9CI)  
 MF C23 H33 Br O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregn-17(20)-en-3-ol, (3.alpha.,5.beta.,17Z)- (9CI)  
 MF C21 H34 O

Absolute stereochemistry.  
 Double bond geometry as shown.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregn-20-yn-3-ol, (3.alpha.,5.alpha.)- (9CI)  
 MF C21 H32 O

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnane-3,20-diol, bis(hydrogen butanedioate), (3.alpha.,5.beta.,20R)-  
(9CI)  
MF C29 H44 O8  
CI COM


Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN 19-Norpregn-17(20)-en-3-ol, (3.alpha.,5.beta.,17Z)- (9CI)  
MF C20 H32 O


Absolute stereochemistry.  
Double bond geometry as shown.






L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-ethynyl-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)  
 MF C23 H34 O2

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-3,20-diol, bis(hydrogen butanedioate), disodium salt,  
 (3.alpha.,5.beta.,20R)- (9CI)  
 MF C29 H44 O8 . 2 Na

Absolute stereochemistry.




● 2 Na




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 21-bromo-3-hydroxy-3-(trifluoromethyl)-,  
 (3.alpha.,5.beta.)- (9CI)  
 MF C22 H32 Br F3 O2

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 21-(3-carboxy-1-oxopropoxy)-3-hydroxy-3-methyl-,  
 monosodium salt, (3.alpha.,5.alpha.)- (9CI)  
 MF C26 H40 O6 . Na


Absolute stereochemistry.



● Na


L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-(ethoxymethyl)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)  
 MF C24 H40 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 2-Propen-1-one, 1-[(3.alpha.,5.beta.,17.beta.)-3-hydroxyandrostan-17-yl]-  
 (9CI)  
 MF C22 H34 O2

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-3,20-dione, cyclic 20-(1,2-ethanediyl acetal), (5.alpha.)- (9CI)  
 MF C23 H36 O3


Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one,  
 21-[[bis(phenylmethoxy)phosphinyl]oxy]-3-hydroxy-3-methyl-


MF , (3.alpha.,5.alpha.)- (9CI)  
C36 H49 O6 P

**Absolute stereochemistry.**




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-,  
(3.alpha.,5.alpha.)- (9CI)  
MF C31 H40 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN 19-Norpregnan-20-one, 3-hydroxy-3-methyl-, (3.alpha.,5.alpha.)- (9CI)  
MF C21 H34 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Estrane-17-carboxaldehyde, 3-hydroxy-, (3.alpha.,5.alpha.,17.beta.)-  
 (9CI)  
 MF C19 H30 O2

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Androstan-17-one, 3-hydroxy-, (3.beta.,5.alpha.)- (9CI)  
 MF C19 H30 O2  
 CI COM


Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 21-Norchol-17(20)-en-3-ol, (3.alpha.,5.alpha.,17Z)- (9CI)  
 MF C23 H38 O


Absolute stereochemistry.

Double bond geometry as shown.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-[(4-nitrophenyl)ethynyl]-,  
 (3.alpha.,5.beta.)-  
 (9CI)  
 MF C29 H37 N O4

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Benzonitrile,  
 4-[[ (3.alpha.,5.beta.)-3-hydroxy-20-oxopregnan-3-yl]ethynyl]-  
 (9CI)  
 MF C30 H37 N O2

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 21-(3-carboxy-1-oxopropoxy)-3-ethynyl-3-hydroxy-,  
 monosodium salt, (3.alpha.,5.beta.)- (9CI)  
 MF C27 H38 O6 . Na


Absolute stereochemistry.



● Na


L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Androstan-17-one, 3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)  
 MF C19 H30 O2  
 CI COM

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Silane, (1,1-dimethylethyl)dimethyl[[(3.alpha.,5.alpha.,17Z)-17-propylideneandrostan-3-yl]oxy]- (9CI)  
 MF C28 H50 O Si

Absolute stereochemistry.  
 Double bond geometry as shown.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregn-17(20)-en-3-one, (5.alpha.)- (9CI)  
 MF C21 H32 O


Absolute stereochemistry.  
 Double bond geometry unknown.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-(1-hexynyl)-3-hydroxy-, (3.alpha.,5.beta.)- (9CI)

MF C27 H42 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS

IN Pregnane-3,20-diol, 3-methyl-, (3.alpha.,5.alpha.,20R)- (9CI)

MF C22 H38 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS

IN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-pentynyl)-,  
[3.alpha.,3(S),5.beta.]- (9CI)

MF C26 H40 O3


Absolute stereochemistry.






L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-ethynyl-3-hydroxy-, (3.alpha.,5.beta.)- (9CI)  
 MF C23 H34 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-3,20-diol, 3,20-dimethyl-, (3.alpha.,5.alpha.)- (9CI)  
 MF C23 H40 O2

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Benzoic acid,  
 4-[[[(3.alpha.,5.beta.)-3-hydroxy-20-oxopregnan-3-yl]ethynyl]-  
 , ethyl ester (9CI)  
 MF C32 H42 O4

Absolute stereochemistry.



The chemical structure shows a steroid nucleus with four fused rings. Substituents include a trifluoromethyl group ( $\text{F}_3\text{C}$ ) at C-13, a hydroxyl group ( $\text{HO}$ ) at C-14, a methyl group ( $\text{Me}$ ) at C-10, and a propenyl group ( $\text{Pr-n}$ ) at C-17. Stereochemistry is indicated with wedges and dashes at various positions.


L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Androstan-3-ol, 17-(methoxymethylene)-, (3.alpha.,5.beta.,17E)- (9CI)  
MF C21 H34 O2

The chemical structure shows a steroid nucleus with the following stereochemical features:
 

- C-3:** A hydroxyl group (HO) is attached with a dashed bond, indicating it is in the *β* position.
- C-10:** A methyl group (Me) is attached with a solid wedge bond, indicating it is in the *α* position.
- C-13:** A hydrogen atom (H) is attached with a solid wedge bond, indicating it is in the *α* position.
- C-14:** A hydrogen atom (H) is attached with a dashed bond, indicating it is in the *β* position.
- C-15:** A methyl group (Me) is attached with a solid wedge bond, indicating it is in the *α* position.
- C-16:** A hydrogen atom (H) is attached with a dashed bond, indicating it is in the *β* position.
- C-17:** A side chain is attached, consisting of a double bond to a carbon atom which is also bonded to a methoxymethyl group (OMe) and an ethyl group (E).


L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-(phenylethynyl)-, (3.beta.,5.beta.)- (9CI)  
 MF C29 H38 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Androstane-17-carboxaldehyde, 3-hydroxy-3-methyl-,  
 (3.alpha.,5.alpha.,17.beta.)- (9CI)  
 MF C21 H34 O2


Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-phenyl-, (3.beta.,5.beta.)- (9CI)  
 MF C27 H38 O2

Absolute stereochemistry.






HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5


L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 19-Norpregnan-20-one, 3,21-dihydroxy-3-(trifluoromethyl)-,  
 (3.alpha.,5.beta.)- (9CI)  
 MF C21 H31 F3 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 19-Norpregn-17(20)-en-3-ol, 3-methyl-, (3.alpha.,5.alpha.,17Z)- (9CI)  
 MF C21 H34 O

Absolute stereochemistry.  
 Double bond geometry as shown.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-hydroxy-3-(2-propenyl)-, (3.alpha.,5.beta.)- (9CI)  
MF C24 H38 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Androstane-3,17-dione, cyclic 3-(1,2-ethanediyl acetal), (5.beta.)- (9CI)  
MF C21 H32 O3

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-ethynyl-3-hydroxy-, cyclic 1,2-ethanediyl acetal, (3.alpha.,5.alpha.)- (9CI)  
MF C25 H38 O3


Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):50


L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-(3-butenyl)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)  
 MF C25 H40 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-pentynyl)-,  
 [3.alpha.,3(R),5.alpha.]- (9CI)  
 MF C26 H40 O3

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 19-Norpregnan-20-one, 3-hydroxy-21-(phosphonooxy)-3-(trifluoromethyl)-,  
 disodium salt, (3.alpha.,5.beta.)- (9CI)  
 MF C21 H32 F3 O6 P . 2 Na


Absolute stereochemistry.



● 2 Na


L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-3,20-dione, cyclic 20-(1,2-ethanediyl acetal), (5.beta.)- (9CI)  
 MF C23 H36 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN 1-Propanone, 3-(dimethylamino)-1-[(3.alpha.,5.beta.,17.beta.)-3-  
 hydroxyandrostane-17-yl]- (9CI)  
 MF C24 H41 N O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-(azidomethyl)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)  
 MF C22 H35 N3 O2

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-(3-hydroxy-1-butynyl)-,  
 [3.alpha.,3(R),5.alpha.]- (9CI)  
 MF C25 H38 O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one,  
 21-(3-carboxy-1-oxopropoxy)-3-hydroxy-3-(trifluoromethyl)-  
 , monosodium salt, (3.alpha.,5.beta.)- (9CI)



MF C26 H37 F3 O6 . Na


Absolute stereochemistry.



● Na


L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnane-3,20-dione, (5.alpha.)- (9CI)  
MF C21 H32 O2  
CI COM

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-fluoro-3-(hydroxymethyl)-, cyclic 1,2-ethanediyl  
acetal,  
(3.alpha.,5.alpha.)- (9CI)  
MF C24 H39 F O3

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-(1-heptynyl)-3-hydroxy-, (3.alpha.,5.beta.)- (9CI)  
 MF C28 H44 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-3-[(4-methylphenyl)ethynyl]-,  
 (3.alpha.,5.beta.)- (9CI)  
 MF C30 H40 O2

Absolute stereochemistry.




L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnan-20-one, 3-(3-bromo-1-propynyl)-3-hydroxy-, (3.alpha.,5.beta.)-  
(9CI)  
MF C24 H35 Br O2

Absolute stereochemistry.



L3 175 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnane-3,20-diol, (3.alpha.,5.beta.,20S)- (9CI)  
MF C21 H36 O2  
CI COM

Absolute stereochemistry.



\~15~

US-PAT-NO: 3959260

DOCUMENT-IDENTIFIER: US 3959260 A

TITLE: Anaesthetic steroids of the pregnane and 19-norpregnane series having a sulfur-containing group at the 21-position

DATE-ISSUED: May 25, 1976

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE
Phillipps; Gordon	Wembley	N/A	N/A
EN			
Hanley	Stoke Poges	N/A	N/A
EN			
Lawrence; Robin	London	N/A	N/A
EN			
Newall; Christopher	Stoke Poges	N/A	N/A
EN			
Earle			
Wright; Michael			

ASSIGNEE INFORMATION:

NAME	CITY	STATE	ZIP CODE
Glaxo Laboratories	Greenford	N/A	N/A
EN 03			
Limited			

APPL-NO: 5/ 488989

DATE FILED: July 16, 1974

PARENT-CASE:

This is a continuation, of application Ser. No. 356,097, filed May 1, 1973.

FOREIGN-APPL-PRIORITY-DATA:

FOREIGN-PRIORITY:

FOREIGN-PRIORITY-APPL-NO: UK 21145/72

FOREIGN-PRIORITY-APPL-DATE: May 5, 1972

INT-CL: [2] C07J043/00

US-CL-ISSUED: 260/239.5, 260/239.55R, 260/397.45

US-CL-CURRENT: 540/110, 540/111, 552/560, 552/582, 552/589, 552/590, 552/591

, 552/603, 552/604, 552/607, 552/608, 552/609

FIELD-OF-SEARCH: 260/239.5

REF-CITED:

PAT-NO	ISSUE-DATE	U.S. PATENT DOCUMENTS PATENTEE-NAME	US-CL
3882151	May 1975	Phillipps et al.	260/239.55R
ART-UNIT: 124			
PRIMARY-EXAMINER: Roberts; Elbert L.			
ATTY-AGENT-FIRM: Bacon & Thomas			
ABSTRACT:			

Steroid anaesthetics of the pregnane and 19-norpregnane series are described, the compounds possessing a 3.alpha.-hydroxy group, a 17.alpha.-hydrogen atom, a 20-oxo group and at the 21-position the residue of a sulphur nucleophile or a sulphone or sulfoxide grouping.

22 Claims, 0 Drawing figures

09/821,882

Page 1

=> d ibib ab hitstr 1-2

## L5 ANSWER 1 OF 2 USPATFULL

ACCESSION NUMBER: 2000:47233 USPATFULL  
 TITLE: Means to achieve sustained release of synergistic drugs by conjugation  
 INVENTOR(S): Ashton, Paul, Boston, MA, United States  
 Crooks, Peter Anthony, Lexington, KY, United States  
 Cynkowski, Tadeusz, Lexington, KY, United States  
 Cynkowska, Grazyna, Lexington, KY, United States  
 Guo, Hone, Malden, MA, United States  
 PATENT ASSIGNEE(S): University Of Kentucky Research Foundation, Lexington, KY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6051576		20000418
APPLICATION INFO.:	US 1997-791071		19970129 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-388855, filed on 15 Feb 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-187462, filed on 28 Jan 1994		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	MacMillan, Keith D.		
LEGAL REPRESENTATIVE:	McDermott, Will & Emery		
NUMBER OF CLAIMS:	37		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1243		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A codrug composition of at least two drug compounds covalently linked to one another via a labile bond to form a single codrug composition, or ionically linked to one another to form a single workings composition, and methods of use of the codrug for the treatment of various medical conditions. The codrug may be administered by itself or in the form of a bioerodible or nonbioerodible substance.

IT 169046-79-1P


(codrug comps. for controlled drug delivery)

RN 169046-79-1 USPATFULL

CN 2,4(1H,3H)-Pyrimidinedione, 1-[[[3.alpha.,5.beta.)-3,17-dihydroxy-20-oxopregnan-21-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

## L5 ANSWER 1 OF 2 USPATFULL (Continued)



## L5 ANSWER 2 OF 2 USPATFULL

ACCESSION NUMBER: 1999:81822 USPATFULL  
 TITLE: Neuroactive steroids of the androstane and pregnane series  
 INVENTOR(S): Upasani, Ravindra B., Foothill Ranch, CA, United States  
 Fick, David B., Mission Viejo, CA, United States  
 Hogenkamp, Derk J., Carlsbad, CA, United States  
 Lan, Nancy C., South Pasadena, CA, United States  
 PATENT ASSIGNEE(S): CoCensys, Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5925630		19990720
APPLICATION INFO.:	US 1996-659192		19960606 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-467404, filed on 6 Jun 1995		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose' G.		
ASSISTANT EXAMINER:	Badio, Barbara		
LEGAL REPRESENTATIVE:	Sterne, Kessler, Goldstein & Fox P.L.L.C.		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	3047		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to 3.alpha.-hydroxy, 17-(un)substituted derivatives of the androstane series and 3.alpha.-hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at a recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. The steroid derivatives of this invention are those having the general structural Formula: ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are further defined herein and the dotted lines are single or double bonds. The structure includes androstanes, pregnanes (R.sub.4 =methyl), 19-norandrostanes, and norpregnanes (R.sub.4 =H).

IT 186264-64-0P 186264-61-9P 186264-63-1P

186264-86-8P 186264-87-9P


(prepn. of neuroactive steroids of androstane and pregnane series)

RN 186264-64-0 USPATFULL

CN Pregnan-20-one, 3-hydroxy-21-(3-pyridinyloxy)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


## L5 ANSWER 2 OF 2 USPATFULL (Continued)



RN 186264-61-9 USPATFULL

CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinyloxy)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 186264-63-1 USPATFULL

CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 2 USPATFULL (Continued)



RN 186264-86-8 USPATFULL  
 CN Quinolinium, 6-[[[3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

● I<sup>-</sup>

RN 186264-87-9 USPATFULL  
 CN Pregnan-20-one, 3-hydroxy-21-[(1-oxido-3-pyridinyl)oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 2 USPATFULL (Continued)





09/821,882

Page 4

=> d ibib 1-6 16

=> d his

(FILE 'HOME' ENTERED AT 09:39:01 ON 24 NOV 2000)

FILE 'REGISTRY' ENTERED AT 09:39:27 ON 24 NOV 2000

L1               STRUCTURE UPLOADED  
L2               0 S L1  
L3               45 S L1 FULL

FILE 'CAPLUS' ENTERED AT 09:41:01 ON 24 NOV 2000

L4               10 S L3  
L5               4 S L4 NOT PY>=1995

FILE 'USPATFULL' ENTERED AT 09:42:12 ON 24 NOV 2000


L6               8 S L3  
L7               4 S L6 NOT L5  
L8               4 S L6 NOT PY>=1995  
L9               0 S L8 NOT L5

FILE 'MARPAT' ENTERED AT 09:43:18 ON 24 NOV 2000

L10              0 S L3  
L11              10 S L3 FULL  
L12              8 S L11/COM  
L13              8 S L12 NOT PY>=1995


=> d ibib ab hitstr 1-14

L17 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 51086-88-5 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(2-iodobenzoyl)thio]-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51086-89-6 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(2-nitrobenzoyl)thio]-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 51086-90-9 CAPLUS  
 CN Pregnane-11,20-dione, 21-[[2-(ethoxycarbonyl)benzoyl]thio]-3-hydroxy-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51086-91-0 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(2-pyridinylcarbonyl)thio]-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 51086-92-1 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(3-pyridinylcarbonyl)thio]-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51086-99-8 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-[[2-(methylthio)benzoyl]thio]-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 51087-12-8 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(phenylmethyl)thio]-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51087-25-3 CAPLUS  
 CN Pregnane-11,20-dione,  
 21-[[3,6-dihydro-1(2H)-pyridinyl]acetyl]thio]-3-hydroxy-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 51086-99-8 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-[[2-(methylthio)benzoyl]thio]-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51087-12-8 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(phenylmethyl)thio]-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 51087-25-3 CAPLUS  
 CN Pregnane-11,20-dione,  
 21-[[3,6-dihydro-1(2H)-pyridinyl]acetyl]thio]-3-  
 hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1973:515783 CAPLUS  
 DOCUMENT NUMBER: 79:115783  
 TITLE: 3.alpha.-Hydroxy-5.alpha.-steroids  
 INVENTOR(S): Clayton, John C. H.; Faulkner, Peter J.; Jones,  
 William Reginald; Philipps, Gordon H.; Bailey,

Esme

PATENT ASSIGNEE(S): Joan Glaxo Laboratories Ltd.

SOURCE: Ger. Offen., 38 pp.

DOCUMENT TYPE: CODEN: GWXXBX

LANGUAGE: Patent

FAMILY ACC. NUM. COUNT: German

PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2255108	A1	19730809	DE 1972-2255108	19721110
DE 2255108	B2	19761202		
DE 2255108	C3	19770728		
GB 1409239	A	19751008	GB 1971-52465	19721108
NL 7215229	A	19730515	NL 1972-15229	19721110
JP 48067263	A2	19730913	JP 1972-112190	19721110
JP 57025560	B4	19820529		
FR 2177695	A1	19731109	FR 1972-39865	19721110
US 3822298	A	19740702	US 1972-305246	19721110
CA 972744	A1	19750812	CA 1972-156154	19721110
DK 133470	B	19760524	DK 1972-5591	19721110
CH 606097	A	19781013	CH 1972-16489	19721110
			GB 1971-52465	19711111

PRIORITY APPLN. INFO.:

AB 3.alpha.-Hydroxypregnanes I and II [R, R3 and R5 = H, Me; R1 = HO; R2 = H;

R4 = H, AcO, MeO, Cl(CH2)3O, Cl(CH2)2O, PhCH2O, cyclopentylloxy; X =

O] (15

comps.) were prepd. in 30-70% yield by reduct. of I or II (R1R2 = O).

Thus, 5.alpha.-pregnane-3,20-dione was treated with H2IrCl6 in the

presence of (MeO)3P to yield 64% I (R and R2-R4 = H, R1 = HO, R5 =

Me, X =

H2). I (R and R2-R4 = H, R1 = HO, R5 = H, X = H2, O), (R5 = Me, X =

H2),

and (R = R5 = Me; X = O) had anesthetic activity.

IT 38601-47-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)


RN 38601-47-7 CAPLUS

CN Pregnane-11,20-dione, 3-hydroxy-21-(phenylmethoxy)-,

(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)




712 G

L17 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)


**Absolute stereochemistry.**



**Absolute stereochemistry.**



L17 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)  
(3.beta.,5.alpha.,6.beta.,16.alpha.)- (9CI) (CA INDEX NAME)  
Absolute stereochemistry.




L17 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 1972:514701 CAPLUS  
 DOCUMENT NUMBER: 77:114701  
 TITLE: 3.alpha.-Hydroxy-5.alpha.-pregnane-11,20-diones  
 INVENTOR(S): Philipps, Gordon Hanley; Newall, Christopher  
 Earle  
 PATENT ASSIGNEE(S): Glaxo Laboratories Ltd.  
 SOURCE: Ger. Offen., 45 pp.  
 CODEN: GWXXEX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2162594	A	19720706	DE 1971-2162594	19711216
NL 7117249	A	19720620	NL 1971-17249	19711216
FR 2118118	A5	19720728	FR 1971-45226	19711216
FR 2118118	B1	19751128		
US 3882151	A	19750506	US 1971-208961	19711216
CA 955662	A1	19760824	CA 1971-130271	19711216
US 3969345	A	19760713	US 1975-551315	19750220
			GB 1970-60065	19701217
			US 1971-208961	19711216

PRIORITY APPLN. INFO.:  
 AB Twenty title compds. [I, R = H<sub>2</sub>, O; R<sub>1</sub> = H, Ac, O<sub>2</sub>N; R<sub>2</sub> = H, Me; R<sub>3</sub> = H, .beta.-MeO, .alpha.-OH, R<sub>4</sub> = OMe, OEt, OCHMe<sub>2</sub>, O(CH<sub>2</sub>)<sub>2</sub>OMe, OCH<sub>2</sub>CH<sub>2</sub>OMe, O(CH<sub>2</sub>)<sub>2</sub>Cl, 2-morpholinoethoxy, 2-(4-methylpiperazinyl)ethoxy, O(CH<sub>2</sub>)<sub>2</sub>CH<sub>2</sub>, O(CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>Et, O(CH<sub>2</sub>)<sub>2</sub>Cl, O(CH<sub>2</sub>)<sub>3</sub>Cl, OCH<sub>2</sub>Ph, cyclohexyloxy], useful as anesthetics, were prepd. by methylation of the corresponding 21-diazo compd. Thus, 21-diazo-3.beta.-nitrate-5.alpha.-pregnane-11,20-dione in dry CH<sub>2</sub>Cl<sub>2</sub>-MeOH was refluxed with 14% BF<sub>3</sub>.MeOH 25 min to give I (R = O, R<sub>1</sub> = NO<sub>2</sub>, R<sub>2</sub> = R<sub>3</sub> = H, R<sub>4</sub> = OMe), which was stirred with Zn powder in HOAc 1.5 hr to give I (R = O, R<sub>1</sub> = R<sub>2</sub> = R<sub>3</sub> = H, R<sub>4</sub> = OMe).  
 IT 38601-47-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)  
 RN 38601-47-7 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-(phenylmethoxy)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)




L17 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 1972:514688 CAPLUS  
 DOCUMENT NUMBER: 77:114688  
 TITLE: 17.alpha.-Hydroxy-20-Oxo- and 17.alpha.,21-dihydroxy-20-oxo-pregnanes and their derivatives and intermediates  
 INVENTOR(S): Crabbe, Pierre; Velarde, Esperanza  
 PATENT ASSIGNEE(S): Syntex Corp.  
 SOURCE: U.S., 14 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3681410	A	19720801	US 1970-62201	19700807
GB 1313148	A	19730411	GB 1970-41785	19700901
ES 383319	A1	19730116	ES 1970-383319	19700902
			US 1969-854742	19690902
			US 1970-62201	19700807

PRIORITY APPLN. INFO.:  
 AB 17-Vinylidene steroids, prepd. by treating the 17.beta.-acetoxy-17.alpha.-ethynyl deriv. with Zn dust, were oxidized with OsO<sub>4</sub> to give the title compds. Thus, androstane (I, R = .beta.-AcO, .alpha.-H; R<sub>1</sub> = .beta.-OAc, .alpha.-C.tplbond.CH<sub>2</sub>; R<sub>2</sub> = R<sub>4</sub> = H, R<sub>3</sub> = H<sub>2</sub>) was added to a mixt. of Zn dust and Me(OCH<sub>2</sub>)<sub>2</sub>OMe and the mixt. refluxed 7.5 hr to give I (R = .beta.-AcO, .alpha.-H; R<sub>1</sub> = C(CH<sub>2</sub>)<sub>2</sub>; R<sub>2</sub> = R<sub>4</sub> = H; R<sub>3</sub> = H<sub>2</sub>). This was oxidized in pyridine with OsO<sub>4</sub> at 20.degree. to give I (R = .beta.-AcO, .alpha.-H; R<sub>1</sub> = .beta.-COCH<sub>2</sub>OH, .alpha.-OH; R<sub>2</sub> = R<sub>4</sub> = H; R<sub>3</sub> = H<sub>2</sub>). An addnl. 16 I [R = .beta.-AcO, .alpha.-H; R<sub>1</sub> = .beta.-COCH<sub>2</sub>OH, .alpha.-OH; R<sub>2</sub> = R<sub>4</sub> = H; R<sub>3</sub> = H<sub>2</sub>]. An O(CH<sub>2</sub>)<sub>2</sub> R<sub>1</sub> = C(CH<sub>2</sub>)<sub>2</sub>; .beta.-COCH<sub>2</sub>OH, .alpha.-H; .alpha.-O<sub>2</sub>CC<sub>6</sub>H<sub>4</sub>Cl-m, .beta.-Et; .beta.-COCH<sub>2</sub>CO<sub>2</sub>CC<sub>6</sub>H<sub>4</sub>Cl-m, .alpha.-OH; .alpha.-AcO, .beta.-Ac; R<sub>2</sub> = F, H; R<sub>3</sub> = .beta.-OH, H; O; R<sub>4</sub> = Me, H, OH] and their .DELTA.4 and .DELTA.4,6 deriva. were prepd. in an analogous manner.  
 IT 35458-61-8P 36025-59-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)  
 RN 35458-61-8 CAPLUS  
 CN Pregnane-20-one, 3-(acetyloxy)-21-[(3-chlorobenzoyl)oxy]-17-hydroxy-, (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 36025-59-9 CAPLUS  
 CN Pregnane-20-one, 21-[(3-chlorobenzoyl)oxy]-3,17-dihydroxy-6,16-dimethyl-, (3.beta.,5.alpha.,6.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2000 ACS


ACCESSION NUMBER: 1972:502035 CAPLUS  
 DOCUMENT NUMBER: 77:102035  
 TITLE: 3.alpha.-Hydroxy-5.alpha.-pregnane-11,20-diones  
 INVENTOR(S): Philipps, Gordon Hanley; Newall, Christopher  
 Barle;  
 PATENT ASSIGNER(S): Cook, Martin Christopher  
 Glaxo Laboratories Ltd.  
 SOURCE: Ger. Offen., 35 pp.  
 CODEN: GWXXEX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2162592	A	19720706	DE 1971-2162592	19711216
BE 776787	A1	19720616	BE 1971-111747	19711216
NL 7117250	A	19720620	NL 1971-17250	19711216
FR 2118119	A5	19720728	FR 1971-45227	19711216
FR 2118119	B1	19751128		
AU 7136960	A1	19730621	AU 1971-36960	19711216
US 3883569	A	19750513	US 1971-208985	19711216
CA 979895	A1	19751216	CA 1971-130274	19711216
ZA 7108464	A	19730829	ZA 1971-8464	19711217
			GB 1970-60066	19701217

PRIORITY APPL. INFO.:  
 AB Sixteen 3.alpha.-hydroxy-11,20-dioxo-5.alpha.-pregnan-21-yl esters  
 (I, R =  
 H, MeO; R1 = O2CH2C6H4NH2-p, nicotinoyloxy, O2CH2Cl, O2CH2I,  
 O2CH2NMe2, morpholinoacetoxy, 4-methyl-1-piperazinylacetoxy, OCO2Et,  
 O2CH2NH2, O2CH2NMe2, O2CH2C6H4NO2-p) were prepd. by bromination of  
 I (R =  
 = H, MeO; R = H) at the 21 position followed by reaction with the  
 corresponding acid. Thus, I (R = R1 = H) in MeOH was treated with Br  
 in  
 the presence of AcCl to give I (R = H, R1 = Br), which reacted with  
 p-ONC6H4CH2CO2H to give I (R = H, R1 = O2CH2C6H4NO2-p).  
 IT 38392-70-0P 38392-71-1P 38392-72-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 38392-70-0 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(4-nitrophenyl)acetyl]oxy]-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 38392-71-1 CAPLUS  
 CN Pregnane-11,20-dione, 21-[(4-aminophenyl)acetyl]oxy]-3-hydroxy-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 38392-72-2 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(3-pyridinylcarbonyl)oxy]-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)




L17 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1972:141212 CAPLUS  
 DOCUMENT NUMBER: 76:141212  
 TITLE: Intermediates and process for preparing  
 progestational  
 and antiinflammatory 17.alpha.-hydroxy- and  
 17.alpha.,21-dihydroxy-20-oxo pregnanes and their  
 derivatives  
 INVENTOR(S): Fried, John H.  
 PATENT ASSIGNER(S): Syntex Corp.  
 SOURCE: U.S., 11 pp.  
 CODEN: USXXAH  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3637670	A	19720125	US 1969-854746	19690902

AB The title pregnanes were prepd. by treating 17-oxoandrostanes with  
 Ph3P:CH2 (I), converting the 17-methyleneandrostanes obtained to  
 17-spiroandrostanes with a dihalocarbene, converting these to  
 17-vinylidene-androstanes, and oxidizing the latter. Thus,  
 5.alpha.-androstane-3.beta.-ol-17-one (II, R = H, (R1R2) = O) with I in  
 C6H6-Me2SO 14 hr at 85.degree. gave II [R = H, (R1R2) = CH2], which on  
 refluxing with CHBr3-KOCHMe3 in Me3COH-C6H6 gave II [R = H, (R1R2) =  
 CBr2CH2]. This was treated with BuLi in Et2O at -10.degree. to give  
 II [R  
 = H, (R1R2) = C:CH2], which was acetylated to give II [R = Ac, (R1R2)  
 =  
 C:CH2] (III). III was oxidized with OsO4 in pyridine 10 days at room  
 temp. to give II [R = Ac, R1 = OH, R2 = HOCH2CO].  
 IT 35458-61-8P 36025-59-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 35458-61-8 CAPLUS  
 CN Pregnane-20-one, 3-(acetoxy)-21-[(3-chlorobenzoyl)oxy]-17-hydroxy-,  
 (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L17 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)

RN 36025-59-9 CAPLUS  
 CN Pregnane-20-one,  
 21-[(3-chlorobenzoyloxy)-3,17-dihydroxy-6,16-dimethyl-,  
 (3.beta.,5.alpha.,6.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1972:46378 CAPLUS  
 DOCUMENT NUMBER: 76:46378  
 TITLE: Two-step synthesis of the pregnane and corticoid  
 sidechains  
 AUTHOR(S): Biollaz, M.; Haefliger, V.; Velarde, E.; Crabbe,  
 P.;

Fried, J. H.  
 CORPORATE SOURCE: Res. Lab., Syntex, S. A., Mexico D. F., Mex.  
 SOURCE: J. Chem. Soc. D. (1971), (21), 1322-3  
 CODEN: CCJDAO

DOCUMENT TYPE: Journal

LANGUAGE: English

AB 17.alpha.-Ethynyl-3.beta.,17.beta.-diacetoxy-5.alpha.-androstane was  
 reduced with Zn dust in refluxing anhyd. diglyme to give 86% the  
 allene

(I). I reacted with OsO<sub>4</sub>-pyridine in benzene, followed by cleavage  
 of the

osmate ester (Na<sub>2</sub>SO<sub>3</sub>-KHC03), to give 53% 17.alpha.,21-diol (II). I  
 reacted with excess m-chloroperbenzoic acid in CHCl<sub>3</sub> buffered with

Na<sub>2</sub>HPO<sub>4</sub>  
 to give a pregnane-3.beta.,17.alpha.-diol on hydrolysis.


IT 35458-61-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)

RN 35458-61-8 CAPLUS

CN Pregnane-20-one, 3-(acetyloxy)-21-[(3-chlorobenzoyloxy)-17-hydroxy-,  
 (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1971:464114 CAPLUS  
 DOCUMENT NUMBER: 75:64114  
 TITLE: Anesthetic pharmaceutical preparations containing  
 Davis, Benjamin; Pearce, Derek R.; Cook, Martin  
 Christopher; Weir, Niell G.; Newall, Christopher

INVENTOR(S):

E.;

Gordon

Ayres, Barry E.; Gregory, Gordon I.; Phillipp,  
 H.  
 Glaxo Laboratories Ltd.  
 S. African, 57 pp.

SOURCE: CODEN: SPXXAB

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ZA 7003861	A	19710224	ZA 1970-3861	19700608
GB 1317184	A	19730516	GB 1969-31371	19690620
BR 6915173	A0	19730208	BR 1969-215173	19691215
IL 34713	A1	19750625	IL 1970-34713	19700612
US 3714352	A	19730130	US 1970-47163	19700617
BE 752165	A	19701218	BE 1970-752165	19700618
SE 406038	C	19790510	SE 1970-8517	19700618
SE 406038	B	19790122		
NL 7009002	A	19701222	NL 1970-9002	19700619
NL 169480	B	19820216		
NL 169480	C	19820716		
FR 2052999	A1	19710416	FR 1970-22783	19700619
FR 2052999	A5	19710416		
FR 2052998	A1	19710416	FR 1970-22782	19700619
FR 2052998	A5	19710416		
DE 2065332	A1	19730405	DE 1970-2065332	19700619
ES 380943	A1	19730701	ES 1970-380943	19700619
DE 2065513	A1	19740404	DE 1970-2065513	19700619
AT 315375	B	19740527	AT 1970-5555	19700619
DK 129390	B	19741007	DK 1970-3179	19700619
NO 133716	B	19760308	NO 1970-2396	19700619
CA 1001073	A1	19761207	CA 1970-85973	19700619
JP 48043905	B4	19731221	JP 1970-53223	19700620
CH 578016	A	19760730	CH 1975-2408	19700622
CH 591517	A	19770930	CH 1970-9417	19700622
US 3763195	A	19731002	US 1971-114036	19710209
US 3816624	A	19740611	US 1971-208922	19711216
DK 134996	B	19770221	DK 1971-6420	19711229
AT 7207108	A	19750315	AT 1972-7108	19720817
JP 51040135	B4	19761101	JP 1972-93152	19720916
US 3781435	A	19731225	US 1973-321274	19730105
SE 401512	B	19780516	SE 1974-2197	19740219
CA 1037026	A2	19780822	CA 1975-217940	19750115
			GB 1969-31371	19690620
			US 1970-47163	19700617
			CA 1970-85973	19700619

PRIORITY APPLN. INFO.:

L17 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)

DK 1970-3179 19700619  
 CH 1970-9417 19700622

AB 3.beta.-Acetoxy-5.alpha.-pregn-16-ene-11,20-dione in dioxane and aq.  
 KOH

was kept 1 hr at room temp. and heated 1 hr at 40.degree. to give  
 3.beta.-hydroxy-5.alpha.-pregn-16-ene-11,20-dione. This in dry C<sub>5</sub>H<sub>5</sub>N

was treated with p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>Cl to give the 3.beta.-p-toluenesulfonate.

This in aq. DMF heated 2.5 hr at 115.degree. with KOAc and worked up gave  
 3.alpha.-hydroxy-5.alpha.-pregn-16-ene-11,20-dione, hydrogenated over

5% Pd-C to give 3.alpha.-hydroxy-5.alpha.-pregnane-11,20-dione. Many  
 other

examples, and compns. for use, were given.


IT 32226-13-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)

RN 32226-13-4 CAPLUS

CN Pregnane-11,20-dione, 21-(benzoyloxy)-3-hydroxy-, (3.alpha.,5.alpha.)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L17 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 1971:420793 CAPLUS  
 DOCUMENT NUMBER: 75:20793  
 TITLE: Anesthetic steroidal compositions  
 INVENTOR(S): Davis, Benjamin; Pearce, Derek R.; Cook, Martin  
 Christopher; Weir, Niall G.; Ayres, Barry E.;  
 Gregory,  
 PATENT ASSIGNEE(S): Gordon I.; Philipps, Gordon Hanley  
 Glaxo Laboratories Ltd.  
 SOURCE: Ger. Offen., 53 pp.  
 CODEN: GWXKEX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2030402	A	19710121	DE 1970-2030402	19700619
DE 2030402	B2	19750430		
DE 2030402	C3	19751211		
GB 1317184	A	19730516	GB 1969-31371	19690620
BR 6915173	A0	19730208	BR 1969-215173	19691215
IL 34713	A1	19750625	IL 1970-34713	19700612
US 3714352	A	19730130	US 1970-47163	19700617
BE 752165	A	19701218	BE 1970-752165	19700618
SE 406038	C	19790510	SE 1970-8517	19700618
SE 406038	B	19790122		
NL 7009002	A	19701222	NL 1970-9002	19700619
NL 169480	B	19820216		
NL 169480	C	19820716		
FR 2052999	A1	19710416	FR 1970-22783	19700619
FR 2052999	A5	19710416		
FR 2052998	A1	19710416	FR 1970-22782	19700619
FR 2052998	A5	19710416		
DE 2065332	A1	19730405	DE 1970-2065332	19700619
ES 380943	A1	19730701	ES 1970-380943	19700619
DE 2065513	A1	19740404	DE 1970-2065513	19700619
AT 315375	B	19740527	AT 1970-5555	19700619
DK 129390	B	19741007	DK 1970-3179	19700619
NO 133716	B	19760308	NO 1970-2396	19700619
CA 1001073	A1	19761207	CA 1970-85973	19700619
JP 48043905	B4	19731221	JP 1970-53223	19700620
CH 578016	A	19760730	CH 1975-2408	19700622
CH 591517	A	19770930	CH 1970-9417	19700622
US 3763195	A	19731002	US 1971-114036	19710209
US 3816624	A	19740611	US 1971-208922	19711216
DK 134996	B	19770221	DK 1971-6420	19711229
AT 7207108	A	19750315	AT 1972-7108	19720817
JP 51040135	B4	19761101	JP 1972-93152	19720916
US 3781435	A	19731225	US 1973-321274	19730105
SE 401512	B	19780516	SE 1974-2197	19740219
CA 1037026	A2	19780822	CA 1975-217940	19750115

L17 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)  
 PRIORITY APPLN. INFO.: GB 1969-31371 19690620  
 US 1970-47163 19700617  
 CA 1970-85973 19700619  
 DK 1970-3179 19700619  
 CH 1970-9417 19700622

AB Aq. solns. contg. more than 1 mg/ml  
 3.alpha.-hydroxy-5.alpha.-pregnane-  
 11,20-dione (I) were prepd. by addn. of more than 1% of a nonionic  
 surface active compd. (HLB-value 9-18) that is tolerated in parental  
 application,  
 such as polyethoxylated derivs. of fatty C12-20 glyceride oils, e.g.  
 Cremophor EL (II), a polyethoxylated castor oil contg. about 40  
 ethylene  
 oxide units per triglyceride unit, polyoxyethylene polyoxypropylene  
 ethers, polyoxyethylene ethers of alkyl phenols, etc. Thus,  
 3.beta.-acetoxy-5.alpha.-pregn-16-ene-11,20-dione was saponif. with  
 aq. KOH  
 to give 3.beta.-hydroxy-5.alpha.-pregn-16-ene-11,20-dione, which was  
 converted into the 3.beta.-tosylate (III) with p-MeCGH4SO2Cl.  
 Treatment  
 of III with KOAc in DMF-H2O 2.5 hr at 115.degree. gave  
 3.alpha.-hydroxy-5.alpha.-pregn-16-ene-11,20-dione, which was  
 hydrogenated  
 in THF over 5% Pd/C to give I. Also prepd. were 4 21-acyloxy derivs.  
 of I  
 and nitrate and hemisuccinate esters of pregnan-3(20)-ols. I  
 (0.03)  
 pulverized to 5 .mu. particles, and 2 g II were mixed and warmed in  
 N-atm.  
 to 70.degree. until a soln. was obtained. Subsequent diln. with H2O  
 contg. 0.025 g NaCl to 10 ml with stirring gave a homogeneous soln.  
 IT 32226-13-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 32226-13-4 CAPLUS  
 CN Pregnane-11,20-dione, 21-(benzoyloxy)-3-hydroxy-, (3.alpha.,5.alpha.)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)



L17 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 1970:121828 CAPLUS  
 DOCUMENT NUMBER: 72:121828  
 TITLE: Pregnane ethers as orally effective  
 mineralo-corticoids  
 PATENT ASSIGNEE(S): Marck, E., A.-G.  
 SOURCE: Brit., 9 pp.  
 CODEN: BRXXAA  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1183899		19700311		
PRIORITY APPLN. INFO.:			DE	19671213
AB Title compds., orally effective mineralo-corticoids without glucocorticoid side effects, were prepd. Thus, 100 mg 3.alpha.,21-dihydroxypregn-4-en-20- one 3-(p-toluenesulfonate) was kept 24 hr in 5 ml MeOH contg. 10 mg p-MeCGH4SO3H to give 3.alpha.-methoxy-21-hydroxypregn-4-en-20-one (I), 143-5.degree.. This (500 mg), 3 ml pyridine, and 3 ml Ac2O stirred 3 hr gave 3.alpha.-methoxy-21-acetoxypregn-4-en-20-one. 20,20- Ethylenedioxy-21-hydroxypregn-4-ene-3.beta.,21-diol (2.6 g) and 230 mg p-MeCGH4SO3H in 1.3 l. MeOH kept 8 hr gave 3.beta.-methoxy-21-hydroxypregn-4-en-20-one, m. 101-3.degree. and 1 (sepd. by chromatog. on silica gel). Other compds. (.apprx.10) were also prepd. IT 26623-69-8P RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of) RN 26623-69-8 CAPLUS CN Pregn-4-en-20-one, 3.beta.-methoxy-21-(trityloxy)- (8CI) (CA INDEX NAME)				

Absolute stereochemistry.



09/321,882

Page 20

L17 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)


L17 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 1991:185851 CAPLUS  
 DOCUMENT NUMBER: 114:185851  
 TITLE: Preparation and formulation of pregnane derivatives as antiangiogenesis agents  
 INVENTOR(S): Aristoff, Paul A.; Skulnick, Harvey I.; Wierenga, Wendell  
 PATENT ASSIGNER(S): Upjohn Co., USA  
 SOURCE: U.S., 17 pp. Cont.-in-part of U.S. Ser. No. 87,228,  
 abandoned.  
 CODEN: USXQAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4975537	A	19901204	US 1989-351977	19890515
PRIORITY APPL. INFO.:			US 1985-790564	19851023
			US 1985-811866	19851220
			US 1987-87228	19870619


OTHER SOURCE(S): MARPAT 114:185851  
 AB Title steroids I [R1 = .beta.-Me, .beta.-Et; R2 = H and R3 = O, OH, alkoxy, alkanoyloxy, (un)substituted aryloxy, aralkanoyloxy, heteroaryloxy, carbamoyloxy, aryloxy-carbonyloxy, alkoxy-carbonyloxy; R2 = .alpha.-Cl, R3 = .beta.-Cl; R2R3 = O, bond; R2 = .alpha.-F, R3 = .beta.-OH; R4 = H, Me, Cl, F; R5 = H, OH, F, Cl, Br, Me, Ph, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>; R6 = H, Me; R9 = H, OH, Me, F, CH<sub>2</sub>; R10 = H, OH, Me; R9R10 = bond; R12 = H; R13 = OH, O, OP(O)(OH)2, O2C(CH2)nCO2H; n = 2-6; R14 = H; R12R14 = bond; R15 = O, H(OH); R23 = OH or various derivs.; R10R23 = .alpha.-OP(O)(OH)2; various specific provisos and excluded compds.] are prepd. as antiangiogenic agents. Dropwise addn. of 0.68 mL distd. pyrophosphoryl chloride to 1.65 g 6.alpha.-fluoro-17,21-dihydroxy-16.beta.-methyl-3,20-dioxopregna-4,9(11)-diene in THF at -35.degree. gave 91.5% of the corresponding 21-phosphate deriv. (II). At 50 .mu.g/10 .mu.L polymeric vehicle in chick embryos and in the presence of a similar amt. of heparin, II inhibited angiogenesis by 58% of control. An injectable soln. contained 155 mg II.2Na and dil. NaOH (to pH 5.3) in sterile H2O to 1 mL.  
 IT 111245-66-0P  
 RL: SPN (Synthetic preparation); FORM (Formation, nonpreparative);  
 PREP

L17 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)  
 CN Pregn-9(11)-en-20-one, 21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-, (5.alpha.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L17 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)  
 (Preparation)  
 (formation of, in prepn. of antiangiogenesis agents)  
 RN 111245-66-0 CAPLUS  
 CN Pregn-9(11)-en-20-one, 21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-, (3.alpha.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.



IT 111245-67-1P 133442-74-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and reaction of, in prepn. of antiangiogenesis agents)  
 RN 111245-67-1 CAPLUS  
 CN Pregn-9(11)-en-20-one, 21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-, (3.beta.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.



RN 133442-74-7 CAPLUS

L17 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 1976:478264 CAPLUS  
 DOCUMENT NUMBER: 85:78264  
 TITLE: 21-Substituted pregnanes  
 INVENTOR(S): Philipps, Gordon H.; Lawrence, Robin; Newall, Christopher E.; Wright, Michael  
 PATENT ASSIGNER(S): Glaxo Laboratories Ltd., Engl.  
 SOURCE: Brit., 21 pp.  
 CODEN: BRXQAA  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1432135	A	19760414	GB 1972-21145	19730504
BE 799103	A1	19731105	BE 1973-130750	19730504
NL 7306233	A	19731107	NL 1973-6233	19730504
DE 2322560	A1	19731115	DE 1973-2322560	19730504
FR 2183794	A1	19731221	FR 1973-16111	19730504
ZA 7303036	A	19740424	ZA 1973-3036	19730504
JP 49047361	A2	19740508	JP 1973-50184	19730504
AU 7355285	A1	19741107	AU 1973-55285	19730504
US 3959260	A	19760525	US 1974-488989	19740716
PRIORITY/APPL. INFO.:			GB 1972-21145	19720505
			US 1973-356097	19730501

AB Forty title compds. I (R = H, Me, alkoxy; R1, R2 = H, Me; R32 = O, R3 = H; R4 = acylthio, heterocycle-substituted acylthio, alkylthio, heterocycle-substituted alkylthio, EtSO2, EtSO, NCS, HS, BuS2CS, morpholinocarbodithio, morpholinoethoxythiocarbonylthio) and 2 related compds., useful as anesthetics, were prepd. from 21-bromo steroids by condensation reactions. Thus, refluxing 21-bromo-3.alpha.-hydroxy-5.alpha.-pregnane-11,20-dione with BzSNa in Me2CO 40 min gave I (R =

R1 = H, R2 = Me, R32 = O, R4 = BzS). Solns. of I in aq. nonionic surfactants are suitable for parenteral administration, as is a similar soln. of 21-acetylthio-3.alpha.-hydroxy-5.beta.-pregnane-11,20-dione.  
 IT 51086-87-4P 51086-88-5P 51086-89-6P  
 51086-90-9P 51086-91-0P 51086-92-1P  
 51086-99-8P 51087-12-8P 51087-25-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (anesthetic, prepn. of)  
 RN 51086-87-4 CAPLUS  
 CN Pregnane-11,20-dione, 21-(benzoylthio)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

L13 ANSWER 6 OF 8 MARPAT COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 123:228632 MARPAT  
 TITLE: Substituted 2.beta.-morpholinoandrostane  
 INVENTOR(S): Campbell, Alexander Cupples  
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.  
 SOURCE: Eur. Pat. Appl., 24 pp.  
 CODEN: EPXKDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 656365	A1	19950607	EP 1994-203468	19941129
EP 656365	B1	19970409		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ZA 9409226	A	19950801	ZA 1994-9226	19941121
CA 2136915	AA	19950603	CA 1994-2136915	19941129
AT 151436	E	19970415	AT 1994-203468	19941129
FI 9405674	A	19950603	FI 1994-5674	19941201
NO 9404626	A	19950606	NO 1994-4626	19941201
AU 9479175	A1	19950608	AU 1994-79175	19941201
AU 681714	B2	19970904		
HU 69391	A2	19950928	HU 1994-3454	19941201
US 5593983	A	19970114	US 1994-347974	19941201
JP 07196684	A2	19950801	JP 1994-299861	19941202
			EP 1993-309663	19931202

PRIORITY APPLN. INFO.:  
 AB The invention is related to substituted 2.beta.-morpholino-androstane  
 deriva. I [R = substituted morpholino, thiomorpholino; R1-R3 = H, Me;

R4 = CN, COCH2R5; R5 = H, halogen, (un)substituted OH, CN, N3, SCH, (un)substituted alkyl, amino; X = O, H2, H, OH; the dotted bonds are single or double bonds; or a pharmaceutically acceptable salt thereof.  
 These steroids are very potent i.v. anesthetics. The compds. have fast onset times and ideal sleep duration vs. recovery to full coordination profiles.  
 Thus, (2.alpha.,3.alpha.,5.alpha.)-2,3-epoxypregnane-11,20-dione cyclic ethylene acetal was treated with 2,2-dimethylmorpholine to give (2.beta.,3.alpha.,5.alpha.)-3-hydroxy-2-(2,2-dimethylmorpholin-4-yl)pregnane-11,20-dione which had a therapeutic index of 13.4 as an anesthetic in mice.

MPTR 1

L13 ANSWER 6 OF 8 MARPAT COPYRIGHT 2000 ACS (Continued)



G9 = 56

$C(=O)CH_2-G10$

G10 = OPh  
 DER: or pharmaceutically acceptable salts  
 MPL: claim 2

L13 ANSWER 7 OF 8 MARPAT COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 122:291311 MARPAT  
 TITLE: Preparation and formulation of 3.alpha.-hydroxypregnanes and analogs as sedatives and hypnotics  
 INVENTOR(S): Gee, Kelvin V.; Lan, Nancy Tsai-Yun  
 PATENT ASSIGNEE(S): Cocoonys, Inc., USA  
 SOURCE: PCT Int. Appl., 152 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9427608	A1	19941208	WO 1994-US5820	19940524

R: AU, CA, JP, KR, NO  
 RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2163748	AA	19941208	CA 1994-2163748	19940523
JP 08511771	T2	19961210	JP 1994-500892	19940523
AU 9469883	A1	19941220	AU 1994-69883	19940524
EP 701444	A1	19960320	EP 1994-918659	19940524
EP 1038880	A2	20000927	EP 2000-200119	19950214

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5939545	A	19990817	US 1997-887229	19970702
US 6143736	A	20001107	US 1999-349902	19990708

PRIORITY APPLN. INFO.:  
 US 1993-68378 19930524  
 US 1994-196919 19940214  
 US 1994-196972 19940214  
 US 1994-246275 19940519  
 WO 1994-US5820 19940523  
 US 1994-346927 19941123  
 EP 1995-913478 19950214  
 US 1995-389820 19950214  
 US 1997-887229 19970702

AB Title compds. (e.g.): R = H, (halo)alkyl, alkenyl, alkynyl, aryl(alkyl), etc.; R1 = H or Me; R2 = cyano, CH2OH, COMe, C.tpbond.CH, etc.; R3 = H; R2R3 = CH2, CHOMe, CHMe, CHet; for interaction with the GABAA receptor complex to induce sleep in humans, were prepd. Thus, 5.alpha.-pregnane-3,20-dione 20-ketal was converted in 2 steps to title compd. II (R = C.tpbond.CH) which was condensed with 4-ICSH4COMe to give II [R = 4-(MeCO)CGH4C.tpbond.C] which had IC50 of 5nM against TBPS binding at rat cerebral cortex prepn. in vitro.

MPTR 1


L13 ANSWER 7 OF 8 MARPAT COPYRIGHT 2000 ACS (Continued)



G4 = 25

$HC-G6$

G6 = 56



DER: and pharmaceutically acceptable esters  
 MPL: claim 1

L13 ANSWER 8 OF 8 HARPAT COPYRIGHT 2000 ACS


L13 ANSWER 8 OF 8 HARPAT COPYRIGHT 2000 ACS (Continued)

ACCESSION NUMBER: 122:231756 HARPAT  
 TITLE: Method for regulating neuropeptide hormone  
 secretion  
 INVENTOR(S): Jackson, Meyer B.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: PCT Int. Appl., 26 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9505826	A1	19950302	WO 1994-US9334	19940819
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9475691	A1	19950321	AU 1994-75691	19940819
PRIORITY APPLN. INFO.:				
			US 1993-109683	19930820
			WO 1994-US9334	19940819

AB Methods are described for regulating neuropeptide, vasopressin and oxytocin, secretion to alleviate premature labor, hypertension, fluid imbalance, and risk of heart disease using neuroactive steroids, such as allopregnanolone and alphaxalone, targeted for a newly-identified site of action in the nerve terminals of neurosecretory neurons in the posterior pituitary.

MSTR 1




G1 = OH  
 G5 = 65

$G_5^C(O)CH_2-O-G_6$

G6 = pyridyl  
 MPL: claim 1


L11 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



L11 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1982:35629 CAPLUS  
 DOCUMENT NUMBER: 96:35629  
 TITLE: Replacement of the butenolide moiety of digitoxigenin by cyclic Michael acceptor systems  
 AUTHOR(S): Guzman, Angel; Muchowski, Joseph M.; Strosberg, Arthur  
 CORPORATE SOURCE: M.; Sims, John M.  
 SOURCE: Div. Invest., Syntex, S. A., Mexico City, Mex.  
 CODEN: CJCHAG; ISSN: 0008-4042  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Digitoxigenin analogs were prepd. in which the butenolide moiety was replaced by other 5- or 6-membered cyclic Michael acceptor systems.  
 IT 80367-29-9p  
 RL: RCT (Reactant); SPM (Synthetic preparation); PREP (Preparation) (prepn. and oxidn. of)  
 RN 80367-29-9 CAPLUS  
 CN Pregnane-20-one, 3-(acetyloxy)-14-hydroxy-21-(phenylthio)-, (3.alpha.,5.alpha.,14.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1976:478264 CAPLUS  
 DOCUMENT NUMBER: 85:78264  
 TITLE: 21-Substituted pregnanes  
 INVENTOR(S): Philipps, Gordon H.; Lawrence, Robin; Nevall, Christopher E.; Wright, Michael  
 PATENT ASSIGNEE(S): Glaxo Laboratories Ltd., Engl.  
 SOURCE: Brit., 21 pp.  
 CODEN: BPOGAA  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1432135	A	19760414	GB 1972-21145	19730504
BE 799103	A1	19731105	BE 1973-130750	19730504
NL 7306233	A	19731107	NL 1973-6233	19730504
DE 2322560	A1	19731115	DE 1973-2322560	19730504
FR 2183794	A1	19731221	FR 1973-16111	19730504
ZA 7303036	A	19740424	ZA 1973-3036	19730504
JP 49047361	A2	19740508	JP 1973-50184	19730504
AU 7355285	A1	19741107	AU 1973-55285	19730504
US 3566260	A	19760525	US 1974-48989	19740716
			GB 1972-21145	19720505
			US 1973-356097	19730501

AB Forty title comps. I (R = H, Me, alkoxy; R1, R2 = H, Me; R32 = O, R3 = H)

R4 = acylthio, heterocycle-substituted acylthio, alkylthio, heterocycle-substituted alkylthio, EtSO<sub>2</sub>, EtSO, NCS, HS, BuS<sub>2</sub>CS, morpholinocarbodithio, morpholinoethoxythiocarbonylthio and 2 related comps., useful as anesthetics, were prepd. from 21-bromo-3.alpha.-hydroxy-5.alpha.-pregnane-11,20-dione with BzSNa in Me<sub>2</sub>CO 40 min gave I (R =


R1 = H, R2 = Me, R32 = O, R4 = BzS). Solns. of I in aq. nonionic surfactants are suitable for parenteral administration, as is a similar soln. of 21-acetylthio-3.alpha.-hydroxy-5.alpha.-pregnane-11,20-dione.

IT 51086-87-4P 51086-88-5P 51086-89-6P  
 51086-90-9P 51086-91-9P 51087-12-8P  
 RL: SPM (Synthetic preparation); PREP (Preparation) (anesthetic, prepn. of)

RN 51086-87-4 CAPLUS  
 CN Pregnane-11,20-dione, 21-(benzoylthio)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 51086-88-5 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(2-iodobenzoyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51086-89-6 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(2-nitrobenzoyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 51086-90-9 CAPLUS  
CN Pregnone-11,20-dione, 21-[[2-(ethoxycarbonyl)benzoyl]thio]-3-hydroxy-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51086-99-8 CAPLUS  
CN Pregnone-11,20-dione, 3-hydroxy-21-[[2-(methylthio)benzoyl]thio]-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 51087-12-8 CAPLUS  
CN Pregnone-11,20-dione, 3-hydroxy-21-[(phenylmethyl)thio]-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1974:37397 CAPLUS  
DOCUMENT NUMBER: 80:37397  
TITLE: Pregnane derivatives  
INVENTOR(S): Phillips, Gordon Hanley; Lawrence, Robin; Newall,  
Christopher E.; Wright, Michael  
PATENT ASSIGNEE(S): Glaxo Laboratories Ltd.  
SOURCE: Ger. Offen., 58 pp.  
CODEN: GWKXBX  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2322560	A1	19731115	DE 1973-2322560	19730504
GB 1432135	A	19760414	GB 1972-21145	19730504
			GB 1972-21145	19720505

PRIORITY APPLN. INFO.:  
AB Pregnanediones I-VIII (R = alkyl, aryl, morpholinoalkyl, piperidinoalkyl) (45 compds.), possessing anesthetic activity, were prepd. from 21-bromo-3.alpha.-hydroxy-5.alpha.-pregnane-11,20-dione (II). Thus, II was treated with EtSH to give VII (R = ET). I-VI and VIII were prepd. similarly.  
IT 51086-87-4P 51086-88-5P 51086-89-6P  
51086-90-9P 51086-99-8P 51087-12-8P  
RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)  
RN 51086-87-4 CAPLUS  
CN Pregnone-11,20-dione, 21-(benzoylthio)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51086-88-5 CAPLUS  
CN Pregnone-11,20-dione, 3-hydroxy-21-[(2-iodobenzoyl)thio]-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


L11 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)

Absolute stereochemistry.



RN 51086-89-6 CAPLUS  
CN Pregnone-11,20-dione, 3-hydroxy-21-[(2-nitrobenzoyl)thio]-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51086-90-9 CAPLUS  
CN Pregnone-11,20-dione, 21-[[2-(ethoxycarbonyl)benzoyl]thio]-3-hydroxy-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1972:514701 CAPLUS  
 DOCUMENT NUMBER: 77:114701  
 TITLE: 3.alpha.-Hydroxy-5.alpha.-pregnane-11,20-diones  
 INVENTOR(S): Philipps, Gordon Hanley; Newall, Christopher  
 PATENT ASSIGNEE(S): Glaxo Laboratories Ltd.  
 SOURCE: Ger. Offen., 45 pp.  
 CODEN: GVXKXB  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2162594	A	19720706	DE 1971-2162594	19711216
NL 7117249	A	19720620	NL 1971-17249	19711216
FR 2118118	A5	19720728	FR 1971-45226	19711216
FR 2118118	B1	19751128		
US 3882151	A	19750506	US 1971-208961	19711216
CA 995662	A1	19760824	CA 1971-130271	19711216
US 3969345	A	19760713	US 1975-551315	19750220
			GB 1970-60065	19701217
			US 1971-208961	19711216

PRIORITY APPLN. INFO.:  
 AB Twenty title compds. [I, R = H2, O; R1 = H, Ac, O2N; R2 = H, Me; R3 = H, .beta.-MeO, .alpha.-OH, R4 = OMe, OEt, OCHMe2, O(CH2)2OMe, OCH2NH2-p, O(CH2)2Cl, 2-morpholinomethoxy, 2-(4-methylpiperazinyl)ethoxy, O(CH2)2CN, O(CH2)2CO2Et, O(CH2)2Cl, O(CH2)2Cl, OCH2Ph, cyclohexyloxy], useful as anesthetics, were prepd. by methylation of the corresponding 21-diazo compd. Thus, 21-diazo-3.beta.-nitrate-5.alpha.-pregnane-11,20-dione in dry CH2Cl2-MeOH was refluxed with 14% BF3.MeOH 25 min to give I (R = O, R1 = NO2, R2 = R3 = H, R4 = OMe), which was stirred with Zn powder in HOAc 1.5 hr to give I (R = O, R1 = R2 = R3 = H, R4 = OMe).  
 IT 38601-34-2P 38601-47-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)  
 RN 38601-34-2 CAPLUS  
 CN Pregnane-11,20-dione, 21-(4-aminophenoxy)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

L11 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 38601-47-7 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-(phenylmethoxy)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.



20) CH<sub>2</sub> Y'-2-G =

103


L11 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1972:514688 CAPLUS  
 DOCUMENT NUMBER: 77:114688  
 TITLE: 17.alpha.-Hydroxy-20-oxo- and 17.alpha.,21-dihydroxy-20-oxo/pregnanes and their derivatives and intermediates  
 INVENTOR(S): Crabbe, Pierre; Velarde, Esperanza  
 PATENT ASSIGNEE(S): Syntex Corp.  
 SOURCE: U.S., 14 pp.  
 CODEN: USXQAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3681410	A	19720801	US 1970-62201	19700807
GB 1313148	A	19730411	GB 1970-41785	19700901
ES 383319	A1	19730116	ES 1970-383319	19700902
			US 1969-854742	19690902
			US 1970-62201	19700807

PRIORITY APPLN. INFO.:  
 AB 17-Vinylidene steroids, prepd. by treating the 17.beta.-acetoxo-17.alpha.-ethynyl deriv. with Zn dust, were oxidized with OsO4 to give the title compds. Thus, androstane (I, R = .beta.-AcO, .alpha.-H; R1 = .beta.-AcO, .alpha.-C.tplbond.CH; R2 = R4 = H, R3 = H2) was added to a mixt. of Zn dust and Me(OCH2)2OMe and the mixt. refluxed 7.5 hr to give I (R = .beta.-AcO, .alpha.-H; R1 = C:CH2; R2 = R4 = H; R3 = H2). This was oxidized in pyridine with OsO4 at 20.degree. to give I (R = .beta.-AcO, .alpha.-H; R1 = .beta.-COCH2OH, .alpha.-OH; R2 = R4 = H; R3 = H2). An addnl. 16 I [R = .beta.-AcO, .alpha.-H; .beta.-OH, .alpha.-H; O(CH2)2; R1 = C:CH2; .beta.-COCH2OH, .alpha.-H; .alpha.-O2CC6H4Cl-m, .beta.-Et; .beta.-COCH2O2CC6H4Cl-m, .alpha.-OH; .alpha.-AcO, .beta.-Ac; R2 = F, H; R3 = .beta.-OH, H; O; R4 = Me, H, OH] and their .DELTA.4 and .DELTA.4,6 derivs. were prepd. in an analogous manner.  
 IT 33458-61-8P 36025-59-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)  
 RN 35458-61-8 CAPLUS  
 CN Pregnane-20-one, 3-(acetyloxy)-21-[(3-chlorobenzoyl)oxy]-17-hydroxy-, (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

L11 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)




RN 36025-59-9 CAPLUS  
 CN Pregnane-20-one, 21-[(3-chlorobenzoyl)oxy]-3,17-dihydroxy-6,16-dimethyl-, (3.beta.,5.alpha.,6.beta.,16.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.



103




L11 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 51086-99-8 CAPLUS  
 CN Pregnone-11,20-dione, 3-hydroxy-21-[(2-(methylthio)benzoyl)thio]-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51087-12-8 CAPLUS  
 CN Pregnone-11,20-dione, 3-hydroxy-21-[(phenylmethyl)thio]-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



L11 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1973:515783 CAPLUS  
 DOCUMENT NUMBER: 79:115783  
 TITLE: 3.alpha.-Hydroxy-5.alpha.-steroids  
 INVENTOR(S): Clayton, John C. H.; Faulkner, Peter J.; Jones,  
 William Reginald; Philipps, Gordon H.; Bailey,  
 Esme  
 PATENT ASSIGNEE(S): Joan  
 Glaxo Laboratories Ltd.  
 SOURCE: Ger. Offen., 38 pp.  
 CODEN: GWXEXX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2255108	A1	19730809	DE 1972-2255108	19721110
DE 2255108	B2	19761202		
DE 2255108	C3	19770728		
GB 1409239	A	19751008	GB 1971-52465	19721108
NL 7215229	A	19730515	NL 1972-15229	19721110
JP 48067263	A2	19730913	JP 1972-112190	19721110
JP 57025560	B4	19820529		
FR 2177695	A1	19731109	FR 1972-39865	19721110
US 3822298	A	19740702	US 1972-305246	19721110
CA 972744	A1	19750812	CA 1972-156154	19721110
DK 133470	B	19760524	DK 1972-5591	19721110
CH 606097	A	19781013	CH 1972-16489	19721110
			GB 1971-52465	19711111

PRIORITY APPLN. INFO.:

AB 3.alpha.-Hydroxypregnes I and II [R, R3 and R5 = H, Me; R1 = HO; R2 = H;

R4 = H, AcO, MeO, Cl(CH2)3O, Cl(CH2)2O, PhCH2O, cyclopentylloxy; X = O] (15 compds.) were prepd. in 30-70% yield by redn. of I or II (R1R2 = O). Thus, 5.alpha.-pregnane-3,20-dione was treated with H2Irc16 in the presence of (MeO)3P to yield 64% I (R and R2-R4 = H, R1 = HO, R5 = Me, X = H2). I (R and R2-R4 = H, R1 = HO, R5 = H, X = H2, O), (R5 = Me, X = H2), and (R = R5 = Me; X = O) had anesthetic activity.

IT 38601-47-7p


RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)

RN 38601-47-7 CAPLUS

CN Pregnone-11,20-dione, 3-hydroxy-21-(phenylmethoxy)-,  
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)



103


L11 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1973:466672 CAPLUS  
 DOCUMENT NUMBER: 79:66672  
 TITLE: 21-(Acyloxy)-3.alpha.-hydroxypregnanes  
 INVENTOR(S): Cook, Martin Christopher; Davis, Benjamin;  
 Gregory, Gordon I.; Newall, Christopher E.; Pearce, Derek  
 R.:  
 PATENT ASSIGNEE(S): Phillips, Gordon H.; Weir, Niall G.  
 SOURCE: Glaxo Laboratories Ltd.  
 Brit., 8 pp. Division of Brit. 1,317,184.  
 CODEN: BRXKAA  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1317185	A	19730516	GB 1972-33162	19690620

AB 21-(Acyloxy)-3.alpha.-hydroxypregnanes, solubilizing promoters for 3.alpha.-hydroxy-5.alpha.-pregnane-11,20-dione (I), (R = H) were prepd. from I (R = H) or 3-O-substituted derivs. by reaction with Pb(OAc)<sub>4</sub>, and from I (R = Br) by treatment with R<sub>1</sub>CO<sub>2</sub>H (R<sub>1</sub> = Et, Me<sub>2</sub>CHCH<sub>2</sub>, and Ph) and NEt<sub>3</sub>.  
 IT 32226-13-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 32226-13-4 CAPLUS  
 CN Pregnane-11,20-dione, 21-(benzoyloxy)-3-hydroxy-, (3.alpha.,5.alpha.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



L11 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)

L11 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2000 ACS (Continued)  
(3.beta.,5.alpha.,6.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1973:148138 CAPLUS  
 DOCUMENT NUMBER: 78:148138  
 TITLE: 17.alpha.-Hydroxy-20-oxo- and 17.alpha.,  
 21-dihydroxy-20-oxopregnanes and their  
 17-vinylidene intermediates  
 INVENTOR(S): Crabbe, Pierre; Velarde, Esperanza  
 PATENT ASSIGNEE(S): Syntex Corp.  
 SOURCE: Ger. Offen., 48 pp.  
 CODEN: GWXKEX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2141127	A1	19730301	DE 1971-2141127	19710817

AB Diacetoxymethylandrostan-1 was treated with Zn dust in refluxing diglyme to give the vinylideneandrostan-11, which was oxidized by OsO<sub>4</sub> to yield the dihydroxypregnanone III. Oxidn. of fluorovinylideneandrostanol IV by CH<sub>3</sub>CO<sub>2</sub>OH gave a mixt of pregnanone V and hydroxypregnanone VI.  
 Approx. 70 compds. were prepd. including the 17-vinylidene derivs. of 1,2-(difluoromethylene)androst-4-en-3-one, 16.alpha.-methyl-3.beta.-hydroxy-androstan-11-one, and 6.alpha.-chloroandrost-4-en-3-one.  
 IT 35458-61-8P 36025-59-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 35458-61-8 CAPLUS  
 CN Pregnan-20-one, 3-(acetyloxy)-21-[(3-chlorobenzoyl)oxy]-17-hydroxy-, (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 36025-59-9 CAPLUS  
 CN Pregnan-20-one,  
 21-[(3-chlorobenzoyl)oxy]-3,17-dihydroxy-6,16-dimethyl-,

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 1974:37397 CAPLUS  
 DOCUMENT NUMBER: 80:37397  
 TITLE: Pregnane derivatives  
 INVENTOR(S): Phillips, Gordon Hanley; Lawrence, Robin; Newall, Christopher E.; Wright, Michael  
 PATENT ASSIGNEE(S): Glaxo Laboratories Ltd.  
 SOURCE: Ger. Offen., 58 pp.  
 CODEN: GWXKEX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2322560	A1	19731115	DE 1973-2322560	19730504
GB 1432135	A	19760414	GB 1972-21145	19730504
			GB 1972-21145	19720505



PRIORITY APPLN. INFO.:  
 AB Pregnanediones I-VIII (R = alkyl, aryl, morpholinoalkyl, piperidinoalkyl) (45 compds.), possessing anesthetic activity, were prepd. from 21-bromo-3.alpha.-hydroxy-5.alpha.-pregnane-11,20-dione (II). Thus, II was treated with EtSH to give VII (R = Et). I-VI and VIII were prepd. similarly.  
 IT 51087-29-7P 51087-32-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)  
 RN 51087-29-7 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-32-2 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.alpha.)-

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2000 ACS (Continued)  
 (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.





L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 1972:514701 CAPLUS  
 DOCUMENT NUMBER: 77:114701  
 TITLE: 3.alpha.-Hydroxy-5.alpha.-pregnane-11,20-diones  
 INVENTOR(S): Phillips, Gordon Hanley; Newall, Christopher  
 Earle  
 PATENT ASSIGNEE(S): Glaxo Laboratories Ltd.  
 SOURCE: Ger. Offen., 45 pp.  
 CODEN: GWXKEX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2162594	A	19720706	DE 1971-2162594	19711216
NL 7117249	A	19720620	NL 1971-17249	19711216
FR 2118118	A5	19720728	FR 1971-45226	19711216
FR 2118118	B1	19751128		
US 3882151	A	19750506	US 1971-208961	19711216
CA 955662	A1	19760824	CA 1971-130271	19711216
US 3969345	A	19760713	US 1975-551315	19750220
			GB 1970-60065	19701217
			US 1971-208961	19711216

PRIORITY APPLN. INFO.:  
 AB Twenty title compds. (I, R = H2, O; R1 = H, Ac, O2N; R2 = H, Me; R3 = H, .beta.-MeO, .alpha.-OH, R4 = OMe, OEt, OCHMe2, O(CH2)2OMe, OCGH4NH2-p, O(CH2)2Cl, 2-morpholinoethoxy, 2-(4-methylpiperazinyl)ethoxy, O(CH2)2CN, O(CH2)2CO2Et, O(CH2)2Cl, O(CH2)3Cl, OCH2Ph, cyclohexyloxy), useful as anesthetics, were prepd. by methylation of the corresponding 21-diazo compd. Thus, 21-diazo-3.beta.-nitrate-5.alpha.-pregnane-11,20-dione in dry CH2Cl2-MeOH was refluxed with 14% BF3.MeOH 25 min to give I (R = O, R1 = NO2, R2 = R3 = H, R4 = OMe), which was stirred with Zn powder in HOAc 1.5 hr to give I (R = O, R1 = R2 = R3 = H, R4 = OMe).  
 IT 38601-34-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)  
 RN 38601-34-2 CAPLUS  
 CN Pregnane-11,20-dione, 21-(4-aminophenoxy)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2000 ACS (Continued)



=> d ibib ab fqhit 1-8

L13 ANSWER 1 OF 8 MARPAT COPYRIGHT 2000 ACS

ACCESSION NUMBER: 131:351537 MARPAT  
 TITLE: Preparation of sterol derivatives as meiosis  
 regulating compounds

INVENTOR(S): Faarup, Peter; Gronwald, Frederik Christian;  
 Blume,

Thorsten; Murray, Ann; Murray, Anthony; Brainholt,  
 Jens

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.  
 SOURCE: PCT Int. Appl., 104 pp.

DOCUMENT TYPE: Patent  
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958549	A1	19991118	WO 1999-DK263	19990511

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU,

CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,

IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG,

MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,

TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG,

KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE,

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,

CG, CI, CH, GA, GM, GV, ML, MR, NE, SN, TD, TG

EP 957108 A1 19991117 EP 1998-250166 19980514

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,

PT, IE, SI, LT, LV, FI, RO

AU 9937011 A1 19991129 AU 1999-37011 19990511

PRIORITY APPLN. INFO.: DK 1998-657 19980513

EP 1998-250166 19980514

US 1998-86306 19980521

DK 1998-811 19980619

US 1998-92983 19980716

WO 1999-DK263 19990511

AB Steroid derivs. of formula I [R1 = H, halo, Me, OH, oxo; R2 = H, OH,

alkyl, alkoxy, halo, etc.; R3 = H, alkoxy, acyloxy, halo, sulfonyloxy,

perfluoroalkyl, etc.; R'3 = H, OH; R3R'3 = oxo, (substituted) NOH;

R4, R'4 = H, halo, OH, alkyl; R4R'4 = CH2, oxo, cyclopropyl; R5 = H, halo, OH,

alkyl, CN, hydroxymethyl, CHO, CO2H, etc.; R'4R5 = methano; R6 = H,

OH,

L13 ANSWER 1 OF 8 MARPAT COPYRIGHT 2000 ACS (Continued)

G39 = Ph (SO (1-) G35)

MPL: claim 1

NTE: substitution is restricted

additional bond, oxo, methylene, oxime and ring formation also

claimed

REFERENCE COUNT: 20

REFERENCE(S): (1) Akihisa, T; "Eight novel sterols from the  
 roots of

Bryonia dioica Jacq"; Accession no 1996 CAPLUS

(2) Akihisa, T; Chem Pharm Bull 1996, V44(6),

CAPLUS

(3) Akzo Nobel N V; WO 9852965 A1 1998 CAPLUS

(4) Akzo Nobel N V; WO 9855498 A1 1998 CAPLUS

(5) Byskov, A; Nature 1995, V374, P559 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

P1202

L13 ANSWER 1 OF 8 MARPAT COPYRIGHT 2000 ACS (Continued)

halo, oxo; R7, R11 = H, OH, alkoxy, acyloxy, halo, alkyl; R'7, R'11,

R14, R17 = H, OH; R8, R9 = H, OH, halo; R12, R15, R16 = H, halo, alkyl,

CH2, OH, alkoxy, acyloxy, oxo, etc.; R20 = H, alkyl, hydroxymethyl, CH2;

R'20 = H, halo, alkyl, OH; R22 = Ph, benzyl, cyclohexyl, alkenyl, etc.; R'22

= H, OH, oxo] are prepd. for regulating the meiosis in oocytes and in male

germ cells. Thus,


3.beta.-hydroxy-4,4-dimethyl-5.alpha.-chola-8,14-dien-24-oic

acid Me ester (prepn. given) was transformed into II in 5 steps. II

showed a mean germinal vesicle breakdown of 88% after culture of naked

oocytes in vitro.

MYSTR 1A



G5 = OH

G29 = 63

G3 = G31

G31 = 0

G32 = 65

G3 = G33

G5 = 70

G34 = 70

H2C = G39

70

L13 ANSWER 2 OF 8 MARPAT COPYRIGHT 2000 ACS

ACCESSION NUMBER: 131:351535 MARPAT

TITLE: synthesis and compositions of angiostatic agents

for controlling ocular hypertension

INVENTOR(S): Clark, Abbot F.

PATENT ASSIGNEE(S): Alcon Laboratories, Inc., USA

SOURCE: U.S., 10 pp., Cont.-in-part of U.S. Ser. No.

990,424,

abandoned.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5990099	A	19991123	US 1997-994114	19971219
US 4876250	A	19891024	US 1988-264918	19881031
US 5371078	A	19941206	US 1992-941485	19920908
US 5698545	A	19971216	US 1996-643387	19960506
WO 9903503	A1	19990128	WO 1998-US12711	19980618

W: AU, BR, CA, JP, MX, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,

NL,

PT, SE

AU 9881515 A1 19990210 AU 1998-81515 19980618

EP 1003553 A1 20000531 EP 1998-931367 19980618

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,

PT,

IE, FI

BR 9811012 A 20001017 BR 1998-11012 19980618

WO 9932127 A1 19990701 WO 1998-US25913 19981207

W: AU, BR, CA, JP, MX

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,

NL,

PT, SE

AU 9917142 A1 19990712 AU 1999-17142 19981207

EP 1039912 A1 20001004 EP 1998-961956 19981207

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,

PT,

IE, FI

BR 9813684 A 20001010 BR 1998-13684 19981207

PRIORITY APPLN. INFO.: US 1988-264918 19881031

US 1989-419226 19891010

US 1990-559123 19900727

US 1992-941485 19920908

US 1994-349342 19941202

US 1996-643387 19960506

US 1997-990424 19971215

US 1997-895184 19970716

US 1997-994114 19971219

WO 1998-US12711 19980618


WO 1998-US25913 19981207

AB Comps. of angiostatic agents for treating GLC1A glaucoma and methods

for

L13 ANSWER 2 OF 8 MARPAT COPYRIGHT 2000 ACS (Continued)  
 their use are disclosed. Prepn. of selected steroid agents of the  
 invention, e.g.  
 3.beta.-acetamido-5.beta.-pregnan-11.beta.,17.alpha.,21-  
 triol-20-one 21-acetate, is described.


MPTR 1A



G4 = Ph  
 G13 = 46



G24 = OH  
 G29 = 233



G48 = 205



DER: and pharmaceutically acceptable salts  
 MPL: claim 1  
 NTE: additional double bond, oxo and methylene formation also claimed  
 NTE: substitution is restricted

REFERENCE COUNT: 28

L13 ANSWER 3 OF 8 MARPAT COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 131:54038 MARPAT  
 TITLE: Steroidal angiotensin agents and compositions for  
 controlling GLC1A glaucoma, compositions, and  
 preparation thereof  
 INVENTOR(S): Clark, Abbot F.  
 PATENT ASSIGNEE(S): Alcon Laboratories, Inc., USA  
 SOURCE: PCT Int. Appl., 35 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932127	A1	19990701	WO 1998-US25913	19981207
W: AU, BR, CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,				
NL, PT, SE				
US 5990099	A	19991123	US 1997-994114	19971219
WO 9903503	A1	19990128	WO 1998-US12711	19980618
W: AU, BR, CA, JP, MX, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,				
NL, PT, SE				
AU 9881515	A1	19990210	AU 1998-81515	19980618
EP 1003553	A1	20000531	EP 1998-931367	19980618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,				
PT, IE, FI				
BR 9811012	A	20001017	BR 1998-11012	19980618
AU 9917142	A1	19990712	AU 1999-17142	19981207
EP 1039912	A1	20001004	EP 1998-961956	19981207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,				
PT, IE, FI				
BR 9813684	A	20001010	BR 1998-13684	19981207
PRIORITY APPL. INFO.:				
US 1997-994114				
US 1988-264918				
US 1989-419226				
US 1990-559123				
US 1992-941485				
US 1994-349342				
US 1996-643387				
US 1997-895184				
US 1997-930424				
WO 1998-US12711				
WO 1998-US25913				

AB Comps. of steroid angiotensin agents for treating GLC1A glaucoma and  
 methods for their use are disclosed. Prepn. of selected steroid  
 agents of  
 the invention, e.g. 3.beta.-acetamido-21-acetoxy-5.beta.-pregnan-  
 11.beta.,17.alpha.-diol-20-one, is described.

MPTR 1A

L13 ANSWER 2 OF 8 MARPAT COPYRIGHT 2000 ACS (Continued)  
 REFERENCE(S):  
 (1) Akarsur Human Molecular Genetics 1996, V5(8),  
 P1199 CAPLUS  
 (3) Clark: US 4876250 1989 CAPLUS  
 (4) Clark: US 5371078 1994 CAPLUS  
 (7) Francois: Ophthalmic Res 1984, V16, P168  
 CAPLUS  
 (9) Knepper: Exp Eye Res 1978, V27, P567 CAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L13 ANSWER 3 OF 8 MARPAT COPYRIGHT 2000 ACS (Continued)



G4 = Ph  
 G13 = 46



G24 = OH  
 G29 = 233



G48 = 205



DER: and pharmaceutically acceptable salts  
 MPL: claim 2  
 NTE: additional double bond, oxo and methylene formation also claimed  
 NTE: substitution is restricted

REFERENCE COUNT: 6  
 REFERENCE(S):  
 (1) Alcon Lab Inc: WO 9310141 A 1993  
 (2) Clark Abbot, F: US 4876250 A 1989 CAPLUS  
 (3) Clark Abbot, F: US 5371078 A 1994 CAPLUS  
 (4) Clark Abbot, F: US 5698545 A 1997  
 (5) Univ Duke: WO 9518621 A 1995  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


## L13 ANSWER 4 OF 8 MARPAT COPYRIGHT 2000 ACS

ACCESSION NUMBER: 129:50104 MARPAT  
 TITLE: Method for regulating neuropeptide hormone secretion  
 INVENTOR(S): Jackson, Meyer B.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S., 14 pp. Cont.-in-part of U. S. 5,550,120.  
 CODEN: USXKAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5763431	A	19980609	US 1996-701869	19960823
US 5550120	A	19960827	US 1995-415741	19950403
PRIORITY APPLN. INFO.:			US 1993-109683	19930820
			US 1995-415741	19950403

AB Methods are described for regulating neuropeptide secretion to alleviate premature labor, hypertension, fluid imbalance, and risk of heart disease using neuroactive steroids targeted for a newly-identified site of action in the nerve terminals of neurosecretory neurons. This class of compounds acts at receptors for the inhibitory neurotransmitter GABA. The compounds covered in this invention act at receptors for the inhibitory neurotransmitter GABA and include various ester, oxime, and thiazolidine derivs. of 3-hydroxylated-5-reduced-20-ones, 5-reduced-3,21-pregnanediol-20-ones, and 5-reduced-3,20-pregnandiols having substituent in the 9-position. The method of the invention is applicable to human patients, farm animals, and pets.

## MYSTR 1



G1 = 60

## L13 ANSWER 4 OF 8 MARPAT COPYRIGHT 2000 ACS (Continued)

60(O)CH<sub>2</sub>O—G4  
 G4 = pyridyl  
 G10 = OH  
 MPL: claim 3

## L13 ANSWER 5 OF 8 MARPAT COPYRIGHT 2000 ACS


ACCESSION NUMBER: 126:89635 MARPAT  
 TITLE: Preparation of 2.beta.-(alkylmorpholino)androstane derivatives as anesthetics  
 INVENTOR(S): Campbell, Alexander Cupples; Hamilton, Nial Morton  
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.; Campbell, Alexander Cupples;  
 SOURCE: Hamilton, Nial Morton  
 PCT Int. Appl., 26 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9639465	A1	19961205	WO 1996-EP2346	19960603
W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KP, KR, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, SD, SG, SI, SK, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, RW, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9661896	A1	19961218	AU 1996-61896	19960603
PRIORITY APPLN. INFO.:			EP 1995-201454	19950602
			WO 1996-EP2346	19960603

AB This invention is related to alkyl substituted 2.beta.-morpholinoandrostane derivs. I [Ra = C3-6-alkyl; Rb = H or C3-6-alkyl; R1, R2 and R3 are independently H or Me; R4 = (H,H), (H,OH), or Z = CN, COCH<sub>2</sub>X; X = H, halogen, OH, CN, N3, SCN, C1-6-alkyl (optionally substituted with halogen), cyclohexyl, alkoxy, PhO, phenyl-C1-6-alkyl, C1-6-alkoxy, C1-6-acyloxy, C1-6-acylthio, pyrrididyl, piperidyl, morpholinyl, thiomorpholinyl, NH<sub>2</sub> (optionally substituted with H(5) C1-6-alkyl); Y is O or S; dotted lines are optional bonds, with H(5) absent when 4,5- and 5,6-links are double bonds] or a pharmaceutically acceptable salt thereof. Thus, II [Ra = CMe<sub>2</sub>-(R), R4 = O, Z = Ac] was prepd. via condensation of epoxide III with 2-propylmorpholine hydrochloride. II [Ra = CMe<sub>2</sub>-(R), Pr-(S), Pr-(R), CH<sub>2</sub>CMe<sub>2</sub>-(R), (CHMeEt-(S))-(R), R4 = O, Z = Ac; Ra = CMe<sub>2</sub>-(R), R4 = (H,H), Z = COCH<sub>2</sub>SH] are very potent i.v. anesthetics with therapeutic indexes (TI) of 4.9-9.9 (TI = LD50/HD50). The compds. have fast onset times and ideal "sleep duration" vs. "recovery to full coordination" profiles.

## MYSTR 1

## L13 ANSWER 5 OF 8 MARPAT COPYRIGHT 2000 ACS (Continued)



G7 = 35

35(O)CH<sub>2</sub>G8

G8 = OPh  
 DER: or pharmaceutically acceptable salts  
 MPL: claim 2

## L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2000 ACS


ACCESSION NUMBER: 1976178264 CAPLUS  
 DOCUMENT NUMBER: 85171264  
 TITLE: 21-Substituted pregnanes  
 INVENTOR(S): Philipps, Gordon H.; Lawrence, Robin; Newall, Christopher E.; Wright, Michael  
 PATENT ASSIGNEE(S): Glaxo Laboratories Ltd., Engl.  
 SOURCE: Brit., 21 pp.  
 CODEN: BROKAA  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1432135	A	19760414	GB 1972-21145	19730504
BE 799103	A1	19731105	BE 1973-130750	19730504
NL 7306233	A	19731107	NL 1973-6233	19730504
DE 2322560	A1	19731115	DE 1973-2322560	19730504
FR 2183794	A1	19731221	FR 1973-16111	19730504
ZA 7303036	A	19740424	ZA 1973-3036	19730504
JP 49047361	A2	19740508	JP 1973-50184	19730504
AU 7355285	A1	19741107	AU 1973-55285	19730504
US 3959260	A	19760525	US 1974-488989	19740716
			GB 1972-21145	19720505
			US 1973-356097	19730501


PRIORITY APPLN. INFO.:  
 AB Forty title compds. I (R = H, Me, alkoxy; R1, R2 = H, Me; R32 = O, R3 = H)  
 R4 = acylthio, heterocycle-substituted acylthio, alkylthio, heterocycle-substituted alkylthio, EtSO2, EtSO, NCS, HS, BuS2CS, morpholinocarbodithio, morpholinocarbonylthio and 2 related compds., useful as anesthetics, were prepd. from 21-bromo steroids by condensation reactions. Thus, refluxing 21-bromo-3.alpha.-hydroxy-5.alpha.-pregnane-11,20-dione with BzSNa in Me2CO 40 min gave I (R =

R1 = H, R2 = Me, R32 = O, R4 = BzS). Solns. of I in aq. nonionic surfactants are suitable for parenteral administration, as is a similar soln. of 21-acetylthio-3.alpha.-hydroxy-5.beta.-pregnane-11,20-dione.  
 IT 51087-29-7P 51087-32-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (anesthetic, prepn. of)  
 RN 51087-29-7 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

## L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 51087-32-2 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.




## L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 197460089 CAPLUS  
 DOCUMENT NUMBER: 8060089  
 TITLE: 3.alpha.-Hydroxy- 5.alpha.-pregnanes  
 INVENTOR(S): Phillips, Gordon Hanley; Lawrence, Robin; Stephenson, Leslie Ayres, Barry E.  
 PATENT ASSIGNEE(S): Glaxo Laboratories Ltd.  
 SOURCE: Ger. Offen., 75 pp.  
 CODEN: GWOXEX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2323950	A1	19731213	DE 1973-2323950	19730511
US 3998829	A	19761221	US 1973-358381	19730508
BE 799433	A1	19731112	BE 1973-131031	19730511
NL 7306606	A	19731114	NL 1973-6606	19730511
FR 2184711	A1	19731228	FR 1973-17079	19730511
JP 49048652	A2	19740511	JP 1973-52424	19730511
ZA 7303218	A	19740529	ZA 1973-3218	19730511
AU 7355616	A1	19741114	AU 1973-55616	19730511
GB 1436324	A	19760519	GB 1972-22489	19730511
DK 135775	B	19770620	DK 1973-2604	19730511
CA 1014947	A1	19770802	CA 1973-171026	19730511
			GB 1972-22489	19720512

PRIORITY APPLN. INFO.:  
 AB Hydroxypregnanes I, II (R = H, alkyl, acyl; R1 = H; R11 = CH2, CH2CH2, O; R2 = H, R3 = alkoxy, alkylthio, acyl, acyloxy, acylthio, morpholino, halo, Me; R2 = R3 = Me) (45 compds.) were prepd. from I and II (R = R1 = H; R2R3 = CH2; R2 = H, R3 = CH2OH) by Claisen condensation with active methylene compds. Thus, 1 g I (R = R1 = H) was treated with AcOEt-NaH to give 0.5 g I (R1 = Ac).  
 IT 51227-92-0P 51228-32-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)  
 RN 51227-92-0 CAPLUS  
 CN 1,3-Propanedione, 1-[(3.alpha.,5.alpha.,17.beta.)-3-hydroxy-11-oxoandrostan-17-yl]-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

## L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2000 ACS (Continued)




RN 51228-32-1 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[(3.alpha.,5.alpha.,17.beta.)-3-hydroxy-11-oxoandrostan-17-yl]-3-oxopropyl]- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.



103



L17 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)




L17 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1974:37397 CAPLUS  
 DOCUMENT NUMBER: 80:37397  
 TITLE: Pregnane derivatives  
 INVENTOR(S): Phillips, Gordon Hanley; Lawrence, Robin; Newall, Christopher E.; Wright, Michael  
 PATENT ASSIGNEE(S): Glaxo Laboratories Ltd.  
 SOURCE: Ger. Offen., 58 pp.  
 CODEN: GWXKX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2322560	A1	19731115	DE 1973-2322560	19730504
GB 1432135	A	19760414	GB 1972-21145	19730504
			GB 1972-21145	19720505


PRIORITY APPL. INFO.:  
 AB Pregnanediones I-VIII (R = alkyl, aryl, morpholinoalkyl, piperidinoalkyl) (45 compds.), possessing anesthetic activity, were prepd. from 21-bromo-3.alpha.-hydroxy-5.alpha.-pregnane-11,20-dione (II). Thus, II was treated with EtSH to give VII (R = Et). I-VI and VIII were prepd. similarly.  
 IT 51086-87-4P 51086-88-5P 51086-89-6P  
 51086-90-9P 51086-91-0P 51086-92-1P  
 51086-99-8P 51087-12-8P 51087-25-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)  
 RN 51086-87-4 CAPLUS  
 CN Pregnane-11,20-dione, 21-(benzoylthio)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.



L17 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)


RN 51086-88-5 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(2-iodobenzoyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51086-89-6 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(2-nitrobenzoyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51086-90-9 CAPLUS  
 CN Pregnane-11,20-dione, 21-[[2-(ethoxycarbonyl)benzoyl]thio]-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 51086-91-0 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(2-pyridinylcarbonyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51086-92-1 CAPLUS  
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(3-pyridinylcarbonyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

4-2-6

102

L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-11,20-dione, 21-bromo-3-hydroxy-16-methyl-,  
 (3.alpha.,5.alpha.,16.alpha.)- (9CI)  
 MF C22 H33 Br O3


Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):31


L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-11,20-dione, 3-(acetyloxy)-21-methoxy-, (3.alpha.,5.alpha.)-  
 (9CI)  
 MF C24 H36 O5

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-11,20-dione, 3-hydroxy-21-(phenylmethoxy)-, (3.alpha.,5.alpha.)-  
 (9CI)  
 MF C28 H38 O4

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-11-one, 20,21-epoxy-3-hydroxy-, (3.alpha.,5.alpha.,20S)- (9CI)  
 MF C21 H32 O3

Absolute stereochemistry.



L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-11,20-dione, 3-hydroxy-21-(1-methylethoxy)-,  
 (3.alpha.,5.alpha.)- (9CI)  
 MF C24 H38 O4


Absolute stereochemistry.



L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS


IN Pregnane-11,20-dione, 3-hydroxy-21-[2-(4-methyl-1-piperazinyl)ethoxy]-,  
(3.alpha.,5.alpha.)- (9CI)  
MF C28 H46 N2 O4

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnane-11,20-dione, 21-hydroxy-3-(nitrooxy)-, (3.alpha.,5.alpha.)-  
(9CI)  
MF C21 H31 N O6

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnane-11-one, 20-hydroxy-21-methoxy-3-(nitrooxy)-,  
(3.alpha.,5.alpha.,20S)- (9CI)  
MF C22 H35 N O6

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-20-one, 3-hydroxy-21-methoxy-, (3.alpha.,5.alpha.)- (9CI)  
 MF C22 H36 O3

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-11,20-dione, 21-(3-chloropropoxy)-3-hydroxy-,  
 (3.alpha.,5.alpha.)- (9CI)  
 MF C24 H37 Cl O4

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-11,20-dione, 21-diazo-3-(nitroxy)-, (3.alpha.,5.alpha.)- (9CI)  
 MF C21 H29 N3 O5

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnane-11,20-dione, 3-hydroxy-21-propoxy-, (3.alpha.,5.alpha.)- (9CI)  
MF C24 H38 O4

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
IN Pregnane-11,20-dione, 3-hydroxy-21-[2-(4-morpholinyl)ethoxy]-,  
(3.alpha.,5.alpha.)- (9CI)  
MF C27 H43 N O5

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-11,20-dione, 21-bromo-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)  
 MF C21 H31 Br O3

Absolute stereochemistry.



L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-11-one, 20,21-epoxy-3-(nitrooxy)-, (3.alpha.,5.alpha.,20S)- (9CI)  
 MF C21 H31 N O5


Absolute stereochemistry.



L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS


IN Pregnane-11,20-dione, 3-hydroxy-21-methoxy-16-methyl-,  
 (3.alpha.,5.alpha.,16.alpha.)- (9CI)  
 MF C23 H36 O4

Absolute stereochemistry.



L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-11,20-dione, 21-(2-chloroethoxy)-3-hydroxy-,  
 (3.alpha.,5.alpha.)- (9CI)  
 MF C23 H35 Cl O4


Absolute stereochemistry.



L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-11,20-dione, 21-methoxy-3-(nitrooxy)-, (3.alpha.,5.alpha.)-  
 (9CI)  
 MF C22 H33 N O6


Absolute stereochemistry.






L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-11,20-dione, 21-ethoxy-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)  
 MF C23 H36 O4

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-11,20-dione, 21-(2-chloroethoxy)-3-(nitroxy)-,  
 (3.alpha.,5.alpha.)- (9CI)  
 MF C23 H34 Cl N O6

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-11,20-dione, 3-hydroxy-21-methoxy-, (3.alpha.,5.beta.)- (9CI)  
 MF C22 H34 O4

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnan-11-one, 21-bromo-20-hydroxy-3-(nitrooxy)-,  
 (3.alpha.,5.alpha.,20S)-  
 (9CI)  
 MF C21 H32 Br N O5

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-11,20-dione, 21-(4-aminophenoxy)-3-hydroxy-,  
 (3.alpha.,5.alpha.)-  
 (9CI)  
 MF C27 H37 N O4

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Propanoic acid, 3-[[[(3.alpha.,5.alpha.)-3-hydroxy-11,20-dioxopregnan-21-yl]oxy]-, ethyl ester (9CI)  
 MF C26 H40 O6

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Androstane-17-carboxylic acid, 3-(nitrooxy)-11-oxo-,  
 (3.alpha.,5.alpha.,17.beta.)- (9CI)  
 MF C20 H29 N O6

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-11,20-dione, 3-hydroxy-21-methoxy-, (3.alpha.,5.alpha.)- (9CI)  
 MF C22 H34 O4

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-11,20-dione, 3-hydroxy-2,21-dimethoxy-,  
 (2.beta.,3.alpha.,5.alpha.)- (9CI)  
 MF C23 H36 O5

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-11,20-dione, 21-(cyclopentyloxy)-3-hydroxy-,  
 (3.alpha.,5.alpha.)- (9CI)  
 MF C26 H40 O4

Absolute stereochemistry.




L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-11,20-dione, 21-bromo-3-(nitrooxy)-, (3.alpha.,5.alpha.)- (9CI)  
 MF C21 H30 Br N O5

Absolute stereochemistry.



L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-11,20-dione, 3-hydroxy-21-(2-methoxyethoxy)-, (3.alpha.,5.alpha.)- (9CI)  
 MF C24 H38 O5


Absolute stereochemistry.



L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS


IN Propanenitrile, 3-[[[(3.alpha.,5.alpha.)-3-hydroxy-11,20-dioxopregnan-21-yl]oxy]- (9CI)  
 MF C24 H35 N O4

Absolute stereochemistry.



L2 32 ANSWERS REGISTRY COPYRIGHT 2000 ACS  
 IN Pregnane-11,20-dione, 3-hydroxy-16-methyl-,  
 (3.alpha.,5.alpha.,16.alpha.)- (9CI)  
 MF C22 H34 O3

Absolute stereochemistry.



## L4 ANSWER 3 OF 9 USPATFULL

ACCESSION NUMBER: 2000:47233 USPATFULL  
 TITLE: Means to achieve sustained release of synergistic drugs by conjugation  
 INVENTOR(S): Ashton, Paul, Boston, MA, United States  
 Crooks, Peter Anthony, Lexington, KY, United States  
 Cynkowski, Tadeusz, Lexington, KY, United States  
 Cynkowska, Grazyna, Lexington, KY, United States  
 Guo, Hone, Malden, MA, United States  
 PATENT ASSIGNEE(S): University Of Kentucky Research Foundation, Lexington, KY, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6051576		20000418
US 1997-791071		19970129 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-388855, filed on 15 Feb 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-187462, filed on 28 Jan 1994

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: MacMillan, Keith D.  
 LEGAL REPRESENTATIVE: McDermott, Will & Emery  
 NUMBER OF CLAIMS: 37  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)  
 LINE COUNT: 1243

## CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A codrug composition of at least two drug compounds covalently linked to one another via a labile bond to form a single codrug composition, or ionically linked to one another to form a single working composition, and methods of use of the codrug for the treatment of various medical conditions. The codrug may be administered by itself or in the form of a bioerodible or nonbioerodible substance.

IT 169046-79-1P


(codrug compns. for controlled drug delivery)

RN 169046-79-1 USPATFULL

CN 2,4(1H,3H)-Pyrimidin-6-one, 1-[[[(3.alpha.,5.beta.)-3,17-dihydroxy-20-oxopregnan-21-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

## L4 ANSWER 3 OF 9 USPATFULL (Continued)



## L4 ANSWER 4 OF 9 USPATFULL

ACCESSION NUMBER: 1999:96496 USPATFULL  
 TITLE: Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series  
 INVENTOR(S): Upasani, Ravindra B., Foothill Ranch, CA, United States  
 Xia, Haiji, Foothill Ranch, CA, United States  
 Hogenkamp, Derk, Carlsbad, CA, United States  
 PATENT ASSIGNEE(S): CoCensys, Inc., Irvine, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5939545		19990817
US 1997-887229		19970702 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-389820, filed on 14 Feb 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-346927, filed on 23 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-196919, filed on 14 Feb 1994, now abandoned

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Dees, Jose G.  
 ASSISTANT EXAMINER: Badio, Barbara  
 LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.  
 NUMBER OF CLAIMS: 17  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 13 Drawing Figure(s); 11 Drawing Page(s)  
 LINE COUNT: 3557

## CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compositions, and compounds for modulating the GABA.sub.A receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.


IT 162883-05-8P

(prepn. and formulation of 3.alpha.-hydroxypregnan-20-one and analogs as sedatives and hypnotics)

RN 162883-05-8 USPATFULL

CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



## L4 ANSWER 5 OF 9 USPATFULL

ACCESSION NUMBER: 1999:91822 USPATFULL  
 TITLE: Neuroactive steroids of the androstane and pregnane series  
 INVENTOR(S): Upasani, Ravindra B., Foothill Ranch, CA, United States  
 Fick, David B., Mission Viejo, CA, United States  
 Hogenkamp, Derk J., Carlsbad, CA, United States  
 Lan, Nancy C., South Pasadena, CA, United States  
 PATENT ASSIGNEE(S): CoCensys, Inc., Irvine, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5925630		19990720
US 1996-659192		19960606 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-467404, filed on 6 Jun 1995

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Dees, Jose' G.  
 ASSISTANT EXAMINER: Badio, Barbara  
 LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.  
 NUMBER OF CLAIMS: 24  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)  
 LINE COUNT: 3047

## CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to 3.alpha.-hydroxy, 17-(un)substituted derivatives of the androstane series and 3.alpha.-hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at a recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. The steroid derivatives of this invention are those having the general structural formula: ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are further defined herein and the dotted lines are single or double bonds. The structure includes androstanes, pregnanes (R.sub.4 =methyl), 19-norandrostanes, and norpregnanes (R.sub.4 =H).

IT 186264-62-0P 186264-74-4P 186264-76-6P


(prepn. of neuroactive steroids of androstane and pregnane series)

RN 186264-62-0 USPATFULL

CN Pregnan-20-one, 3-hydroxy-3-methyl-21-(4-nitrophenoxy)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 9 USPATFULL (Continued)



RN 186264-74-4 USPATFULL  
CN Pregnan-20-one, 3-hydroxy-2-propoxy-21-(4-pyridinylthio)-,  
(2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-76-6 USPATFULL  
CN Pregnan-20-one, 21-[(4-fluorophenyl)sulfonyl]-3-hydroxy-3-(methoxymethyl)-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 9 USPATFULL (Continued)




RN 186264-27-7 USPATFULL  
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 186264-31-3 USPATFULL  
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-nitrophenylthio)-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 9 USPATFULL (Continued)



IT 162883-05-8P 186264-24-4P 186264-27-7P  
186264-31-3P 186264-33-5P 186264-34-6P  
186264-35-7P 186264-36-8P 186264-37-9P  
186264-38-0P 186264-54-0P 186264-51-1P  
186264-63-1P 186264-64-2P 186264-65-3P  
186264-66-4P 186264-67-5P 186264-69-7P  
186264-79-9P 186264-81-3P 186264-82-4P  
186264-84-6P 186264-85-7P 186264-86-8P  
186264-87-9P 203719-57-7P 230958-75-5P  
(prepn. of neuroactive steroids of androstane and pregnane series)  
RN 162883-05-8 USPATFULL  
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 186264-24-4 USPATFULL  
CN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-butynyl)-21-(4-pyridinylthio)-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 9 USPATFULL (Continued)


RN 186264-33-5 USPATFULL  
CN Pregnan-20-one, 21-[(4-fluorophenyl)thio]-3-hydroxy-3-(methoxymethyl)-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-34-6 USPATFULL  
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 186264-35-7 USPATFULL  
CN Pregnan-20-one, 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-,  
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 9 USPATFULL (Continued)



RN 186264-36-8 USPATFULL

CN Pyridinium, 4-[[[(3.alpha.,5.beta.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.


● I<sup>-</sup>

RN 186264-37-9 USPATFULL

CN Pyridinium, 4-[[[(3.alpha.,5.alpha.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 9 USPATFULL (Continued)

● I<sup>-</sup>

RN 186264-38-0 USPATFULL

CN Pyridinium, 4-[[[(2.beta.,3.alpha.,5.alpha.)-3-hydroxy-20-oxo-2-propoxypregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.


● I<sup>-</sup>

RN 186264-54-0 USPATFULL

CN Pregnan-20-one, 3-hydroxy-21-(3-pyridinyloxy)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 9 USPATFULL (Continued)



RN 186264-61-9 USPATFULL

CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinyloxy)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 186264-63-1 USPATFULL

CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyloxy)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 9 USPATFULL (Continued)



RN 186264-64-2 USPATFULL

CN Pregnan-20-one, 21-[4-(dimethylamino)phenoxy]-3-hydroxy-3-methyl-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 186264-65-3 USPATFULL


CN Pregnan-20-one, 21-[4-(dimethylamino)phenylthio]-3-hydroxy-3-methoxymethyl-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 9 USPATFULL (Continued)




RN 186264-66-4 USPATFULL  
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[(4-nitrophenyl)sulfonyl]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.




RN 186264-67-5 USPATFULL  
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[(4-(1-pyrrolidinyl)phenyl)sulfonyl]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

L4 ANSWER 5 OF 9 USPATFULL (Continued)




RN 186264-69-7 USPATFULL  
 CN 1-Propanone, 1-[(3.alpha.,5.beta.,17.beta.)-3-hydroxyandrost-17-yl]-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.




RN 186264-79-9 USPATFULL  
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

L4 ANSWER 5 OF 9 USPATFULL (Continued)




RN 186264-81-3 USPATFULL  
 CN Pregnan-20-one, 21-[(4-aminophenyl)thio]-3-hydroxy-3-(methoxymethyl)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.




RN 186264-82-4 USPATFULL  
 CN Benzenaminium, 4-[[[(2.beta.,3.alpha.,5.alpha.)-3-hydroxy-20-oxo-2-propoxy]pregnan-21-yl]oxy]-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

L4 ANSWER 5 OF 9 USPATFULL (Continued)




● I -

RN 186264-84-6 USPATFULL  
 CN Pregnan-20-one, 3-hydroxy-21-(1H-imidazol-2-ylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.




RN 186264-85-7 USPATFULL  
 CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylsulfinyl)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.

L4 ANSWER 5 OF 9 USPATFULL (Continued)



RN 186264-86-8 USPATFULL  
 CN Quinolinium, 6-[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy-1-methyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

● I<sup>-</sup>


RN 186264-87-9 USPATFULL  
 CN Pregnan-20-one, 3-hydroxy-21-[(1-oxido-3-pyridinyl)oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 9 USPATFULL (Continued)


● I<sup>-</sup>

L4 ANSWER 5 OF 9 USPATFULL (Continued)



RN 203719-57-7 USPATFULL  
 CN Pregnan-20-one, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 230958-75-5 USPATFULL  
 CN Pyridinium, 4-[(2.beta.,3.beta.,5.alpha.)-3-hydroxy-20-oxo-2-propoxypregnan-21-yl]thio-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 9 USPATFULL

76:69178 USPATFULL  
 TITLE: Steroid anaesthetics of the pregnane and 19-norpregnane series  
 INVENTOR(S): Phillips, Gordon Hanley, Wembley, England  
 Lawrence, Robin, London, England  
 Stephenson, Leslie, London, England  
 Ayres, Barry Edward, Amersham, England  
 PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, England  
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3998829		19761221
APPLICATION INFO.:	US 1973-358381		19730508 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1972-22489	19720512
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	Bacon & Thomas	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1636	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Steroid anaesthetics of the pregnane and 19-norpregnane series are described, the compounds possessing a 3.alpha.-hydroxy group, a 5.alpha.-hydrogen atom or a 4,5-double bond, a 17.alpha.-hydrogen atom, a 20-oxo group and at the 21-position a hydrocarbon group which may be substituted by an oxo, ether, hydroxy, acyloxy, esterified carboxy, thioether, thioester, heterocyclic, amino or aromatic group, or a fluorine or chlorine atom. The acetals and 20-enol ethers of compounds having a 21-formyl group are also described.

IT 51227-92-0P 51228-32-1P


(prepn. of)  
 RN 51227-92-0 USPATFULL  
 CN 1,3-Propanedione, 1-[(3.alpha.,5.alpha.,17.beta.)-3-hydroxy-11-oxoandrostane-17-yl]-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51228-32-1 USPATFULL  
 CN 1H-isoindole-1,3(2H)-dione, 2-[3-[(3.alpha.,5.alpha.,17.beta.)-3-hydroxy-

L4 ANSWER 6 OF 9 USPATFULL (Continued)  
 11-oxoandrostan-17-yl]-3-oxopropyl]- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.



L4 ANSWER 7 OF 9 USPATFULL  
 ACCESSION NUMBER: 76:39285 USPATFULL  
 TITLE: 20.beta.,21-Epoxy-3.alpha.-hydroxy-5.alpha.-pregnanes and derivatives thereof  
 INVENTOR(S): Philipps, Gordon Hanley, Wembley, England  
 Newall, Christopher Earle, London, England  
 PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, England (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3969345		19760713
APPLICATION INFO.:	US 1975-551315		19750220 (5)
RELATED APPLN. INFO.:	Division of Ser. No. US 1971-208961, filed on 16 Dec 1971, now patented, Pat. No. US 3882151		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1970-60065	19701217
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	Bacon & Thomas	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1213	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides 3.alpha.-oxygenated pregnane 21-ethers possessing a hydroxy group in the 3.alpha.-position; a hydrogen atom or a methyl group at the 10-position; a hydrogen atom in the 17.alpha.-position; a keto group in the 20-position; and an etherified hydroxyl group in the 21-position.


IT 38601-34-2P

(prepn. of)

RN 38601-34-2 USPATFULL

CN Pregnane-11,20-dione, 21-(4-aminophenoxy)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 7 OF 9 USPATFULL (Continued)

L4 ANSWER 8 OF 9 USPATFULL  
 ACCESSION NUMBER: 76:29138 USPATFULL  
 TITLE: Anaesthetic steroids of the pregnane and 19-norpregnane series having a sulfur-containing group at the 21-position  
 INVENTOR(S): Philipps, Gordon Hanley, Wembley, England  
 Lawrence, Robin, Stoke Poges, England  
 Newall, Christopher Earle, London, England  
 Wright, Michael, Stoke Poges, England  
 PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, England (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3959260		19760525
APPLICATION INFO.:	US 1974-488989		19740716 (5)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1973-356097, filed on 1 May 1973, now Defensive Publication No.		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1972-21145	19720505
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	Bacon & Thomas	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1493	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Steroid anaesthetics of the pregnane and 19-norpregnane series are described, the compounds possessing a 3.alpha.-hydroxy group, a 17.alpha.-hydrogen atom, a 20-oxo group and at the 21-position the residue of a sulphur nucleophile or a sulphone or sulfoxide grouping.


IT 51087-29-7P 51087-32-2P

(prepn. of)

RN 51087-29-7 USPATFULL

CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 51087-32-2 USPATFULL

CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 9 USPATFULL (Continued)

Absolute stereochemistry.



L4 ANSWER 9 OF 9 USPATFULL

ACCESSION NUMBER: 75:23860 USPATFULL  
 TITLE: Chemical compounds  
 INVENTOR(S): Philipps, Gordon Hanley, Wembley, England  
 Newall, Christopher Earle, London, England  
 PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, Middlesex,  
 England (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3882151		19750506
APPLICATION INFO.:	US 1971-208961		19711216 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1970-60065	19701217
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	Bacon & Thomas	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1258	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides 3.alpha.-oxygenated pregnane 21-ethers possessing a hydroxy group in the 3.alpha.-position; a hydrogen atom or a methyl group at the 10-position; a hydrogen atom in the 17.alpha.-position; a keto group in the 20-position; and an etherified hydroxyl group in the 21-position.


IT 38601-34-2P

(prepn. of)

RN 38601-34-2 USPATFULL

CN Pregnane-11,20-dione, 21-(4-aminophenoxy)-3-hydroxy-, (3.alpha.,5.alpha.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d ibib ab hitstr 1-11

## LS ANSWER 1 OF 2 USPATFULL

ACCESSION NUMBER: 2000:47233 USPATFULL  
 TITLE: Means to achieve sustained release of synergistic drugs by conjugation  
 INVENTOR(S): Ashton, Paul, Boston, MA, United States  
 Crooks, Peter Anthony, Lexington, KY, United States  
 Cynkowski, Tadeusz, Lexington, KY, United States  
 Cynkowska, Grazyna, Lexington, KY, United States  
 Guo, Hone, Malden, MA, United States  
 PATENT ASSIGNEE(S): University Of Kentucky Research Foundation, Lexington, KY, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6051576		20000418
US 1997-791071		19970129 (B)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-388855, filed on 15 Feb 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-187462, filed on 28 Jan 1994

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: MacMillan, Keith D.  
 LEGAL REPRESENTATIVE: McDermott, Will & Emery  
 NUMBER OF CLAIMS: 37  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)  
 LINE COUNT: 1243

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A codrug composition of at least two drug compounds covalently linked to one another via a labile bond to form a single codrug composition, or ionically linked to one another to form a single working composition, and methods of use of the codrug for the treatment of various medical conditions. The codrug may be administered by itself or in the form of a bioerodible or nonbioerodible substance.

IT 169046-79-1P


(codrug compns. for controlled drug delivery)

RN 169046-79-1 USPATFULL

CN 2,4(1H,3H)-Pyrimidinone, 1-[(3.alpha.,5.beta.)-3,17-dihydroxy-20-oxopregnan-21-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

## LS ANSWER 1 OF 2 USPATFULL (Continued)



## LS ANSWER 2 OF 2 USPATFULL

ACCESSION NUMBER: 1999:81822 USPATFULL  
 TITLE: Neuroactive steroids of the androstane and pregnane series  
 INVENTOR(S): Upasani, Ravindra B., Foothill Ranch, CA, United States  
 Fick, David B., Mission Viejo, CA, United States  
 Hogenkamp, Derk J., Carlsbad, CA, United States  
 Lan, Nancy C., South Pasadena, CA, United States  
 PATENT ASSIGNEE(S): CoCensys, Inc., Irvine, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5925630		19990720
US 1996-659192		19960606 (B)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-467004, filed on 6 Jun 1995

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Dees, Jose' G.  
 ASSISTANT EXAMINER: Badio, Barbara  
 LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.  
 NUMBER OF CLAIMS: 24  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)  
 LINE COUNT: 3947

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to 3.alpha.-hydroxy, 17-(un)substituted derivatives of the androstane series and 3.alpha.-hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at a recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. The steroid derivatives of this invention are those having the general structural formula: ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are further defined herein and the dotted lines are single or double bonds. The structure includes androstanes, pregnanes (R.sub.4 = methyl), 19-norandrostanes, and norpregnanes (R.sub.4 = H).

IT 186264-64-0P 186264-61-8P 186264-63-1P

186264-66-8P 186264-87-9P


(pregn. of neuroactive steroids of androstane and pregnane series)

RN 186264-64-0 USPATFULL

CN Pregnan-20-one, 3-hydroxy-21-(3-pyridinyloxy)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


## LS ANSWER 2 OF 2 USPATFULL (Continued)



RN 186264-61-9 USPATFULL

CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinyloxy)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 186264-63-1 USPATFULL

CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyloxy)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 2 USPATFULL (Continued)



RN 186264-86-8 USPATFULL  
 CN Quinolinium, 6-[[3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

● I<sup>-</sup>

RN 186264-87-9 USPATFULL  
 CN Pregnan-20-one, 3-hydroxy-21-[(1-oxido-3-pyridinyl)oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 2 USPATFULL (Continued)





09/321,882

Page 4

=> d ibib 1-6 16

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 2000:790531 CAPLUS  
DOCUMENT NUMBER: 133:350392  
TITLE: Preparation of 3.alpha.-hydroxy-3.beta.-methoxymethyl-21-heterocyclic substituted steroids with anesthetic activity  
INVENTOR(S): Hogenkamp, Derk L.  
PATENT ASSIGNEE(S): Cocensys, Inc., USA  
SOURCE: PCT Int. Appl., 25 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066614	A1	20001109	WO 2000-US11680	20000428
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000010060	A	20020115	BR 2000-10060	20000428
EP 1177206	A1	20020206	EP 2000-930250	20000428
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002543218	T2	20021217	JP 2000-615643	20000428
NO 2001005262	A	20011219	NO 2001-5262	20011026
PRIORITY APPLN. INFO.: US 1999-131578 P 19990429 WO 2000-US11680 W 20000428				
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 1999:778442 CAPLUS  
DOCUMENT NUMBER: 132:132237  
TITLE: Response-rate suppression in operant paradigm as predictor of anesthetic potency in rats and identification of three novel sedative-hypnotic neuroactive steroids  
AUTHOR(S): Vanover, Kimberly E.; Edgar, Dale M.; Seidel, Wesley F.; Hogenkamp, Derk J.; Fick, David B.; Lan, Nancy C.; Gee, Kelvin W.; Carter, Richard B.  
CORPORATE SOURCE: CoCensys, Inc., Irvine, CA, USA  
SOURCE: Journal of Pharmacology and Experimental Therapeutics (1999), 291(3), 1317-1323  
CODEN: JPETAB; ISSN: 0022-3565  
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 1999:450892 CAPLUS  
DOCUMENT NUMBER: 131:102428  
TITLE: Preparation of neuroactive steroids of the androstane and pregnane series  
INVENTOR(S): Upasani, Ravindra B.; Fick, David B.; Hogenkamp, Derk J.; Lan, Nancy C.  
PATENT ASSIGNEE(S): Cocensys, Inc., USA  
SOURCE: U.S., 28 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5925630	A	19990720	US 1996-659192	19960606
CA 2223996	AA	19961219	CA 1996-2223996	19960606
CN 1190404	A	19980812	CN 1996-195360	19960606
PRIORITY APPLN. INFO.: US 1995-467404 A2 19950606 MARPAT 131:102428				
OTHER SOURCE(S): REFERENCE COUNT: 81 THERE ARE 81 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 1998:112239 CAPLUS  
DOCUMENT NUMBER: 128:188632  
TITLE: Use of GABA agonists and NMDA receptor antagonists for the treatment of migraine headache  
INVENTOR(S): Lan, Nancy C.  
PATENT ASSIGNEE(S): Cocensys, Inc., USA; Lan, Nancy C.  
SOURCE: PCT Int. Appl., 47 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9805337	A1	19980212	WO 1997-US13430	19970731
V: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9739672	A1	19980225	AU 1997-39672	19970731
PRIORITY APPLN. INFO.: US 1996-223377 P 19960801 WO 1997-US13430 W 19970731				

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1997:113460 CAPLUS  
 DOCUMENT NUMBER: 126:131695  
 TITLE: Preparation of neuroactive steroids of the androstane and pregnane series  
 INVENTOR(S): Upasani, Ravindra B.; Fick, David B.; Hogenkamp, Derk J.; Lan, Nancy C.  
 PATENT ASSIGNEE(S): Cocensys, Inc., USA  
 SOURCE: PCT Int. Appl., 94 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640043	A2	19961219	WO 1996-US10115	19960606
WO 9640043	A3	19970327		
V: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
CA 2223996	AA	19961219	CA 1996-2223996	19960606
AU 9661725	A1	19961230	AU 1996-61725	19960606
AU 725214	B2	20001005		
EP 837874	A2	19980429	EP 1996-919372	19960606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1190404	A	19980812	CN 1996-195360	19960606
BR 9608592	A	19990629	BR 1996-8592	19960606
JP 11507643	T2	19990706	JP 1996-502210	19960606
NO 9705608	A	19980206	NO 1997-5608	19971204
FI 9704448	A	19971205	FI 1997-4448	19971205
PRIORITY APPLN. INFO.:			US 1995-467404 A	19950606
			WO 1996-US10115 W	19960606
OTHER SOURCE(S):			MARPAT 126:131695	

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1995:858705 CAPLUS  
 DOCUMENT NUMBER: 123:266118  
 TITLE: Codrugs as a method of controlled drug delivery  
 INVENTOR(S): Ashton, Paul; Crooks, Peter Anthony; Riggs, Robert Mack; Cynkowski, Tadeusz; Cynkowska, Grazyna  
 PATENT ASSIGNEE(S): University of Kentucky Research Foundation, USA  
 SOURCE: PCT Int. Appl., 57 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 6  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9520567	A1	19950803	WO 1994-US1659	19940217
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2182228	AA	19950803	CA 1994-2182228	19940217
AU 9462545	A1	19950815	AU 1994-62545	19940217
AU 705226	B2	19990520		
EP 740650	A1	19961106	EP 1994-909643	19940217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09509151	T2	19970916	JP 1994-520023	19940217
US 6051576	A	20000418	US 1997-791071	19970129
PRIORITY APPLN. INFO.:			US 1994-187462	19940128
			WO 1994-US1659	19940217
			US 1995-388855	19950215

=> d ibib 1-6 l6 hitstr ab


L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2000:790531 CAPLUS  
 DOCUMENT NUMBER: 133:350392  
 TITLE: Preparation of 3.alpha.-hydroxy-3.beta.-methoxymethyl-21-heterocyclic substituted steroids with anesthetic activity  
 INVENTOR(S): Hogenkamp, Derk L.  
 PATENT ASSIGNEE(S): Cocensys, Inc., USA  
 SOURCE: PCT Int. Appl., 25 pp.  
 CODEN: P1XXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066614	A1	20001109	WO 2000-US11680	20000428
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000010060	A	20020115	BR 2000-10060	20000428
EP 1177206	A1	20020206	EP 2000-930250	20000428
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002543218	T2	20021217	JP 2000-615643	20000428
NO 2001005262	A	20011219	NO 2001-5262	20011026
PRIORITY APPLN. INFO.: US 1999-131578P P 19990429 WO 2000-US11680 W 20000428				

IT 304910-83-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (prepn. of 3.alpha.-hydroxy-3.beta.-methoxymethyl-21-heterocyclic substituted steroids with anesthetic activity)  
 RN 304910-83-6 CAPLUS  
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[(1-oxido-6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2002 ACS (Continued)



AB 3.alpha.-Hydroxy-3.beta.-methoxymethyl-21-heterocyclic substituted steroids I (R1 = H, Me; R2 = 5.alpha.- or 5.beta.-H; R3 = optionally substituted N-attached heteroaryl group or -XR4 where R4 = optionally substituted carbon-attached heteroaryl group; X = O, S, N) or a pharmaceutically acceptable salt, prodrug or solvate thereof were prepd. Thus II was prepd. from 3.alpha.-hydroxy-3.beta.-methoxymethyl-5.alpha.-pregnan-20-one and imidazole which was then converted to the hydrochloride salt. Steroids I are useful as anticonvulsants, sedative/hypnotics and anesthetics [no data].


REFERENCE COUNT: 3  
 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2002 ACS (Continued)



IT 256955-85-8P 304910-84-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of 3.alpha.-hydroxy-3.beta.-methoxymethyl-21-heterocyclic substituted steroids with anesthetic activity)  
 RN 256955-85-8 CAPLUS  
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[(1-oxido-6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 304910-84-7 CAPLUS  
 CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(1-oxido-6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:778442 CAPLUS  
 DOCUMENT NUMBER: 132:132237  
 TITLE: Response-rate suppression in operant paradigm as predictor of soporific potency in rats and identification of three novel sedative-hypnotic neuroactive steroids  
 AUTHOR(S): Vanover, Kimberly E.; Edgar, Dale M.; Seidel, Wesley F.; Hogenkamp, Derk J.; Fick, David B.; Lan, Nancy C.; Gee, Kelvin W.; Carter, Richard B.  
 CORPORATE SOURCE: CoCensys, Inc., Irvine, CA, USA  
 SOURCE: Journal of Pharmacology and Experimental Therapeutics (1999), 291(3), 1317-1323  
 CODEN: JPETAB; ISSN: 0022-3565  
 PUBLISHER: American Society for Pharmacology and Experimental Therapeutics  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

IT 256955-85-8, Co 177843  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (response-rate suppression in operant paradigm as predictor of soporific potency; novel sedative-hypnotic neuroactive steroids identification)  
 RN 256955-85-8 CAPLUS  
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[(1-oxido-6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Novel neuroactive steroids were evaluated for their effects on operant responding, rotarod motor performance, and EEG recording in rats. Co 134444, Co 177843, and Co 127501 were compared with the prototypical .gamma.-aminobutyric acid-pos. allosteric modulators triazolam, zolpidem, pentobarbital, pregnanolone, and UCD 3693. Each of the compds. produced a dose-related decrease in response rates under a variable-interval 2-min schedule of pos. reinforcement in an operant paradigm. In addn., all compds. produced a dose-related increase in ataxia and significant increases in nonrapid eye movement sleep in this expt. or have been previously reported to do so. Co 134444, Co 177843, and Co 127501 increased nonrapid eye movement sleep at doses that had no effect on rapid eye movement sleep. All of the compds. were more potent at decreasing


L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2002 ACS (Continued)  
 operant responding than they were at increasing ataxia. Furthermore, the potency of compds. to produce response-rate suppression in an operant paradigm appeared to be a better predictor of soporific potency than did potency in the rotarod assay. The screening for sedative-hypnotic activity resulted in the identification of the novel orally active neuroactive steroids Co 134444, Co 177843, and Co 127501.  
 REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1999:450892 CAPLUS  
 DOCUMENT NUMBER: 131:102428  
 TITLE: Preparation of neuroactive steroids of the androstane and pregnane series  
 INVENTOR(S): Upasani, Ravindra B.; Fick, David B.; Hogenkamp, Deck J.; Lan, Nancy C.  
 PATENT ASSIGNEE(S): Cencys, Inc., USA  
 SOURCE: U.S., 28 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5925630	A	19990720	US 1996-659192	19960606
CA 2223996	AA	19961219	CA 1996-2223996	19960606
CN 1190404	A	19980812	CN 1996-195360	19960606
			US 1995-467404	A2 19950606

PRIORITY APPL. INFO.: MARPAT 131:102428  
 OTHER SOURCE(S):  
 IT 186264-54-OP 186264-61-9P 186264-63-1P  
 186264-86-8P 186264-87-9P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of neuroactive steroids of androstane and pregnane series)  
 RN 186264-54-0 CAPLUS  
 CN Pregnan-20-one, 3-hydroxy-21-(3-pyridinyloxy)-, (3.alpha.,5.beta.)- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-61-9 CAPLUS  
 CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinyloxy)-, (3.alpha.,5.beta.)- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 186264-63-1 CAPLUS  
 CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-86-8 CAPLUS  
 CN Quinolinium, 6-[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy-1-methyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 186264-87-9 CAPLUS  
 CN Pregnan-20-one, 3-hydroxy-21-[(1-oxido-3-pyridinyl)oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Neuroactive steroids of formula I [R = H, NH<sub>2</sub>, thio, sulfinyl, sulfonyl, halo, alkoxy, alkyl, alkenyl, alkynyl, etc.; R<sub>1</sub> = H, alkyl, alkenyl, alkynyl, haloalkyl, aryl, etc.; R<sub>2</sub> = H, alkoxy, keto, Me<sub>2</sub>N; R<sub>3</sub> = alkoxy, alkenyloxy, alkynyloxy; R<sub>4</sub> = H, Me; R<sub>5</sub> = H, absent; R<sub>6</sub> = H, alkanoyl, etc.; R<sub>7</sub> = H, halo, OH, alkoxy, etc.; R<sub>8</sub> = H, halo; R<sub>9</sub> = H, halo, alkyl, alkoxy, arylalkoxy, amino; R<sub>10</sub> = H, halo, alkyl, OH, alkoxy, CN, etc.] are prepd. These derive. are capable of acting at a recently identified site on the GABA receptor complex (GRC), thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. Thus, 2-methyl-1-buten-3-yne was added to 17.beta.-methoxy-5.beta.-androstane-3-one to give II. II protected 87.5% of mice injected with metrazol from convulsions.


REFERENCE COUNT: 81 THERE ARE 81 CITED REFERENCES AVAILABLE FOR THIS

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2002 ACS (Continued)  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 1998:112239 CAPLUS  
DOCUMENT NUMBER: 128:188632  
TITLE: Use of GABA agonists and NMDA receptor antagonists for the treatment of migraine headache  
INVENTOR(S): Lan, Nancy C.  
PATENT ASSIGNEE(S): Cicensys, Inc., USA; Lan, Nancy C.  
SOURCE: PCT Int. Appl., 47 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9805337	A1	19980212	WO 1997-US13430	19970731
<p>W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LN, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p> <p>RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG</p>				
AU 9739672	A1	19980225	AU 1997-39672	19970731
PRIORITY APPLN. INFO.: US 1996-22937P P 19960801				
WO 1997-US13430 W 19970731				
IT 186264-54-0 186264-61-9 186264-63-1				
186264-86-8 186264-87-9				
<p>RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)</p> <p>(GABA agonists and NMDA receptor antagonists for migraine headache treatment)</p>				
RN 186264-54-0 CAPLUS				
CN Pregnan-20-one, 3-hydroxy-21-(3-pyridinyloxy)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2002 ACS (Continued)  
RN 186264-61-9 CAPLUS  
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinyloxy)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-63-1 CAPLUS  
CN Pregnan-20-one, 3-hydroxy-21-[(6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-86-8 CAPLUS  
CN Quinolinium, 6-[[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2002 ACS (Continued)



• I<sup>-</sup>

RN 186264-87-9 CAPLUS  
CN Pregnan-20-one, 3-hydroxy-21-[(1-oxido-3-pyridinyl)oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Methods are disclosed for treating or preventing migraine headache by administering to an animal a GABA receptor agonist (e.g. a neuroactive steroid) and/or an NMDA receptor antagonist (e.g. a dihydroquinoxaline deriv.). Also disclosed are pharmaceutical compns. and kits for the treatment or prevention of migraine headache.


L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1997:113460 CAPLUS  
 DOCUMENT NUMBER: 126:131695  
 TITLE: Preparation of neuroactive steroids of the androstane and pregnane series  
 INVENTOR(S): Upasani, Ravindra B.; Fick, David B.; Hogenkamp, Derk J.; Lan, Nancy C.  
 PATENT ASSIGNEE(S): Cocensys, Inc., USA  
 SOURCE: PCT Int. Appl., 94 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640043	A2	19961219	WO 1996-US10115	19960606
WO 9640043	A3	19970327		
V: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
CA 2223996	AA	19961219	CA 1996-2223996	19960606
AU 9661725	A1	19961230	AU 1996-61725	19960606
AU 725214	B2	20001005		
EP 837874	A2	19980429	EP 1996-919372	19960606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1190404	A	19980812	CN 1996-195360	19960606
BR 9608592	A	19990629	BR 1996-8592	19960606
JP 11507643	T2	19990706	JP 1996-502210	19960606
NO 9705608	A	19980206	NO 1997-5608	19971204
FI 9704448	A	19971205	FI 1997-4448	19971205
PRIORITY APPLN. INFO.: US 1995-467404 A 19950606 WO 1996-US10115 W 19960606				

OTHER SOURCE(S): MARPAT 126:131695  
 IT 186264-54-0P 186264-61-9P 186264-63-1P  
 186264-86-8P 186264-87-9P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of neuroactive androstanes and pregnanes)  
 RN 186264-54-0 CAPLUS  
 CN Pregnan-20-one, 3-hydroxy-21-(3-pyridinyloxy)-, (3.alpha.,5.beta.)- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 186264-61-9 CAPLUS  
 CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinyloxy)-, (3.alpha.,5.beta.)- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-63-1 CAPLUS  
 CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 186264-86-8 CAPLUS  
 CN Quinolinium, 6-[[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-87-9 CAPLUS  
 CN Pregnan-20-one, 3-hydroxy-21-[(1-oxido-3-pyridinyl)oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2002 ACS (Continued)



AB Compds. of formula I [R = H, NH<sub>2</sub>, thio, sulfinyl, sulfonyl, halogen, alkoxy, alkyl, etc.; R<sub>1</sub> = H, alkyl, alkenyl, alkynyl, aryl, etc.; R<sub>2</sub> = H, OH, alkoxy, alkanoyloxy, carbalkoxy, keto, amino; R<sub>3</sub> = H, alkoxy, alkenyloxy, etc.; R<sub>4</sub> = H, alkyl; R<sub>5</sub> = H, absent; R<sub>6</sub> = H, alkanoyl, aminocarbonyl, alkoxy, carbalkoxy; R<sub>7</sub> = H, halogen, OH, alkoxy, alkanoyloxy, carbalkoxy; R<sub>8</sub> = H, halogen; R<sub>9</sub> = H, halogen, alkyl, alkoxy, arylalkoxy, amino; R<sub>10</sub> = H, halogen, OH, alkyl, etc.] are prepd. as neuroactive prodrugs, due to their ability to modulate the GABAA receptor-chloride ionophore complex. These derivs. are capable of acting at a recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. Thus, 2-methyl-1-buten-3-yne was added to 17.beta.-methoxy-5.beta.-androstane-3-one to give II. II (10 mg/kg IP) protected 87.5% of mice injected with metrazol from convulsions.